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Abstract 
Clinical and forensic toxicology analysts rely heavily in their daily tests on the 
analysis of the conventional samples (blood and urine). However, these specimens 
are limited in the time scale they reflect with regard to drug intake history and also in 
terms of drug stability within the matrices. Alternative matrices such as hair, oral 
fluids and dried blood spots (DBS) provide new horizons and new opportunities. 
Drugs incorporated within hair are very stable. Hair also provides a very long 
detection window, for at least one year, if not a lot longer.  Oral fluids on the other 
hand are non-intrusive, easy to collect and much cleaner sample matrix than blood 
or urine. DBS also offer great drug stability, are easy to collect, faster to analyse and 
suitable for automated analysis. However, a number of studies are needed to 
assess the limits of these alternative samples in terms of the correlation of their 
results with the results of conventional samples and with regard to drug stability. 
Such studies will enable a more reliable and confident interpretation of results 
obtained from these matrices especially for medico-legal purposes. 
The main aims of this research were: to develop and validate analytical methods for 
detection and quantitation of drugs of use and abuse in hair, oral fluids, blood and 
DBS samples, to investigate the correlation between dose and drug concentration in 
hair, blood and oral fluids after controlled chronic drug administration, to investigate 
the stability of anti-psychotic drugs in DBS (from patients) stored under different 
conditions and the effect of addition of preservative, and to investigate the alcohol 
intake prevalence among Kuwaiti drug addicts and correlate these results with self-
reported intake. 
As the majority of drugs were basic, an extraction method based on methanolic 
incubation was developed for detection of basic/weak basic drugs in hair. It was 
compared to alkaline digestion (with NaOH) followed by liquid-liquid extraction 
(LLE). Detection was achieved by LC-MS/MS (Sciex2000) after separation on a C18 
column. When applying both methods on positive authentic hair samples the results 
showed that the methanolic method was capable of extracting most basic drugs in 
hair but only partially, while the alkaline digestion method was found to degrade 
 V 
 
some unstable drugs like sulpiride, but was capable of fully extracting the alkaline 
stable drugs such as quetiapine.  
After development and validation of the LLE-LC-MS(Exactive) method for the 
analysis of anti-psychotics in blood, oral fluids and hair, an investigation was carried 
out on the correlation pattern between trough concentrations in those three 
matrices. The most significant correlation coefficients (r) found were those between 
blood and hair concentrations, procyclidine r=0.83 (18 subjects p=<0.001), 
risperidone r=0.96 (14 subjects p=<0.001), haloperidol r=0.90 (10 subjects 
p=<0.001), OH-risperidone r=0.24 (13 subjects p=>0.44), quetiapine r=0.28 (14 
subjects p=>0.33) and chlorprothixene r=0.32 (13 subjects p=>0.32). Among the 
interesting results was the strong correlation found between drugs half-lives and the 
mean ratio of hair concentration/dose (r=0.96, p=<0.003).  
The stability of anti-pyschotics in DBS from patients’ samples was assessed by 
storing them at four different temperatures (25, 4, -20 and -80°C) with and without 
prior impregnation of the DBS cards with sodium fluoride. After development and 
validation of the LLE-LC-MS method, samples were analysed at days 0, 45, 90 and 
180. Results showed good stability of all the compounds (procyclidine, quetiapine, 
risperidone, OH-risperidone, chlorprothixene and haloperidol) in all the different 
storage conditions and no significant increase or decrease in drug concentrations 
with sodium fluoride impregnation. 
Finally, after trials with five different HPLC columns, two SPE cartridges, two LLE 
extraction procedures and two mass spectrometer instruments, a method was 
developed and validated for the detection and quantitation of alcohol’s minor and 
specific metabolite in hair, ethyl glucuronide (EtG). The method has a limit of 
detection (LOD) of 3pg/mg and lower limit of quantitation (LLOQ) of 9pg/mg. This 
method was applied to 59 hair samples from patients at a general addiction centre 
and alcohol prevalence was investigated and its correlation with self-reported use 
was investigated. 
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1. Chapter 1 - Introduction 
1.1. Introduction to hair 
Hair is a unique continuously regenerating mini-organ covering the human 
and animal body. It serves many physiological and psychosocial functions. The 
average human displays an estimated number of 5 million hair follicles, of which 
80,000 to 150,000 are located on the scalp (Krause, Foitzik 2006). These hairs are 
divided into three basic types: terminal, vellus and intermediate hair. Each one of 
these hair types has its own characteristics of length, colour, texture, shape and 
diameter. The terminal hair is usually coloured, long hair and has a wide cross 
sectional area which is mostly found in the scalp, beard & moustache, eyelashes, 
eyebrows, pubic hair and axilla. The vellus hair is the very small colourless hair that 
covers almost the whole human body, clearly seen on the bald scalp or forehead. 
The intermediate hair is that found on the hands and legs of adults that has an 
intermediate size and length and intermediate cross sectional area. However, the 
main focus of this research is mostly on the terminal scalp hair. 
1.1.1. Hair structure 
Hairs are mini shafts that are cylindrical in shape which grow from small pouches 
known as hair follicles. The morphology of the hair differs between individuals and 
within individuals. For instance, African hair structure is clearly different from 
Caucasian hair, both microscopically and in its natural appearance. It differs as well 
within the body regions of the same individual. It can exist as single strand or double 
or even group of strands emerging from the skin (Montagna, Ellis 1959). Basically 
this tiny structure consists of three main layers of cells as can be seen in Figure 1. 
The outermost layer, the cuticle, serves as a protector to the inner layers and cells 
of the hair shaft. It consists of elongated single overlapping layers of melanin free 
cells pointing outward and upward like palm trunk shingles. These cells have a 
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diameter of about 45µm and thickness of about 0.7µm (Harkey 1993). Although the 
cuticle layer protects and preserves the components of the hair, it can be vulnerable 
against environmental, chemical or physical insults.  
 
Figure 1: Cross section of the human hair shaft (Pragst, Balikova 2006) 
 
The middle and the bulk layer is the cortex where the melanin and the keratinized 
cells are located. The melanin granules are the source of colour and its intensity in 
the hair. It is divided into two main types: eumelanin and pheomelanin, which will be 
discussed further under separate headings. Within the cortex cells there are 
irregular-shaped airspaces of varying sizes called cortical fusi filled with fluid and 
replaced by air as the hair grows and dries out (Harkey 1993). 
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Figure 2: Longitudinal-section of hair shaft (Bisbing 2002) 
 
As shown in Figure 2, the innermost layer of the hair shaft is the medulla. It is not 
always continuous along the shaft; it is sometimes discontinuous or absent. The 
medulla layer holds many keratinized cells. Intra and intercellular airspaces can 
exist as well in this layer (Montagna, Ellis 1959). It is also possible to find granules 
of melanin present in the medulla. 
1.1.2. Hair composition 
The main component of hair is the keratin proteins which produce the structure of 
the hair. These proteins are rich in sulphur to form the disulphide bonds between the 
amino acids which are required in shaping the hair. Proteins account for 65-95% of 
the total hair composition while the remaining constituents include water (15-35%), 
lipids (1-9%), melanin/pigment (0.1-5%), trace elements and minerals (0.25-0.95%) 
and small amounts of polysaccharides (Robbins 2002). These percentages vary 
between individuals.  
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1.1.3. Hair follicle 
Hair follicles are rooted 3-4mm underneath the skin’s surface within the dermis 
layer. This small sac is surrounded by apocrine and eccrine sweat and sebaceous 
glands that lubricate the hair shaft through secretary ducts in an upward direction 
just before the skin opening. These sweat and lipid secretions can contain body 
excreted toxins. The eccrine glands can be located on the surface of the whole body 
but higher in density on soles of feet, forehead and palms, whereas apocrine glands 
are mainly found in axillaries, eyelids, perineal region and in the external auditory 
canal. The hair follicle can be divided into three parts: innermost, middle and 
uppermost part. The innermost part is the place of hair cell synthesis, proliferation 
and differentiation, which is the lower segment in and around the bulb. The middle 
segment or the second part is the keratinization area where keratin gene 
expression, pigment incorporation, hair hardening, disulfide bonding, and 
dehydration are carried out. The last part is the zone of hair maturation, the 
uppermost segment of the hair follicle, where degradation of the inner root sheath 
and the dehydrated cornified hair cells shape up the shaft as seen in Figure 3 
(Krause, Foitzik 2006, Harkey 1993, Pragst, Balikova 2006).  
 
Figure 3: Hair follicle (Phoenixbio 2008) 
 
There are three types of follicles according to Harkey (Harkey 1993) that generate 
different hair on the human skin. The first type are the nonsexual hair follicles, which 
produce the intermediate hair. These follicles are not affected by hormones and are 
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the same before and after puberty. The second type are the ambosexual hair 
follicles which are sensitive to hormones, such as pubic hair, axilla and temple hair 
of the scalp. Consequently these are altered after puberty. The third are the male 
hair follicles which play a role in the characteristic features of men which include hair 
in beard, moustache, abdomen, chest, nose, ears and some part of the scalp.  
1.1.4. Hair growth cycle 
The hair follicle cycle goes through three different phases.  
1.1.4.1. Anagen 
The anagen phase is the growth phase of the cycle when the follicle becomes 
metabolically active and the matrix cells are in production and the hair shaft is 
getting elongated. The keratinization and hair cell production are actively 
processing. Under normal circumstances the duration of this phase is from 2-4 years 
and usually depends on the body region with the growing rate varying as well. 
Drugs, metals and toxins which are transported by blood capillaries can be 
incorporated into hair during this phase.   
1.1.4.2. Catagen 
The catagen phase is the regression and dynamic transition phase between anagen 
and telogen (resting phase). Generally, this phase lasts only 4 to 6 weeks. The root 
of the hair becomes keratinized and starts to split from the hair follicle’s bulb and 
starts forming what is known as the club hair. Apoptosis of epithelial cells in the bulb 
and outer root sheath will take place and a white node will form as shown in Figure 
4. The follicle will start shrinking and getting shorter. 
Chapter 1 - Introduction  
Page 26 of 255 
 
1.1.4.3. Telogen 
The telogen phase is the resting phase which is typified as the club. In this phase 
the hair will became even shorter and easily plucked as it is completely separated 
from the bulb. This phase will last normally for 2 to 3 months, but it differs between 
body regions and can be longer with old individuals or certain conditions.  
The anagen and telogen phases account for more than 95% of the hair growth 
process in the scalp at any one time. In the catagen phase the new growing hair 
may force the old one out and let it fall out naturally (Krause, Foitzik 2006, Harkey 
1993, Nakahara 1999). The three phases is shown in Figure 4.   
 
Figure 4: Phases of hair cycle (Furdon, Clark 2003)  
 
1.1.5. Hair pigmentation 
The hair pigment melanin (synthetic pathway shown in Figure 5) is formed in the 
cytoplasmic melanosomes of the melanocytes, melanin cells in the hair bulb. These 
organelles biosynthesize the melanin and condense it in a process called follicular 
melanogenesis. They then transfer it into the keratinocytes of the cortex and the 
medulla of the hair shaft. A number of enzymes, proteins, transporters and receptors 
are involved in this process which takes place during the anagen phase. One of the 
known enzymes is tyrosinase. It has been found that pigment dilution results 
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primarily from a reduction in tyrosinase activity within hair bulbar melanocytes 
(Cheze, Villain & Pepin 2004). Melanin is mostly found in the cortex with some in the 
medulla and seldom in the cuticle (Slominski et al. 2005). 
Table 1: Average melanin content in hair (Uhl, Scheufler 2005) 
Hair colour Samples (n) 
Total melanin 
(µg/mg hair) 
Median 
(µg/mg hair) 
Light blond 20 0.8 – 2.4 2 
Medium blond 15 1.2 – 5.0 3 
Reddish 5 3.8 – 5.7 4 
Brown 15 3.3 – 11.5 5.7 
Black 10 8.0 – 20.0 12 
 
There are two types of melanin in human hair; eumelanin and pheomelanin. One 
study suggests that two other types exist, oxyeumelanin and oxypheomelanin, which 
both represent the oxidative products of the earlier types (Prota 2000). According to 
that study eumelanin is predominant in black hair and it gets lightened as the 
percentage of oxyeumelanin increase. So, blond hair has a large quantity of 
oxyeumelanin, while the pheomelanin and oxypheomelanin content in hair reflects 
the red/carroty colour and its degree (Kintz 2007a). The hair colour classification is 
shown in Tables 1 and 2. 
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Figure 5: General outline of melanin formation (Dernroth 2009) 
 
Table 2: Classification of human hair pigmentation according to melanin type (Kintz 2007a) 
Pigmentation Colour PTCA* BTCA* TTCA* 
Eumelanin Black to dark brown 100-300 - - 
Oxyeumelanin Brown to blond 50-80 - ≥200 
Pheomelanin Fiery/carroty red - 1000-2500 - 
Oxypheomelanin Other red hues - - 100-300 
*Pyrroletricarboxylic acid (PTCA), Benzothiazolecarboxylic acid (BTCA), Thiazoletricarboxylic (TTCA).  
Yields (ng/mg) 
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1.1.6. Hair ageing 
As humans get older, their hair physical appearance changes. The dominantly clear 
characteristics of hair ageing are dryness of hair, thinning and loss of colour. 
Surprisingly, there are only few studies that have addressed hair ageing. From the 
hair growth perspective, Courtois et al observed the effect of ageing on 10 men 
during a period of 8-14 years and they found a noticeable decrease in the duration 
of hair growth and in the diameter of hair shafts with prolongation in the time 
between the loss of a hair in the telogen phase and the appearance of a substitute 
hair in the anagen phase (Courtois et al. 1995). All these signs contribute to overall 
progressive impoverishment in hair growth. 
1.1.6.1. Pigmentary unit ageing 
Follicular melanogenesis is thought to be as important regulator of hair growth. It 
was found that white beard hair grows at up to three times faster than the adjacent 
pigmented hair (Van Neste, Tobin 2004). The intact follicular pigmentary unit goes 
through cyclic reconstruction and maintenance throughout the first 10 hair cycles, 
which roughly equates to 40 years of age, with subsequently a genetically regulated 
exhaustion of the pigmentary potential of each individual hair follicular unit leading to 
the formation of white and grey hair (Van Neste, Tobin 2004). Melanocytic stem 
cells of the secondary hair germ involved in apoptosis might be an important factor 
for hair greying as well (Krause, Foitzik 2006). 
1.1.7. Rate of hair growth 
As this research mainly focuses on the scalp hair, the growth of the scalp hair in 
general is mosaic or asynchronous  (Chamberlain, Dawber 2003). This means each 
hair is in a different phase of growth to the neighbouring hairs with approximately 
85% to 90% of all scalp hairs being in the anagen phase (Krause, Foitzik 2006). 
Therefore for assessing the rate of hair growth a number of studies have been 
conducted. These studies concluded that scalp hair in general grows in the range of 
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0.6-1.4cm per month in normal healthy individuals from different ethnicities 
(Pecoraro, Astore 1990, Pragst et al. 1998). However, Potsch found that in alopecic 
individuals it may get to as low as 0.02 cm/month and at the same time it can get to 
2.3cm/month in healthy individuals with the majority (82%) of the examined 
population falling in the range of 1-1.4 cm/month (Potsch 1996). In addition to that 
scalp hair growth was also found to slightly differ in its anatomical site as it been 
suggested that the posterior vertex region is the most constant in the scalp while the 
margins are the least (Chamberlain, Dawber 2003). The other hair sites in the body 
such as axillary and pubic hair have more telogen and catagen phases (~50%) 
which make their growth rate slower and fluctuating or heterogenic (Pragst, Balikova 
2006). 
 
1.2. Hair analysis 
1.2.1. Chronology 
In the fifties, hair analysis was used for the analysis of drugs when Goldblum et al 
first analysed barbiturates in guinea pig hair (Goldblum, Goldbaum & Piper 1954). 
This was followed in the sixties and seventies by metals and trace element analysis 
(Smith, Forshufvud & Wassen 1962, Cumbie, Jenkins 1974, Hambidge et al. 1976). 
Hair analysis was also proposed at that time as a means of assessing nutritional 
status but Sorenson et al soon disputed that by claiming difficulties in agreeing 
normal levels due to the variations among laboratories and possibilities of external 
contamination from cosmetic products, air or water (Sorenson et al. 1973). In the 
same decade Forrest et al investigated the passage of some drugs through the hair 
of mammals (Forrest et al. 1972). Detection of drugs of abuse in hair was initiated in 
late seventies by Baumgartner et al who investigated opiate addiction (Baumgartner 
et al. 1979). A number of studies followed during the eighties on detection of other 
drugs of abuse. In 1989, Sato et al suggested the possible use of hair analysis for 
therapeutic drug monitoring (Sato et al. 1989). From the nineties onward the 
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attention to hair analysis has increased considerably owing to the advances in 
detection sensitivity. Immunoassays, GC-MS and tandem mass spectrometry 
instruments (GC-MS/MS and LC-MS/MS) enabled the detection of even a single 
dose or single hair strand (Kintz 2007a).    
1.2.2. Introduction 
Hair analysis is becoming increasingly popular in forensic laboratories especially 
those dealing with drug facilitated crime cases. Hair differs from other traditional 
biological samples used for human toxicological analysis such as urine, blood, liver, 
or oral fluids because of its significantly longer detection window (months to years) 
allowing retrospective investigation and measurement of chemical/drug 
consumption. Hair analysis is now accepted in many of the developed countries for 
substance consumption related issues in a wide range of sectors; medico-legal 
sector, workplace, forensics, treatment monitoring, schools, research, insurance and 
driving licence.  
Due to the fact that hair testing can provide evidence of drug facilitated crimes the 
analytical laboratories are assumed to be highly responsible in providing the most 
accurate results to the justice system. This accuracy requires implementation of a 
series of procedures that have been adequately validated and reviewed. 
Furthermore, these procedures need to be undertaken in a highly organized and 
precise manner to avoid any possible error. Extraction of drugs from hair is 
considered the most important step in the whole process. The drugs are enclosed 
tightly in the hair shaft and to a certain extent could be bound to proteins, melanin or 
even lipids of the cell membrane complex. The hair matrix type, structure of the 
drug, method and duration of extraction, and solvent used are all important factors 
affecting the final extraction yield (Musshoff, Madea 2007b). In this research the 
extraction strategies for the main illicit drug groups have been reviewed. In addition, 
the steps preceding extraction, sampling, storage, decontamination and digestion 
are also covered.  
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1.2.3. Mechanism of drug incorporation 
The precise mechanism of drug incorporation into the hair shaft is still unclear. 
However, most scientists if not all of them in this field, agree on the possible routes 
by which drugs can be entrapped in hair (Kintz 2007a). The multi compartment 
model which has been suggested more than 15 years ago stated that ingested or 
injected drug can be incorporated into hair mainly through the blood stream feeding 
to newly growing hair cells in the dermal papilla part of the hair’s root. The other 
routes are sweat and sebum secretions that lubricate the hair shaft and also 
diffusion from the surrounding tissue is possible (Henderson 1993). To elucidate the 
theory, Pragst et al mentioned that during the anagen phase of the hair growth a 
drug dose can be incorporated, within the hair follicle, to a drug-containing zone of 
approximately 2-5mm width from the base of the hair follicle, which appears at the 
skin surface 1-5 days after drug exposure and moves regularly away following the 
hair shaft’s growth rate (Pragst et al. 1998). This process may be followed by sweat 
and sebum baths which possibly carry drugs that can be incorporated as well. In 
addition to these routes an external source of drug is probable through 
environmental contamination with drug smoke, powder or even solution. 
Nevertheless, these routes differ significantly in their relative contribution or 
importance among drugs and individuals. Some drugs distribute more in lipid 
compartments and are excreted more in sebum, while others favour aqueous 
compartments and so are excreted more in sweat. However, interpretively the most 
important one is the bloodstream route because it can help in predicting the time of 
drug intake when analyzing hair samples in segments. These segments can serve 
as pages of the hair’s chronological diary note telling retrospectively about an 
individual’s drug intake history.    
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Figure 6: Drug incorporation mechanism (Pragst, Balikova 2006) 
 
1.2.3.1. Blood stream incorporation 
The assumed model for drug incorporation from blood is that drug enters the 
growing matrix hair cells by passive diffusion from the capillaries surrounding and 
feeding these cells. The area of the contact is estimated to be between 1.2 to 1.5 
mm in length covering the main zones of the hair follicle root (zone of cell 
proliferation and differentiation, zone of keratinization and pigmentation, and zone of 
hardening and disulfide bonding) (Pragst, Balikova 2006). The matrix hair cells are 
exposed to the drug during the time when the drug is present in the blood, which is 
represented by drug area under the curve (AUC). So, theoretically the higher the 
drug AUC the longer exposure time and consequently the higher incorporation rate 
but practically this is not always the case, because lots of other elements are 
involved in the incorporation rate which will be discussed later. It is worth mentioning 
as well that blood AUC for any given drug has possibly poor inter-individual 
correlation with the dose according to Pragst (Pragst, Balikova 2006), so it will not 
be a surprise if the concentration of a given drug in the hair for the same given dose 
differs between individuals. Some studies showed that no correlation between blood 
concentration and hair concentration for drugs such as tricyclic antidepressants 
(Pragst et al. 1997) and methadone (Paterson et al. 2003). Kinz et al also could not 
find a clear correlation between the dose of heroin and the concentration of total 
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opiates in hair after controlled administration (Kintz et al. 1998). In contrast, 
Musshoff et al repeated the experiment by injecting the subjects with pharmaceutical 
heroin and found a correlation between the dose and the total opiate concentration 
in the hair (r=0.66) and as the analyte’s plasma half-life increased the correlation 
was increased (Musshoff et al. 2005). Another controlled study supported these 
findings with codeine and cocaine (Scheidweiler et al. 2005). Another study also 
showed some correlation between plasma and hair concentrations for clozapine 
(r=0.542) (Cirimele et al. 2000). 
1.2.4. Bias in hair analysis 
The main sources of bias in hair analysis are cosmetic treatment and hair colour, 
which both can be related to race in many cases. Cosmetic treatment of hair, such 
as bleaching, dyeing, permanent waving and chemical straightening, can cause 
structural damage which will make it more penetrable. Consequently, incorporated 
drugs can be removed by for example normal hygiene practices or oppositely drug 
can penetrate and bind to hair from external sources like smokes for instance 
leading to false negative or positive results. Study showed that after such hair 
treatments, drug concentrations can decrease by 50-80% of their original 
concentration (Kintz 2004). This issue is of concern particularly for interpretation of 
recreational drug analysis. Cocaine and codeine were found to be 3 fold higher in 
concentration in brown hair strand compared to bleached ones of the same female 
subject (Joseph, Su & Cone 1996). On the other hand many studies showed that 
melanin content in hair play major role in drug incorporation particularly basic drugs. 
Therefore, there may be a bias in drug analysis with hair from different ethnicities. 
African American hair samples were found to contain significantly higher cocaine 
samples than hair from black/brown Caucasian hair (Kidwell, Lee & DeLauder 
2000). Animal studies as well showed that pigmented hair incorporate more basic 
drugs than non-pigmented hair (Pötsch, Skopp & Moeller 1997).  
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1.2.5. Sampling 
Most hair analysts agreed that all sampling should be done preferably by laboratory 
staff with a clearly written sampling protocol provided to the collectors. Along with 
sampling, a good documentation of all the relevant case history information (e.g. 
date and time of drug intake) and all the hair characteristics should be noted such as 
hair colour, type, ethnicity of the person and the length of hair sample after cutting. 
After sampling the proximal side of the hair tuft should be clearly identified and 
labelled. Ensuring alignment of hair at the root is very important. Date and site of 
collection on the head must be recorded as well as any cosmetic treatment history. 
 
Figure 7: Sampling from the posterior region of the scalp (ChemTox 2009) 
 
A recommendation of the hair testing society (SoHT 2004) states that a tuft with a 
thickness of a pencil or several small tufts with a thickness of straw should be taken 
from the occipital region (least variation in growth rate) of the scalp hair as close as 
possible from the skin. A fine-tipped pair of surgical scissors would be a good tool. 
Preferably two separate samples tied with string should be taken to allow analysis 
and conformation or reanalysis. Alternative hair, such as pubic and axillary hair, can 
be sampled, if head hair is not available, but they differ in the growth rate and are 
less prone to cosmetic exposure. Therefore, estimating the period of drug ingestion 
would be very difficult. When taking a postmortem sample it should be done before 
the autopsy to avoid any source of contamination like body fluids. Wet hair samples 
from autopsies stored in a fridge were found to have remarkably decreased 
concentrations of heroin and 6-monoacetylmorphine (6-MAM) due to hydrolysis after 
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sampling (Musshoff, Madea 2007a). The sampling and analysis process should not 
be carried out where the drugs being tested for are handled to protect samples from 
external contamination. A hair sampling kit is available commercially. In cases of 
criminal assaults it is necessary to wait for a few weeks (4 to 5) after the offence 
before sampling to ensure the drug has been incorporated in the hair (Kintz 2007a).   
1.2.6. Storage 
The first issue with storage is adequate labelling which is highly important to avoid a 
mix up with other samples. Most, if not all, scientists working in this field are 
recommending the following storing protocol (Pragst, Balikova 2006, Musshoff, 
Madea 2007a). Hair samples must be stored dry and light must be avoided. A study 
done by Skopp et al on the stability of cannabinoids in hair samples clearly showed 
significant reduction and degradation of their initial concentrations after 10 weeks of 
exposure to sunlight (Skopp, Potsch & Mauden 2000). A dry sample should be 
wrapped in aluminium foil, then put into a labelled paper envelope and stored at 
room temperature. By these measures most drugs are very stable and will be 
detected even years after sampling (Pragst, Balikova 2006). Plastic containers and 
bags should be avoided as they may extract lipophilic drugs or the softeners or the 
stabilizers may interact with hair samples if not protected with foil (Peters 2007).     
1.2.7. Decontamination 
This step of the hair analysis process is necessary to ensure that all the drugs 
detected in hair are those which have been ingested and not incorporated from 
environmental sources such as smoke, laboratory contamination or any other form 
of drug contact. Decontamination or washing will also help in removing hair cosmetic 
products, dust, sweat and sebum, therefore improving the analytical sensitivity by 
working with a cleaner sample. Washes should be kept for analysis, especially the 
first wash, to investigate if there was any external drug incorporation. One of the 
ways to assure consumption is the measurement of metabolite to parent drug 
concentration ratios, a metabolite that cannot be formed by hydrolysis.  
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In terms of solvent choice there is no general agreement on which solvent should be 
used but the SoHT guidelines recommend an initial organic solvent wash to remove 
oils, followed by aqueous washes (SoHT 2004). The most popular and widely used 
organic solvent is dichloromethane. Because it is a non-protic solvent it will not swell 
the hair and thus extract the drugs. Acetone is another non-protic solvent but is 
being used to a lesser degree or mostly as a last step drying off solvent. Protic 
solvents like methanol and phosphate buffers can swell the hair and encourage the 
extraction of the drugs (Kintz 2007a). One study found that three phosphate buffer 
washes removed up to 20% of the total drug (codeine and cocaine) present in hair 
(Ropero-Miller et al. 2000). Wilkins et al (Wilkins et al. 1995) found that a methylene 
chloride wash procedure reduced the measured THC concentration by up to 50%. 
Several publications reported the use of shampooing in postmortem samples as a 
first step in washing. This is obviously due to the fact that autopsy samples are 
usually less hygienic. Detergents like 0.1% sodium dodecylsulfate (SDS) have been 
reported to remove external methamfetamine (MA) contamination under 
ultrasonication, when control hair was soaked in an aqueous solution containing 
10mg/ml of MA hydrochloride for 24 hours, but when the concentration doubled to 
20mg/ml a few ng/mg was found in hair (Nakahara 1999). However, it seems difficult 
to recommend a particular washing procedure based on the conclusion of a study 
comparing different washing practices for morphine (Marsh et al. 1992). Paulsen et 
al concluded that the use of improper solvents can significantly affect the analytical 
results of hair analysis (Paulsen et al. 2001).  Another study showed that the hair 
type can influence the decontamination process. It concluded that thick black hair is 
more resistant to decontamination than lighter hair and if it is dyed it will be more 
susceptible to external drug incorporation than lighter hair (Blank, Kidwell 1995) this 
could be due to the damages to hair structures with basic dyes. It worth mentioning 
as well that a formula proposed by Tsanaclis (Tsanaclis, Wicks 2008) suggested the 
use of analyte concentration ratio found in the washes (W) with that found in hair (H) 
and dividing it into three categories. If W/H is less than 0.1 or null, it may indicate 
genuine drug use, while if the W/H ratio is between 0.1 and 0.5 this indicates 
possible use or combined with external contamination, but a W/H ratio more than 
0.5 is likely to indicate external contamination. 
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To sum up no single procedure could be recommended (Kintz 2007a) but to help in 
excluding possible external contamination from the environment four criteria should 
be considered: use of non-intensive multiple washing steps for not more than 15 
minutes each with no temperature higher than 37°C, analysis of the washes after 
washing, identification of unambiguously endogenous metabolites with their ratios to 
the parent drug and finally use of cut-off levels. 
Segmentation of hair usually follows the decontamination process and tentatively 
every centimetre of hair represents a month based on an average growth rate of 
1cm/month. 
1.2.8. Homogenization 
The hair homogenization process seems to be controversial in the literature as 
some reports prefer cutting the hair into small snippets and others prefer grinding. 
Almost two thirds of the hair analysis published studies have used the cutting into 
snippets method and mostly with scissors, while roughly the remaining third used 
the pulverizing method by ball mills (Goulle et al. 1995), mortar and pestle (Hadidi et 
al. 2003)  or beadbeaters (Joseph et al. 1997). However, the use of grinding is 
noticeably increasing in recent publications. Some other studies used a direct 
application of hair solubilising enzymes or digestive agents such as concentrated 
NaOH, pronase and proteinase K to hydrolyze hair proteins (Musshoff, Madea 
2007b, Offidani, Strano Rossi & Chiarotti 1993). Incongruously, Pragst mentioned 
that grinding generally results in loss of sample material and does not improve the 
extraction process (Pragst, Balikova 2006), in contrast to a study done by Eser et al, 
which showed that pulverizing hair has a lower risk of missing drugs than using hair 
snippets (Eser et al. 1997).  Also, in another hair test done on healthy volunteers, a 
higher amount of bromozepam in powdered hair than scissors cut hair into 1-2mm 
snippets was found (Cheze, Villain & Pepin 2004). Moreover, analysts working in 
minerals detection in hair reported the appropriateness of using powdered hair 
samples (Okamoto et al. 1985, Kamogawa et al. 2001). Scientists researching in the 
organic pollutants field also stated that the more powdered is the hair sample, the 
more efficient will be the subsequent extraction (Schramm 2008). In another option, 
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1M NaOH digestion for 1 h at 80°C offers high yields from alkaline-stable drugs such 
as cannabinoids, amfetamines, nicotine, some antidepressants and some 
neuroleptics, in addition to several other drugs, but generally cannot be used for the 
analysis of cocaine, heroin, 6-monoacetylmorphine (6MAM) and other ester 
compounds in hair (Nakahara 1999). For example cocaine will convert to 
benzoylecgonine under these alkaline conditions (Musshoff, Madea 2007b). The 
digestive enzymes work by breaking down the hydrogen and disulfide bonds within 
the hair and cause degradation and destruction of its fibre structure. These enzymes 
are proteinase K, protease E and VIII. The advantage of these enzymatic methods 
is to solubilise the hair sample without degradation of the unstable compounds like 
cocaine and heroin/6MAM (Nakahara 1999). The disadvantage of this method is 
that it is quite expensive. Normally the process consists of mixing the enzyme with 
10-30mg aliquot of hair and incubating it at a relatively high temperature (40-60°C) 
for ~2 hours, then centrifugation and the supernatant is extracted by either solid 
phase extraction (SPE) or liquid-liquid extraction (LLE) (Nakahara 1999). 
The sample size to be used for these homogenizing methods and the rest of the 
extraction process varies noticeably among laboratories, normally depending on the 
drug to be analyzed and the test protocol. For instance, if GHB or benzodiazepines 
are tested, the sample size should be at least 5 or 20mg per segment, respectively 
(Kintz 2007a). 
1.2.9. Extraction 
After decontamination and homogenization, comes the challenging step which is the 
release of the drug substance from the hair matrix. Drugs are incorporated and 
entrapped most likely within the hair’s keratin, melanin, lipids and fibres and can 
form a stable complex that may be preserved for years. Therefore, a reliable 
extraction method should be implemented in order to release these compounds from 
hair. Ideally, the extraction conditions have to make possible the extraction of 100% 
of the compounds present without significant degradation (Kintz 2007a). Many 
extraction techniques have been published. The most appropriate and 
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recommended ones for each major forensically important drug groups are discussed 
in the following paragraphs. 
1.2.9.1. Opiates 
Musshoff & Madea (Musshoff, Madea 2007b) have reviewed and outlined the recent 
extraction procedures for opiates in the literature and they found three dominating 
methods; heat assisted hydrolysis by HCl acid overnight introduced by Kintz and 
Mangin (Kintz, Mangin 1995) followed by liquid-liquid extraction (LLE), enzymatic 
hydrolysis introduced by Moeller et al (Moeller, Fey & Wennig 1993) with β-
glucuronidase/arylsulfatase followed by SPE and methanolic ultrasonication (Kauert, 
Rohrich 1996). The first two are enhanced with derivatization and both have the 
drawback that heroin and 6-acetylmorphine can be hydrolyzed to morphine. The 
third is the only method that has been suggested to identify heroin itself in hair 
samples and it could be improved if followed by clean-up procedures with LLE or 
SPE to reduce the noise (Musshoff et al. 2009). Ultrasonic methanolic incubation at 
45°C for several hours was found to be good because methanol swelled the hair 
samples and facilitated the release of drugs as Eser et al reported (Eser et al. 1997). 
Balikova et al (Balikova, Habrdova 2003) also evaluated the opiate extraction 
methods and concluded that 1M NaOH or 0.1M HCl digestions produced the highest 
recoveries of morphine and codeine but decomposed 70–86% of the acetylated 
opiates, while the use of the neutral Soerensen buffer (pH7.4) incubation has lower 
recovery but did not change the ratios of labile metabolites and/or parent 
compounds in the original sample, with minor (7-18%) decomposition of acetylated 
opiates. Kronstrand et al (Kronstrand et al. 2004) proposed a simpler extraction 
method for opiates, cocaine and amfetamines by incubating the hair samples in the 
mobile phase (acetonitrile:methanol:20mM formate buffer, pH3 (10:10:80)) overnight 
at 37°C and it had a good recoveries (~84%) for morphine, codeine, 6-
acetylmorphine and ethylmorphine. 
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1.2.9.2. Cocaine 
There are many successful extraction protocols for the analysis of cocaine and its 
family, benzoylecgonine BE, ecgonine methylester EME, norcocaine NC, 
cocaethylene CE and norcocaethylene NCE in hair samples, along with the 
pyrolysis product of cocaine the anhydroecgonine methyl ester AEME which 
differentiates crack from cocaine (Musshoff, Madea 2007b, Kintz, Mangin 1995). 
Similar to opiates most of the methods are based on treatment with acid, enzymes, 
methanol or buffers, but not alkaline treatment as it hydrolyses cocaine to BE and 
EME. Most acid extractions (e.g. 0.01, 0.1M HCl, 0.05M sulfuric acid) are adequate 
but all can cause partial hydrolysis of cocaine (Musshoff, Madea 2007b). The 
method of enzymatic treatment showed good performance and high recoveries in 
general and the only two hold-ups are the cost and some large interfering peaks 
noticed throughout the whole run when tried with proteinase and pronase (Kintz 
2007a, Musshoff, Madea 2007b). Extraction by phosphate buffer 0.1N at pH5 
showed good recoveries (all >81%) for cocaine, BE and opiates (Romolo et al. 
2003). Methanol has similar extractability to the buffers, which is relatively lower 
than the previous methods, and can extract all types of drugs. However the addition 
of trifluoroacetic acid TFA significantly improved the recoveries (Musshoff, Madea 
2007b). Two separate studies tested the extractability of methanol/TFA (9:1) in 
comparison with methanol, 0.1M phosphate buffer and 0.1M HCl and both 
confirmed that methanol/TFA has the highest recoveries for cocaine and BE and 
high recoveries also for opiates (Romolo et al. 2003, Jurado et al. 2004). In terms of 
stability Romolo et al found almost no degradation of cocaine and 6-MAM with 
methanol/TFA (1.4%), while the other incubation media results were methanol or 
buffer (pH5-6)=1.3-4.2%, 0.01M HCl=3%, 0.1M HCl=12% and buffers pH>7=50%< 
(Romolo et al. 2003). For clean-up, SPE is considered to be the gold standard, and 
many such procedures are useful for the simultaneous determination of cocaine and 
its metabolites as well as opiates (Musshoff, Madea 2007b). 
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1.2.9.3. Amphetamines 
The method previously mentioned (Kronstrand et al. 2004) for simultaneous 
detection of opiates, cocaine and amfetamines through incubation with the mobile 
phase has been shown to detect amfetamine (A), methamfetamine (MA), 
3,4methylendioxymethamfetamine (MDMA) and 3,4-methylendioxyamfetamine 
(MDA) with high extraction recoveries (91-100%). However, the majority of 
published methods use alkaline (1-10M NaOH), acidic (0.25-5M HCl), or enzymatic 
digestion with some using methanol. Methanol/TFA seems to work well with 
amfetamines as it has high recoveries, very low detection and quantitation limits 
(LOD/LOQ) and the precision of intra- and inter-day assay as the relative standard 
deviation (RSD) were in the range 1.5–6.8% and 2.7–4.7%, respectively, for A, MA, 
MDA and MDMA (Nakamura et al. 2006). Kintz & Cirimele compared four different 
procedures; methanol sonication, acid (0.1M HCl), alkaline (1M NaOH) and β-
glucuronidase/arylsulfatase hydrolysis (Kintz, Cirimele 1997). They found highest 
recoveries with the alkaline hydrolysis. A method proposed by Cirimele et al for 
detection of A, MA, MDMA, MDA, and MDEA together with N-methyl-1-(3,4-
methylenedioxyphenyl)-2-butanamine (MBDB) and its metabolite 3,4-
methylendioxyphenyl-2-butanamine (BDB) in hair samples was found to have low 
LODs (0.02–0.05 ng/mg) (Musshoff, Madea 2007b). It consists of digestion with 1M 
NaOH followed by extraction with ethyl acetate and evaporation to dryness, in the 
presence of 2-propanol-HCl (99:1, v/v) and the target compounds were derivatized 
with HFBA (Musshoff, Madea 2007b). 
The HS–SPME technique for determining semi-volatile amfetamines in hair samples 
has been shown to reduce time and effort and was introduced by Koide and co-
workers (Koide et al. 1998). A modern SPDE technique with solventless extraction 
in a so-called inside-needle capillary absorption trap (a hollow needle with an 
internal coating of polydimethylsiloxane/charcoal) was found to have a higher 
extraction rate and faster operation, especially in combination with GC–MS/MS 
(Musshoff, Madea 2007b). Finally the vast majority of amfetamine extraction 
methods included clean up and derivatization steps. 
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1.2.9.4. Cannabinoids 
Cannabinoids testing in hair is considered a challenge because of the low 
incorporation rate of especially the metabolites (Musshoff, Madea 2007b). It has 
been found that 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) has 
an incorporation rate that is 3600-fold lower than cocaine (Nakahara, Takahashi & 
Kikura 1995). In addition cannabinoids are present in smoke and sweat and 
therefore there is a high possibility of contamination. The selection of an appropriate 
extraction and decontamination method is difficult (Uhl 2006). To indicate definite 
endogenous cannabinoids use a detection of one or both of the metabolites, 11-
hydroxy-THC and THC-COOH, is essential to prevent false positives (Uhl 2006). 
The majority of the published extraction methods depend on dissolving the hair 
matrix in alkaline solutions (0.1-2M NaOH or 10M KOH) with some preferring 
enzymatic digestion and very few using methanolic ultrasonication (Kintz 2007a). 
The general step of the alkaline digestion for cannabinoids is incubating the samples 
with the alkali for about half an hour at >70°C, then extraction with n-hexane after 
adjusting the pH to 5±0.5 and some prefer the addition of SPE to clean up. Baptista 
et al compared the use of GC-MS-EI and GC-MS-NCI for detection of THC-COOH 
and found the latter to be more convenient with a minimum chance of false 
negatives (Baptista et al. 2002). They extracted the samples after β-
glucuronidase/arylsulfatase hydrolysis for 2h at 40°C followed by a liquid-liquid 
extraction procedure (with chloroform/isopropyl alcohol, after alkalinization, and n-
hexane/ethyl acetate, after acidification). A different method proposed by Uhl & 
Sachs consists of mixing methanol and 10M KOH (1:1) and adding it to the hair 
sample with ultrasonication and vortexing for 30 minutes at 70°C then adjusting the 
pH to 4-5 and cleaning up with SPE (Uhl, Sachs 2004). As a final point in this 
context Wilkins et al validated the alkaline digestion method (18h in 1N NaOH at 
37°C) followed by LLE and detected the 11-OH-THC, THC-COOH and THC with 
intra-assay and inter-assay imprecision (2.1 to 11.2% and 4.4 to 13.0%) and limit of 
detection 10pg/mg for THC and THC-COOH and 100pg/mg for 11-OH-THC (Wilkins 
et al. 1995). However, the regulation proposed by the US federal regulations for the 
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detection of THC-COOH in hair requires a confirmatory detection level of 0.05pg/mg 
(Moore et al. 2006), which is fairly difficult.  
1.2.9.5. Benzodiazepines 
Hypnotic drugs such as benzodiazepines are at the top of the list for drug facilitated 
crimes. Their extraction from hair samples is mainly through incubation with 
phosphate buffers, methanol or digestive enzymes (Musshoff, Madea 2007b). Most 
reviews (Musshoff, Madea 2007b, Kintz 2007b, Villain, Kintz 2006) focus on the 
method proposed by Villain et al which is incubation in phosphate buffer (pH8.4) 
overnight followed by LLE with methylene chloride/diethylether (9:1) (Villain et al. 
2005). This method was able to screen 14 benzodiazepines plus zolpidem and 
zaleplon with LOQ ranges 0.5-5pg/mg and extraction recovery ranges from 32 to 
76% and imprecision <20%. With a different incubation medium, Laloup et al 
validated a new method capable of identifying 26 benzodiazepines plus zopiclone 
and zolpidem simultaneously (Laloup et al. 2005). The method works simply by 
incubating the pulverized samples with methanol at 45°C for 2 hours with orbital 
shaking followed by LLE with 1-chlorobutane/ammonium chloride buffer (4:1). The 
LOQ was between 0.5 and 10 pg/mg, precision (CV <20% in most cases) and 
extraction recoveries from 53.0% to 103.8%. 
1.2.9.6. Alcohol 
From the ethanol metabolites two markers have been suggested for the 
identification of alcohol consumption, fatty acid ethyl esters (FAEEs) and ethyl 
glucuronide (EtG). FAEEs are lipid soluble and incorporated into the hair from the 
sebum, so segmentation will be of no use because their incorporation does not 
associate with the growth rate of the hair and they are also found in the hair of strict 
teetotallers (Auwarter et al. 2001). Therefore generally they can be classified as co-
indicators of general drinking behaviour if detected in abnormal levels. As a 
consequence EtG attracted attention because it is water soluble and incorporated 
from blood. Although only 0.02–0.06% of ingested alcohol is eliminated as EtG it 
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can still indicate alcohol abuse (Pragst, Yegles 2006). The general extraction 
method for EtG in hair is simply incubation in water preferably with ultrasonication. 
Jurado et al showed that this method was superior to methanol, methanol/H2O or 
aqueous trifluoroacetic acid (Jurado et al. 2004). 
1.2.9.7. Screening 
There are numerous accounts of screening strategies published for analyzing 
different forensic drug groups, most of which are designed for screening by 
immunochemical, GC-MS and LC-MS/MS assays. As in this review, the interest is 
mainly in the extraction part of the process. Four of the recent, with the widest 
detection window protocols, are discussed below plus one extraction method for 
immunoscreening. Starting with the most recent one, Miller et al validated a 
quantitative method for the detection of 17 drugs (amfetamines, diazepam and its 
metabolites, cocaine and its metabolites and opiates) by LC-MS/MS with total 
extraction recoveries >76%, LOD were between 0.02 and 0.09ng/mg and 
imprecisions were generally <20% (Miller, Wylie & Oliver 2008). Their extraction 
method was based on incubation of hair samples in phosphate buffer (pH5) for 18 h 
at 45°C and then clean up with SPE. Phosphate buffer (pH5) was chosen because 
of the high stability of cocaine and 6-monoacetylmorphine in this medium. The 
second method was proposed by Hegstad et al for the detection of 22 drugs and 
metabolites (nicotine, cotinine, morphine, 6-MAM, codeine, A, MA, MDMA, cocaine, 
BE, zopiclone, zolpidem, carisoprodol, meprobamate, buprenorphine, methadone 
and 6 benzodiazepines) with validation results of <15% RSD for within- and 
between-assay, imprecision range from 16-24% and recoveries between 25-100% 
(Hegstad et al. 2008). The extraction was through incubating the samples with 
acetonitrile/25mM formic acid (5:95 v/v) in a water bath at 37°C for 18 h. Similarly, 
four years earlier Kronstrand et al introduced incubation in the mobile phase 
(acetonitrile:methanol:20mM formate buffer, pH3 (10:10:80)) at 37°C for 18 h but 
their method detected only 13 drugs from the 22 detected by Hegstad et al’s method 
plus ethylmorphine (Kronstrand et al. 2004). Cordero & Paterson also proposed a 
simultaneous quantification method for opiates, amfetamines, cocainics, diazepam 
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and nordiazepam (14 drugs) with RSD results <25% (inter/intra-day), LOQ 0.1-
0.2ng/mg sample (Cordero, Paterson 2007). They used 0.1M HCl incubation 
overnight at 50°C followed by SPE clean-up, but they adjusted the pH to 7±0.4 with 
phosphate buffer (0.1M, pH7) and potassium hydroxide (1M). Finally Tsanaclis & 
Wicks showed a two steps extraction method for ELISA screening and confirmation 
with GC-MS or GC-MS/MS (Tsanaclis, Wicks 2007). The method was mainly 
incubating the samples in methanol with sonication for ≥6 h. The methanol was then 
decanted into a clean test tube and then the hair sample was digested using sodium 
hydroxide and extracted with a mixture of chloroform:iso-propanol (9:1). The two 
solvent extracts were combined and after solvent evaporation the residues 
reconstituted in phosphate buffer pH7.2. The reconstituted sample extract was 
screened using an ELISA test. Positive samples were cleaned up with SPE and 
derivatized prior to GC-MS confirmation analysis. This method can be used for the 
detection of 28 drugs and metabolites (opiates, cocainics, amfetamines, 
cannabinoids, benzodiazepines and methadones). 
 
1.2.10. Society of hair testing main guidelines 
Please see appendix 8.3.  
 
1.3. Aims and objectives 
 
The application of alternative matrices in analytical toxicology is a novel field of 
study.  The main aim of this research is to investigate the value of these matrices, 
hair, oral fluid and dried blood spots, with the following objectives, as described 
below: 
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 To develop a method to enable the detection and quantification of basic and 
weakly basic drugs in hair simultaneously based on a methanolic solution 
extraction technique and to compare its efficiency with an alkaline digestion 
technique followed by liquid-liquid extraction (LLE) through applying them on 
real hair samples. 
 To investigate incorporation rate of some psychoactive drugs into hair and to 
look into the correlation pattern, if it exists between the daily dose, plateau in 
blood, plateau in oral fluids and plateau in hair. Also, to see if drug half-life 
has an effect on the incorporation. 
 To develop and validate a method to enable the use of the dried blood spots 
(DBS) technique for the analysis and quantification of some of the common 
psychoactive drugs used in psychiatric clinics in Kuwait. Also, to investigate 
the stability of these drugs DBS stored for 6 months in freezers (-20 and -
80°C), refrigerator (4°C) and at room temperature (25°C). Another objective 
was to see the effect of impregnating the cards with sodium fluoride on the 
stability of the drugs. 
 To develop and validate a sensitive and specific method for ethyl glucuronide 
EtG detection and quantitation in hair based on comparing different extraction 
methods (LLE and SPE) and also different separation columns (hydrophilic 
interaction liquid chromatography HILIC and reversed phase column C18). 
 To determine the alcohol prevalence or consumption behaviour among 
Kuwaiti addicts and to draw a picture of addiction trends starting with this 
alcohol focused study. Also, to analyse the data statistically to look for any 
patterns or correlations between alcohol consumption, age and other drugs of 
abuse. 
 To compare the results with self-reports received from addicts and see if they 
are in agreement, in other words, to investigate if addicts tend to reveal their 
alcohol consumption or they try not to. 
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2. Chapter 2 - Analysis of basic drugs in 
human hair 
2.1. Introduction 
Drug analysis in hair has grabbed the attention of toxicology analysts and 
researchers in recent years. This is mainly because it has provided some ability of 
proving drug ingestion when conventional samples could not. Hair differs from other 
traditional biological samples used for human toxicological analysis such as urine, 
blood, liver or oral fluids with its significantly longer detection window (months) 
allowing retrospective investigation and measurement of drug consumption. Hair 
analysis is becoming accepted in many developed countries for substance 
consumption related issues in a wide range of sectors; the medico-legal sector, 
workplace testing, treatment monitoring, schools, forensics, research, insurance 
companies, environmental biomonitoring and driving licensing (Pragst, Balikova 
2006, Kintz 2007a, Kempson, Lombi 2011, Smolders et al. 2009). 
Extraction of drugs from hair is considered one of the most important steps in hair 
analysis. Apart from external drug deposition on hair, drugs are mainly enclosed 
tightly in the hair shaft and to a certain extent maybe bound to proteins, melanin or 
lipids of the cell membrane complex. Therefore, hair matrix type, structure of the 
drug, method and duration of extraction, and solvent used are all important factors 
affecting the final extraction yield (Musshoff, Madea 2007b). 
There are numerous reports of screening strategies published for analysing different 
forensic basic drugs groups. Hypnotic drugs such as benzodiazepines are at the top 
of the list of drug facilitated crimes. These are weak basic drugs and have been 
reported to be extracted from hair by different methods, with phosphate buffers, 
methanol or digestive enzymes (Musshoff, Madea 2007a, Villain et al. 2005, Laloup 
et al. 2005). Other basic drug groups like anti-psychotics, antidepressants and 
amfetamines have frequently been reported to be extracted with alkaline digestion 
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(NaOH) (Couper, McIntyre & Drummer 1995b, Josefsson et al. 2003, Villamor et al. 
2005, Gottardo et al. 2007). However, recently there has been some focus on using 
methanolic solutions as an extraction medium consisting of varying ratios of 
methanol, acetonitrile and formate buffer for extraction of several groups of basic 
drugs simultaneously (Hegstad et al. 2008, Broecker, Herre & Pragst 2011, Nielsen 
et al. 2010). However, the extent of their efficiency has not been examined most of 
the time. 
2.1.1. Liquid chromatography-mass spectrometry 
In the last few decades there has been a huge increase in the use of liquid 
chromatography coupled with mass spectrometric detection that is primarily due to 
the development of suitable interfaces that allowed the liquid mobile phase to enter 
the mass spectrometer with the help of vacuum negative pressure. This successful 
combination of liquid chromatography-mass spectrometry (LC-MS) became almost 
essential in many analytical fields. This instrument was recognized initially as a 
complementary analytical tool to gas chromatography-mass spectrometry (GC-MS) 
for the analysis of non-volatile compounds and high molecular weight compounds. 
However, it been estimated now that more than seventy percent of toxicology 
analysis can be done by this machine (Van Bocxlaer et al. 2000). In addition LC-MS 
has several advantages such as fast running time, normally no derivatization 
required, and optimization of the ionisations and the MS parameters and tuning are 
performed semi-automatically. 
A triple quadrupole mass spectrometer (MS-MS) comprises of two mass analysers 
(Q1 and Q3) separated by a collision cell (Q2). Q1 filters parent or precursor ions 
(ions of interest), while Q3 filters (second mass analyser) product or daughter ions 
which are produced after fragmentation of the parent ions in the collision cell (Q2). 
Ions finally pass into a mass detector and specialist software is used to process the 
data qualitatively and quantitatively. Illustrating figure is shown in appendix 8.4.  
The most common interface used in LC-MS(MS) to carry the analytes from the liquid 
phase to the gas phase is electrospray ionisation (ESI). In electrospray process ions 
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are generated from droplets after spraying of the mobile phase that passes through 
high electric field needle. With the assistant of warm gas (nitrogen) flow droplets 
vaporize and leaves highly charged analyte molecules. The charging of the analytes 
is achieved with nebulizing needle at ground potential surrounded with electrodes 
with a high voltage. The potential difference between the nebuliser and the electrode 
produces a strong electric field that charges the surface of the mobile phase droplets 
(Ho et al. 2003). Illustrating figure is shown in appendix 8.5. 
ESI known as a soft ionisation method, because the amount of energy transferred to 
the analyte during the ionisation process is small. Thus pseudo-molecular ions [M + 
H]+ or [M + H]ˉ will normally be formed and that will lead to a small degree of 
molecular fragmentation or even no fragmentation. So the amount of structural 
information it can reveal will be very scant. On the other hand LC-MS, especially 
with tandem MS/MS, is highly sensitive and very useful quantitatively, as most of the 
total ion count (TIC) relates to one precursor ion in the MS/MS mode. However, it is 
possible as well with this technique to find cluster of charged ions formed between 
the analyte and the solvent (e.g. acetonitrite ACN [M + 42]+ and methanol [M + 32] +) 
or with the adducts (sodium [M + 23] +, potassium [M + 39] + or ammonium [M + 18] 
+). As a result it is advisable to use the protonated or deprotonated pseudomolecular 
ions as precursor ions instead of using cluster ions or adducts as they can cause 
poor reproducibility of the assay. 
Application of LC-ESI-MS/MS is wide and varied. It is been used in chemical and 
drug detection in toxicological, pharmacokinetic, environmental, proteomics and 
therapeutic drug monitoring studies. Most of the analysis of the drugs of abuse is 
carried out currently by LC-MS as well as this research. LC-MS drugs of abuse 
screening methods have been developed and published already (Kintz 2007a, 
Kronstrand et al. 2004, Hegstad et al. 2008). 
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2.2. Hair analysis 
2.2.1. Aim of the study 
In this study the aim was to develop a method to enable the detection and 
quantification of basic and weakly basic drugs in hair simultaneously based on the 
methanolic solution extraction technique and to compare its efficiency with the 
alkaline digestion technique which was followed by liquid-liquid extraction (LLE). 
2.2.2. Materials and reagents 
2.2.2.1. Chemicals  
All chemicals were of HPLC or analytical grade. Methanol, acetonitrile, acetone, 
propanol, methyl-tert-butyl-ether (MTBE), citalopram, clobazam, clonazepam, 
cocaine, codeine, desmethyldiazepam, 3,4-methylenedioxyamfetamine (MDA), 3,4-
methylenedioxy-N-ethylamfetamine (MDEA), 3,4-Methylenedioxymethamfetamine 
(MDMA), midazolam, sulpiride, zaleplon and zolpidem were purchased from Sigma-
Aldrich Co, Dorset UK. 7-aminoclonazepam, amfetamine, amfetamine-D11, 
benzoylecgonine-D8, benzoylecognine, codeine-D3, diazepam, diazepam-D5, 
ecognine methyl ester, medazepam, oxazepam and temazepam were purchased 
from LGC standards, Middlesex UK. Other prescription drug standards were 
supplied from their manufacturer. Deionised water was obtained on site (ELGA 
Limited). Dichloromethane, 7.5M ammonium acetate solution and all consumables 
(tubes, etc) were from VWR International Ltd, Lutterworth UK. The rest of the 
chemicals used in the solutions below were from Sigma-Aldrich Co, Dorset UK. 
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2.2.2.2. Solutions 
Standard solutions 
1000µg/mL or 100µg/mL working standards were made with MS grade methanol of 
each analyte and internal standard. All were stored at -20⁰C and diluted to the 
required concentration prior to the experiment. 
0.1M phosphate solution 
One litre of solution was prepared by dissolving 1.7g of anhydrous disodium 
orthophosphate and 12.14g of sodium dihydrogen orthophosphate monohydrate in 
800mL of de-ionized water. The pH was adjusted to 6 with 1M potassium hydroxide 
and the solution made up to volume with de-ionized water.  
0.1% formic acid (v/v) 
100µL of concentrated formic acid (98/100) was mixed with 99.9mL of de-ionized 
water, mixed well and stored at room temperature. 
Methanolic extraction solution 
60mL of methanol, 10mL of acetonitrile and 30mL of 0.1% formic acid were 
measured into a measuring cylinder, mixed well and stored at room temperature. 
1M NaOH solution 
40g of NaOH (MW 40.0) pellets were measured into a 1000mL volumetric flask and 
made up to the 1000mL mark with de-ionized water. This was mixed thoroughly and 
stored at room temperature. 
2M ammonium acetate 
266.6mL of 7.5M ammonium acetate solution were measured into a 1000mL 
volumetric flask and made up to the 1000mL mark with de-ionized water. This was 
mixed thoroughly and stored at room temperature. 
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2.2.3. Hair preparation 
The decontamination process was by using three washing steps with two solvents 
and one aqueous solution: 0.01M phosphate solution (pH6), dichloromethane and 
propanol/acetone (1:1), used in the respective order. The uncut hair was put in a 
6ml glass tube, then 2mL of the first solution added and vortex mixed for 1 minute. 
After that the solvent was decanted and then the next solvent was added. After the 
last washing step (2mL propanol/acetone) the hair was left to dry at room 
temperature or the process was speeded up with the speed-vac. This 
decontamination method was found to be quick and very efficient when used for 
cleaning some encountered post-mortem hair samples.  
After the hair had dried segments of 0-0.6cm each were cut into small pieces (1–
3mm) with scissors and ideally 25mg were weighed directly, larger segments were 
considered in some cases (e.g. 0-1.5cm). If this was not possible any amount 
between 10 and 80mg was considered and placed into a 2mL glass tube with a 
screw cap. 
2.2.4. Methanolic extraction 
Five hundred µL of the methanolic extraction solution (described earlier) was added 
to the hair in each tube and left in a sonicator for 16 hours at 40°C. In the case of 
calibrators, the required concentrations were made based on adding 25μL of drugs 
standard (e.g. 1µg/mL in methanol) to the calibrators’ tubes containing 25mg blank 
hair (from lab personnel not on any drug for ~1year) each and these 25μL were 
deducted from the extraction solution (475μL). Also 25μL of internal standards 
(bromperidol and the deuterated standards amfetamine-D11, benzoylecgonine-D8, 
codeine-D3 and diazepam-D5) were added as well at a concentration similar to the 
middle calibrator. After centrifugation for 10 minutes the extracted solutions were 
transferred to auto-sampler vials and evaporated to dryness followed by 
reconstitution with 125μL of 25% methanol and filtered with the syringeless mini-
uniprep filters (Whatman GE). Finally 20μL of this filtrate was injected into the LC-
MS/MS system. 
Chapter 2 - Analysis of basic drugs in human hair  
Page 54 of 255 
 
2.2.5. Alkaline digestion 
Twenty five mg of washed blank/patient hair was incubated with 0.5mL of 1M NaOH 
for 3 hours in a water bath (50°C) to allow for digestion of the hair. Samples were 
then extracted after digestion with 2mL MTBE by 30 minutes rotary mixing and 10 
minutes centrifugation. Solvent layers were transferred into clean tubes containing 
150µL 1% formic acid, then mixed on a rotary mixer for 20 minutes and removed 
after 10 minutes of centrifugation by aspiration. From the remaining aqueous layer 
20µL was injected into the LC-MS/MS system. 
2.2.6. Instrumentation and ion identification 
The LC-MS/MS analysis was carried out with an HPLC system consisting of a 
Perkin Elmer PE200 series autosampler, pump and column oven. The MS/MS part 
was a SCIEX API 2000 Triple Quadrupole MS/MS instrument (Applied Biosystems) 
equipped with an electrospray interface (Turbo Ion Spray) set on the positive mode. 
Ion spray voltage was set to 5500V. Nitrogen was used as the nebulizer gas-GS1 
(30psi), auxiliary gas-GS2 (20psi heated to 300°C), curtain gas (20psi) and as the 
CAD gas (set on 3). 
Chromatography was achieved using a C18 column (Altech Alltima C18, 15cm x 
2.1mm, 5μm) maintained at 50°C. The mobile phase consisted of (A) 950mL 
methanol, 50mL de-ionised water, 1mL 2M ammonium acetate and 1mL formic acid 
(98/100) and (B) 998mL de-ionised water, 1mL 2M ammonium acetate and 1mL 
formic acid (98/100). The running of the system was isocratic and the percentage of 
A and B of the mobile phase was kept at 50% of (A) and was pumped at 
0.25mL/min. The output from the column was split 10:1 before entering the mass 
spectrometer. The volume of injection was 20μL. 
Analytes were infused at 0.25mL/minute to the LC-MS/MS system at a 
concentration of 1µg/mL in 50% methanol/2mM ammonium acetate solution. The 
precursor and product ion identification and parameter tuning were completed by 
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automatic and manual tuning. Optimum tuning parameters, precursor and product 
quantitation ions are shown in Table 3. 
2.2.6.1. Ion Identification results 
Table 3: Optimized MRM and MS/MS parameters for analytes and internal standards 
Analyte Q1 (m/z) 
Q3 
(m/z) Internal Standard 
Retention 
Time 
(min) 
DP 
(V) 
FP 
(V) 
EP 
(V) 
CE 
(V) 
CXP 
(V) 
7-Aminoclonazepam 285.92 120.94 Diazepam_D5 2.9 51 370 10.5 41 2.0 
Alprazolam 308.98 280.84 Diazepam_D5 11.2 71 240 10.5 35 4.0 
Amfetamine 135.99 91.15 Amfetamine_D11 2.7 11 340 5.5 21 8.9 
Amfetamine_D11 147.29 98.20 - 2.6 36 360 4.0 25 12.0 
Amisulpiride 370.05 242.07 Diazepam_D5 2.2 51 370 10.5 37 10.0 
Amlodipine 408.90 237.90 Bromperidol 8.5 35 330 3.6 35 10.0 
Aripiprazole 448.23 176.20 Bromperidol 13.6 76 370 6.5 43 2.0 
Benzoylecgonine 289.92 168.04 Benzoylecgonine_D8 3.4 26 350 10.0 27 6.5 
Benzoylecgonine_D8 298.15 171.10 - 3.3 20 200 10.0 30 6.6 
Bromperidol 420.17 123.20 - 6.3 66 370 8.5 59 0.0 
Carbamazepine 237.02 194.06 Diazepam_D5 7.3 56 290 10.5 29 4.0 
Chlordiazepoxide 299.98 227.03 Diazepam_D5 6.8 56 170 10.5 35 4.0 
Citalopram 325.05 109.14 Diazepam_D5 4.3 61 170 10.5 37 2.0 
Clobazam 300.97 259.18 Diazepam_D5 9.1 56 370 10.5 31 4.0 
Clonazepam 315.91 269.98 Diazepam_D5 7.5 66 250 10.5 37 4.0 
Cocaine 303.92 182.04 Benzoylecgonine_D8 3.2 26 350 10.0 27 6.8 
Codeine 300.09 165.00 Codeine_D3 2.2 26 350 10.5 63 12.0 
Codeine_D3 303.00 165.00 - 2.2 31 370 10.5 63 16.0 
Dehydroaripiprazole 446.02 284.90 Bromperidol 11.9 76 350 10.0 33 8.0 
Desmethyldiazepam 270.97 140.02 Diazepam_D5 14.1 66 350 8.5 41 6.0 
Diazepam 284.98 193.05 Diazepam_D5 18.1 46 350 8.5 45 8.0 
Diazepam_D5 290.02 198.04 - 18.1 46 330 8.5 43 4.0 
Ecgonine M.Ester 200.07 182.10 Benzoylecgonine_D8 2.0 51 340 5.5 25 28.0 
Lorazepam 320.86 274.89 Diazepam_D5 13.3 46 360 10.5 33 6.0 
Lormetazepam 334.89 288.87 Diazepam_D5 13.6 46 280 10.5 31 6.0 
MDA 180.10 105.10 Amfetamine_D11 2.6 26 340 4.5 31 14.0 
MDEA 208.11 163.10 Amfetamine_D11 2.7 36 350 6.0 19 24.0 
MDMA 194.22 163.10 Amfetamine_D11 2.5 36 360 6.0 17 8.0 
Medazepam 270.99 91.00 Diazepam_D5 5.5 56 350 10.5 49 2.0 
Midazolam 325.95 290.89 Diazepam_D5 5.6 81 270 10.5 39 6.0 
Mirtazapine 265.92 195.11 Bromperidol 3.4 36 350 8.5 35 8.0 
Nitrazepam 282.01 235.89 Diazepam_D5 7.4 66 370 10.5 33 4.0 
OH-risperidone 427.11 207.09 Bromperidol 3.6 46 360 7.5 39 8.0 
Oxazepam 286.96 240.89 Diazepam_D5 10.2 96 350 8.5 35 8.0 
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Analyte Q1 (m/z) 
Q3 
(m/z) Internal Standard 
Retention 
Time 
(min) 
DP 
(V) 
FP 
(V) 
EP 
(V) 
CE 
(V) 
CXP 
(V) 
Phenazepam 350.79 206.04 Diazepam_D5 15.3 61 350 8.0 49 24.0 
Quetiapine 384.22 253.24 Bromperidol 7.2 76 350 10.5 31 12.8 
Risperidone 411.18 191.05 Bromperidol 4.5 51 120 10.5 39 11.3 
Sulpiride 342.02 213.90 Bromperidol 2.1 41 370 10.0 51 24.0 
Temazepam 300.99 255.03 Diazepam_D5 12.4 41 270 8.5 33 10.0 
Zaleplon 305.92 235.96 Diazepam_D5 5.5 56 350 8.5 39 8.1 
Zolpidem 308.06 234.93 Diazepam_D5 3.2 66 270 10.5 49 4.0 
Q1=precursor ion, Q3=product ion Q1=precursor ion, Q3=product ion, DP = declustering potential, FP = focusing 
potential, EP = entrance potential, CE = collision energy, CXP = collision cell exit potential 
 
2.2.7. Methods and results with partial validation for 
selected analytes  
2.2.7.1. Comparison of Mini-Uniprep filter media 
Three filter materials were compared by using spiked blank hair samples at 
concentrations of 0.5ng/mg hair. 25mg of blank hair were weighed out in glass 
tubes. Then the whole extraction/incubation method was applied to all the samples. 
The three materials were 0.45µm pore size glass microfiber (GMF), 0.2µm pore size 
polytetrafluroethylene (PTFE) and 0.2µm pore size polyvinylidenefluoride (PVDF) 
used in manufacturing Whatman Mini-UniPrep Syringeless Filters. The filters 
efficiency was calculated by comparing the percentage of extraction recovery 
through their peak area ratio of product ion/external standard for each drug after 
filtration. 
Table 4 shows clearly that the PTFE filter medium has the greatest recovery 
(mean=100%) of all the analytes while the GMF and PVDF filters (mean=89 and 
72%, respectively) reduced significantly the response of amisulpride and citalopram. 
Also the responses of medazepam, midazolam and zolpidem were considerably 
reduced by the PVDF filter. 
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Table 4: Mini-UniPrep filter media: comparison of results for % recovery of 0.5ng/mg spiked analytes 
Analyte GMF PTFE PVDF 
7-Aminoclonazepam 114 94 93 
Alprazolam 100 98 101 
Amisulpiride 7 92 21 
Carbamazepine 108 98 94 
Chlordiazepoxide 116 99 84 
Citalopram 7 113 <1 
Clobazam 106 100 94 
Clonazepam 103 104 93 
Desmethyldiazepam 99 100 101 
Diazepam 103 99 98 
Lorazepam 104 97 99 
Lormetazepam 109 96 94 
Medazepam 86 100 2 
Midazolam 59 104 25 
Nitrazepam 109 97 93 
Oxazepam 105 102 92 
Phenazepam 105 103 92 
Temazepam 100 101 99 
Zaleplon 106 96 98 
Zolpidem 100 96 18 
Mean 92.3 99.5 78.5 
      GMF= Glass Microfiber, PTFE= Polytetrafluroethylene, PVDF= Polyvinylidenefluoride 
2.2.7.2. Efficiency of the selected filter medium (PTFE) 
To further check the efficiency of PTFE media filters two unextracted standards 
were prepared at the same concentration in the mobile phase and submitted to the 
LC-MS/MS with another two unextracted standards but filtered with PTFE Mini-
UniPrep filters. Filter efficiency was calculated as the percentage of total extraction 
recovery by dividing the filtered over the unfiltered standards (n=3). Also blank 
samples (mobile phase) filtered and unfiltered were run in conjunction to see if any 
interfering peaks eluted from the filter.  
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2.2.7.2.1. PTFE filter results  
Interestingly, as seen in Table 5 most of the drugs showed good recoveries when 
repeating the experiment with PTFE filtered standards in addition to blank standards 
and comparing them against the unfiltered standards except for medazepam and 
citalopram. Their recoveries were reduced by almost 50%. Also, no eluting peaks 
were found in any of the drugs’ detection windows.  
 
Table 5: Mini-UniPrep filters with PTFE media comparison results for 0.5 ng/mg benzodiazepine 
standards (n=2) 
Analyte Blank Blank-Filtered Filtered Standard 
7-Aminoclonazepam 0 0 122.1 
Alprazolam 0 0 116.2 
Amisulpiride 0 0 97.1 
Carbamazepine 0 0 127.7 
Chlordiazepoxide 0 0 112.1 
Citalopram 0 0 54.4 
Clobazam 0 0 115.3 
Clonazepam 0 0 132.3 
Desmethyldiazepam 0 0 97.3 
Diazepam 0 0 89.5 
Lorazepam 0 0 125.4 
Lormetazepam 0 0 94.7 
Medazepam 0 0 30.4 
Midazolam 0 0 84.2 
Nitrazepam 0 0 128.2 
Oxazepam 0 0 108.9 
Phenazepam 0 0 85.9 
Temazepam 0 0 115.6 
Zaleplon 0 0 129 
Zolpidem 0 0 107.3 
Mean 0 0 101.6 
PTFE= Polytetrafluroethylene 
2.2.7.3. Linearity 
The linearity study reflects the relationship between change of spiked analyte 
concentration and detector response to that change (Hartmann et al. 1998). It was 
attained by spiking hair samples with 50, 75, 100, 500, 1000 and 2000pg/mg of each 
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analyte. The linear correlation coefficients (r2) values were better than 0.99 for all 
analytes. 
2.2.7.4. LOD and LOQ 
Limit of detection and limit of quantification were assessed by spiking blank hair with 
the analytes in decreasing concentrations. The LOD and LOQ were calculated at a 
signal to noise ratio of 3 and 10, respectively. LOD values for all analytes were 0.5–
23pg/mg and LOQ values were 1.7–76.7pg/mg (Table 7). 
2.2.7.5. Selectivity 
Selectivity in drug analysis is the ability of an analytical method to differentiate and 
quantify the analyte of interest in the presence of other components in the sample 
(Peters, Drummer & Musshoff 2007). In order to achieve that, a low standard 
(0.1ng/mg) of each drug from the group was injected individually into the LC-MS/MS 
system and all the other drug detection windows and retention times were observed 
to see if there were any interfering peaks or false positive results that might appear 
in the same retention time and same window as the injected analyte. No 
interference was found in the same detection window at the retention times for any 
of the analytes. Also drug-free hair samples showed no false positive results. 
2.2.7.6. Matrix effect 
The matrix effect (ME) is basically the ion suppression or enhancement of the 
analyte peak caused by co-eluting compounds from the biological matrix (urine, 
blood, hair, etc). The aim of this experiment was to acquire more accurate data on 
the extent of matrix influence on the results when matrices come from different types 
of hair. As proposed by Matuszewski et al the ME was assessed by comparing the 
mean peak area of product ion of extracted drug-free hair samples from 5 different 
sources (black, baby-brown, black dyed, white and blonde) spiked with 0.2ng/mg 
low standard solution following filtration (i.e. after extraction/incubation) with the 
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mean peak area of product ion of neat unextracted standards prepared in the mobile 
phase (Matuszewski, Constanzer & Chavez-Eng 2003). The percentage of the ME 
was calculated by dividing the mean of the extracted samples by the mean of 
unextracted ones according to Equation 1. 
Equation 1  
ۻ۳	(%) = ܛܘܑܓ܍܌	܉܎ܜ܍ܚ	ܑܖ܋ܝ܊܉ܜܑܗܖ
ܝܖ܍ܠܜܚ܉܋ܜ܍܌	ܛܜ܉ܖ܌܉ܚ܌
   X 100 
This percentage represents the absolute ME (both ion suppression and ion 
enhancement).  
The ME results shown in Table 6 indicate that there was no significant ion 
suppression or enhancement affecting the analytes, except with amisulpiride and 
the 7-amino metabolite of clonazepam. Some of the analytes such as diazepam and 
clobazepam showed slight ion enhancement, but the rest of the drugs were within 
91.4 - 110.2% ME. Also the %CV was in the range of 1.1 – 12.1% showing a good 
agreement level between the different hair samples. 
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Table 6: Matrix effect (ME) results for 0.2ng/mg hair samples spiked with the analytes (n=5) 
Analyte Black Brown Dyed White Blond %ME %CV 
7-Aminoclonazepam 91 92 65 62 75 77 18 
Alprazolam 103 104 93 92 91 97 7 
Amisulpiride 46 52 58 28 62 49 27 
Carbamazepine 120 106 96 98 98 103 10 
Chlordiazepoxide 109 104 93 95 94 99 7 
Citalopram 97 120 99 99 109 105 9 
Clobazam 121 121 108 112 110 114 5 
Clonazepam 112 99 95 93 95 99 8 
Desmethyldiazepam 118 111 107 100 106 109 6 
Diazepam 117 120 113 113 116 116 3 
Lorazepam 118 112 100 102 102 98 10 
Lormetazepam 113 114 106 110 108 107 7 
Medazepam 98 116 96 102 94 110 3 
Midazolam 100 109 95 93 96 101 8 
Nitrazepam 112 105 95 96 100 99 6 
Oxazepam 113 111 97 97 100 101 7 
Phenazepam 117 114 92 97 98 104 1 
Temazepam 119 115 109 109 109 104 7 
Zaleplon 99 99 87 86 87 112 4 
Zolpidem 95 98 91 92 94 91 8 
Mean 106 106 95 94 97 100 8 
2.2.7.7. Absolute recovery with methanolic incubation 
Recoveries were estimated by determining peak areas of analytes obtained when 
the drugs spiked with blank hair (in extraction solution) at three concentrations 0.5, 
1, and 2ng/mg (n=3) were compared with unextracted/unfiltered standards. 
Therefore, this recovery takes into account all the extraction steps including 
filtration, incubation and matrix effect (absolute). The recovery was calculated as a 
percentage by dividing the average peak area ratio of the extracted standards over 
the average peak area ratio of the unextracted standards and multiplied by 100. 
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The results in Table 7 show that all the analytes had good recoveries (> 58%) at all 
three concentrations with %CV below 13.4%, except for three analytes which gave 
low recoveries (12.9 - 29.8%) and high %CV (< 34.7%). 
Table 7: Linearity, LOD, LOQ and Absolute Recovery (RE%) results for 0.5, 1 and 2ng/mg of 
analytes (n=3) 
Absolute Recovery (RE%) 
Analyte Linearity (r2) 
LOD 
pg/mg 
LOQ 
pg/mg 
0.5 
ng/mg %CV 
1 
ng/mg %CV 
2 
ng/mg %CV 
%CV 
for 3 
Conc. 
7-Aminoclonazepam 0.991 2.5 8.3 67.4 7.3 62.6 5.6 64.2 1.9 3.8% 
Alprazolam 0.997 1.5 5.0 98.3 0.8 93.7 1.3 93.1 0.7 3.0% 
Amisulpiride 0.997 1.0 3.3 28.4 3.4 29.0 6.0 29.8 2.6 2.4% 
Carbamazepine 0.996 1.3 4.3 98.0 2.7 93.0 1.6 94.0 1.8 2.8% 
Chlordiazepoxide 0.999 2.6 8.7 78.9 4.1 75.6 6.8 72.5 4.0 4.2% 
Citalopram 0.991 4.8 16.0 12.9 11.3 16.5 34.7 13.9 2.5 12.9% 
Clobazam 0.999 1.2 4.0 103.8 1.6 98.7 2.5 96.8 2.1 3.6% 
Clonazepam 0.999 2.2 7.3 94.6 5.0 89.3 5.5 90.7 0.9 3.0% 
Desmethyldiazepam 0.999 12.0 40.0 98.4 0.2 92.8 4.8 91.3 3.9 4.0% 
Diazepam 0.999 2.6 8.7 87.6 3.8 87.6 9.9 82.4 3.6 3.5% 
Lorazepam 0.996 2.7 9.0 79.9 4.2 72.4 6.3 75.3 6.0 5.0% 
Lormetazepam 0.995 3.4 11.3 101.0 7.4 94.8 4.8 94.3 4.7 3.9% 
Medazepam 0.996 7.0 23.3 104.4 3.9 103.1 6.3 94.8 2.0 5.2% 
Midazolam 0.998 1.0 3.3 60.4 13.4 57.8 6.6 60.1 6.4 2.4% 
Nitrazepam 0.998 6.5 21.7 102.0 2.0 98.1 3.2 100.3 4.3 2.0% 
Oxazepam 0.996 23.0 76.7 118.8 5.0 100.1 2.3 100.1 4.2 10.2% 
Phenazepam 0.998 6.5 21.7 90.2 5.9 79.0 6.2 81.1 6.6 7.1% 
Temazepam 0.999 2.6 8.7 95.8 0.4 93.1 2.1 91.8 2.8 2.2% 
Zaleplon 0.998 1.3 4.3 80.5 1.4 77.7 2.8 78.7 1.8 1.8% 
Zolpidem 0.999 0.5 1.7 73.5 4.0 71.2 2.2 68.3 3.1 3.7% 
 
2.2.7.8. Stability during methanolic extraction 
All analytes were prepared at 0.5µg/mL (~=ng/mg) of the extraction solution 
(mentioned in solutions section) and incubated/sonicated with slightly harsher 
conditions at 50⁰C for 18h without the blank hair. Then the mean peak area ratio of 
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product ion/internal standard was compared with the mean peak area ratio of 
product ion/internal standard of unextracted/unincubated standards prepared in 25% 
MeOH at the same concentration (n=3).  
2.2.7.9. Stability/recovery with alkaline digestion 
Extraction of hair with various solvents following alkaline digestion has been widely 
mentioned in many publications (Villamor et al. 2005, Pelander et al. 2008, Villain 
2004, Stanaszek, Piekoszewski 2004). In order to investigate whether the proposed 
method has any advantages over the alkaline digestion method, the first step was to 
check how stable the analytes would be during the incubation/extraction with 
NaOH/MTBE. Twenty five mg of blank/washed hair was incubated for 3 hours at 
50°C with the analytes at a concentration of 1ng/mg and mixed with 0.5mL 1M 
NaOH. Extraction was with 2mL of MTBE on an orbital shaker for 30 minutes 
followed with back extraction with 150µL of 1% formic acid. 20µL were injected into 
the LC-MS/MS system.    
 
The stability results shown in Table 8 indicate that almost all the analytes are stable 
under the extraction/incubation conditions of the methanolic method. The least 
stable analyte was oxazepam with 56.1% recovery. The average recovery was 
89.6% with a coefficient of variation of 4.2%. The stability of the analytes under 
alkaline conditions was much lower with an average of 51.7%. 
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Table 8: Stability of the analytes after sonication/incubation at 50⁰C/18h (n=3) and after extraction 
and digestion with 1M NaOH at 50⁰C/3h (n=2) 
Analyte 
% Stability with 
methanolic 
extraction 
% CV % Stability with NaOH digestion %CV 
7-Aminoclonazepam 98.3 3 19.7 36 
Alprazolam 97.5 2 67.2 8 
Amisulpiride 93.6 4 25.0 41 
Carbamazepine 101.8 3 66.3 2 
Chlordiazepoxide 70.3 9 83.6 19 
Citalopram 101.3 7 28.3 37 
Clobazam 104.5 4 61.3 7 
Clonazepam 92.3 0 50.4 7 
Desmethyldiazepam 76.3 4 76.4 28 
Diazepam 98.5 1 51.1 16 
Lorazepam 64.2 4 52.6 19 
Lormetazepam 98.2 1 60.7 13 
Medazepam 100.6 6 30.5 5 
Midazolam 100.5 4 32.6 12 
Nitrazepam 73.3 6 49.2 14 
Oxazepam 56.1 8 54.4 30 
Phenazepam 86.1 5 75.6 41 
Temazepam 81.1 1 60.4 20 
Zaleplon 97.7 7 36.7 12 
Zolpidem 98.9 4 52.0 15 
Mean 89.6 4.2 51.7 19.04 
 
 
Figure 8: Stability of analytes during methanolic and alkaline conditions 
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2.2.8. Real samples (methanolic versus alkaline 
extraction) 
The methanolic method was applied to 10 cases, one of them postmortem. Hair 
samples were taken from the posterior vertex region of the scalp. Nine of these 
cases were patients taking doses of different classes of drugs. Seven of the nine 
were addicts under rehabilitation. 
About a 0.6 cm segment from the root end (proximal) of each sample was 
decontaminated and extracted by the methanolic method. However, there was an 
additional step added to the analysis of those cases. After full incubation and 
extraction steps, hair sample remains in the tubes were not discarded. Instead they 
were re-extracted with the alkaline digestion method described earlier. The 
measurement was based on one-point calibration (cut-off). 
Case 1 NR   
Age: 32yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Drug name Strength Daily dose 
Duration of 
use Addiction history 
Quetiapine 400mg 1600mg 07-26May09 Benzodiazepines 
Valproic acid 500mg 2000mg 07-26May09  
Atrovastatin 20mg 20mg 07-26May09  
Aspirin 100mg 100mg 07-26May09  
 
Case 2 MD   
Age: 28yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Drug 
name Strength 
Daily 
dose 
Duration of 
use Addiction history 
Fenetylline
* 50mg ~300mg 1year Amfetamines 
   *Fenetylline is metabolized in the body to amfetamine and theophylline. 
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Case 3 AZ   
Age: 34yrs Hair Colour: Dark Brown  Sample Collection Date: 26 May 09 
Drug name Strength Daily dose Duration of use 
Addiction 
history 
Quetiapine 400mg 800mg 11-12,17-26May09 Benzodiazepines 
Valproic acid 500mg 1000mg 17-26May09 Cannabis 
Chlordiazepoxide 10mg 30mg 11-15May09 Alcohol (1/2 bottle/day of whisky) 
Sulpiride 300mg 600mg 12-17May09  
 
Case 4 ED   
Age: 45yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Drug name Strength Daily dose 
Duration of 
use Addiction history 
Risperidone 2mg 4mg 07-26May09 Poly-Addict 
Procyclidine 5mg 10mg 07-26May09  
 
Case 5 MN   
Age: 38yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Drug name Strength Daily dose 
Duration of 
use Addiction history 
Risperidone 2mg 2mg 03-26May09 Poly-Addict 
Mirtazapine 30mg 30mg 03-20May09  
 
Case 6 HR   
Age: 37yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Drug name Strength Daily dose 
Duration of 
use Addiction history 
Quetiapine 200mg 400mg 20-26May09 Benzodiazepines 
Mirtazapine 30mg 30mg 20-26May09  
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Case 7 AR   
Age: 35yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Addiction Drug Strength Daily dose 
Duration of 
use 
Addiction 
history 
Heroin 1-2g 1-2g April07-April08 Poly-Addict 
Cannabis cigarette - 1-10 April07-April08  
Cocaine 1g 1g April07-April08  
Flunitrazepam 2mg 4mg April07-April08  
Alprazolam 0.5mg 1mg April07-April08  
Diazepam 10mg 20mg April07-April08  
Amfetamines  - Rarely April07-April08  
 
Case 8 MQ   
Age: 44yrs Hair Colour: Black  Sample Collection Date: 26 May 09 
Drug name Strength Daily dose 
Duration of 
use Addiction history 
Mirtazapine 30mg 30mg 14-26May09 Benzodiazepines 
Aripiprazole 15mg 15mg 14-26May09  
 
Case 9 DH   
Age: 66yrs Hair Colour: Grey  Sample Collection Date: July 09 
Drug 
name Strength 
Daily 
dose 
Duration of 
use Other Drug 
Amlodipine 5-10mg 10mg >5years - 
 
Case 10 SK   
Age: 35yrs Hair Colour: Brown  Sample Collection Date: May 08 
Addiction Drug Strength Daily dose 
Duration of 
use Addiction history 
Cannabis  -  - - Cannabis  
Cocaine  -  -  - Cocaine 
Amfetamines  -  -  - Amfetamines  
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Table 9: Real samples (cases): comparison of results 
Case Hair Colour 
Hair 
Segments MeOH/ACN/FA Incubation NaOH Digestion 
1 NR Black 20.3mg (0.6cm) 0.134ng/mg Codeine 2.53ng/mg Quetiapine 
0.763ng/mg Codeine 
31.7ng/mg Quetiapine 
2 MD Black 17.5mg (0.6cm) 42.3ng/mg Amfetamine 0.173ng/mg Amfetamine 
3 AZ Dark Brown 22.6mg (0.6cm) 
19.1ng/mg Amfetamine 
0.88ng/mg Sulpiride 
3.41ng/mg Quetiapine 
0.123ng/mg Amfetamine 
Negative Sulpiride 
11.46ng/mg Quetiapine 
4 ED Black 17.4mg (0.6cm) 
13.5ng/mg Amfetamine 
0.019ng/mg Mirtazapine 
0.039ng/mg OH-risperidone 
0.059ng/mg Risperidone 
0.036ng/mg Amfetamine 
0.010ng/mg Mirtazapine 
0.035ng/mg OH-risperidone 
0.18ng/mg Risperidone 
5 MN Black 24.5mg (0.6cm) 
16ng/mg Mirtazapine 
0.138ng/mg OH-risperidone 
1.37ng/mg Risperidone 
40ng/mg Mirtazapine 
0.134ng/mg OH-risperidone 
4.1ng/mg Risperidone 
6 HR Black 19.9mg (1.5cm) 
14.8ng/mg Mirtazapine 
1.26pg/mg Risperidone 
6.58ng/mg Quetiapine 
43.2ng/mg Mirtazapine 
0.022ng/mg Risperidone 
33ng/mg Quetiapine 
7 AR Black 33.6mg (0.6cm) 0.08ng/mg Mirtazapine 0.016ng/mg Amfetamine 
0.3ng/mg Mirtazapine 
Negative Amfetamine 
8 MQ Black 33.4mg (0.6cm) 
3.7ng/mg Amfetamine 
0.067ng/mg Codeine 
18.9ng/mg Mirtazapine 
Negative Aripiprazole 
Negative Dehydroaripiprazole 
0.015ng/mg Amfetamine 
1.225ng/mg Codeine 
41.4ng/mg Mirtazapine 
Positive Aripiprazole 
Positive Dehydroaripiprazole 
9 DH Grey 80mg (~1.5cm) 0.015ng/mg Amlodipine Negative Amlodipine 
10 
SK* Dark Brown 
27mg (1cm) 1st  
4.52ng/mg Amfetamine 
6.46ng/mg MDMA 
0.258ng/mg MDA 
0.143ng/mg MDEA 
2.68ng/mg Cocaine 
28.42ng/mg Benzoylecognine 
0.644ng/mg Ecognine methyl ester 
35mg (2cm) 2nd  
4.75ng/mg Amfetamine 
6.72ng/mg MDMA 
0.272ng/mg MDA 
0.147ng/mg MDEA 
1.434ng/mg Cocaine 
27.83ng/mg Benzoylecognine 
0.165ng/mg Ecognine methyl ester 
* Results of this subject are from combined method (methanolic and alkaline extraction) 
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Figure 9: Real samples: comparison of results for methanolic and alkaline extraction (Drug-Case No.) 
 
2.3. Discussion and conclusion 
The development of the proposed basic drugs extraction method was based on 
previous studies showing that methanolic and aqueous solutions are capable of 
extracting drugs from hair samples (Kintz 2007a). However, a comparison between 
this extraction solution and the digestion with NaOH was not probably suggested in 
this specified way, particularly with general basic drugs screening. Therefore, the 
mixture of methanol, 0.01M formic acid and acetonitrile (methanolic solution) was 
proposed to extract basic drugs. Methanol and 0.01M formic acid are protic solvents 
and capable of swelling the hair and attracting/ionizing basic drugs entrapped inside 
the hair shaft, at least theoretically. Acetonitrile was added in a small amount (10%) 
as it was recommended by some articles (Kronstrand et al. 2004, Hegstad et al. 
2008). 
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The first early recovery experiments with the methanolic method produced extracts 
that were turbid in colour which brought about the necessity of adding a filtration 
step to the method and checking the effect of these filters on the drugs’ recovery. 
Mini-UniPrep filters were chosen as they are syringeless, simple and fast. As these 
filters come in different materials, a comparison study was carried out and showed 
that PTFE based filters gave the highest recoveries for the analytes. 
It was seen from the stability results that digestion with NaOH reduces the stability 
of most of the analytes whereas methanolic incubation has no such effect on 
stability as the great majority of drugs showed >90% stability with or without blank 
hair.  
Some method validation steps have been carried out on the methanolic method, 
such as recovery, LOD/LOQ, matrix effect and selectivity. Absolute recovery 
experiments showed that all the analytes have a recovery ranging between 59.4 and 
106.3% with a CV from 0.2 to 13.4% after excluding the results of four drugs. 
Amisulpiride and citalopram gave low recoveries (14.4 - 29.1%, CV 2.5-34.7%). 
During the matrix effect study five different sources of hair have been incorporated 
(different colours and ethnicities). Results showed that all the drugs have ME 
ranging between 91.4 and 115.6% (CV 1.1 – 12.1%) except 7-aminoclonazepam 
and amisulpiride (ME 77 and 49.1%, CV 18.4 and 26.8%, respectively). The 
selectivity study also showed no major problem affecting the method selectivity as 
no analyte eluted in the same retention time and window of the other analytes and 
there were no false positives from blank hair. 
Last but not least, analysis of authentic hair samples from a group of subjects taking 
basic or weak basic drugs revealed the usefulness of the proposed method at least 
for the detection of basic drugs in hair. To further examine the extent of extraction 
the same samples were digested with 1M NaOH after the methanolic extraction to 
compare the extractability of both methods on the administered drugs by using the 
exact same samples. Results revealed that the methanolic method was able to 
extract most of the investigated drugs from hair samples, but the downside about it 
was the fact that it only extracted part of the incorporated drug in hair. In addition, 
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this part or this percentage of the incorporated drug varied between the investigated 
compounds. Results showed that 100 to 50.7% of found amfetamine, amlodipine, 
sulpiride and 9-OH-risperidone were extracted by the methanolic method, whereas, 
the percentage of extraction for the rest of the investigated drugs was from 0 to 
31.3% as shown in Figure 9, with the exception of mirtazapine which gave a high 
percentage of extraction (65%) in one subject out of five. These results suggest that 
the incorporated drugs in hair need either complete digestion of the hair samples or 
maybe powdering the samples to ensure complete release of the entrapped 
compounds. Although some drugs have been extracted or revealed only by the 
methanolic method without digestion, like sulpiride and amlodipine, it does not mean 
that the percentage of recovery was really 100%. It is likely that these drugs were 
not stable under NaOH digestion which may led to their degradation and 
disappearance. High pH possibly has caused hydrolysis to both amlodipine’s ester 
moiety and sulpiride’s amide type link.  
This way of comparison between alkaline and methanolic methods is different from 
the direct comparison with two matching hair samples. It was design specifically this 
way to investigate the amount of residual drug left behind from the methanolic 
extraction, especially because not all drugs are stable under alkaline digestion and 
would not be detected if only alkaline digestion was used.   
With regard to the analysis of hair washes, it was not been done due to a number of 
reasons. The washes are three per sample and that will add up a large amount of 
samples to be analysed and instrument time was extremely limited. Also the 
research was focusing mainly on drug incorporated from blood so external 
contamination or incorporation from sebum or sweat were beyond the scope of the 
research. Lastly, extraction of drugs through washes is very unlikely because each 
washing step takes less than 1 min.    
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Amfetamine (136/91) 
 
Amfetamine-D11 
(147/98) 
 
Aripiprazole (448/176) 
 
Bromperidol-IS (420/165) 
 
Codeine (300/165) 
 
Codeine-D3 (303/165) 
 
Dehydroaripiprazole 
(446/285) 
 
Mirtazapine (266/195) 
 
OH-risperidone (427/207) 
 
Quetiapine (384/253) 
 
Risperidone (411/191) 
 
Sulpiride (342/214) 
Figure 10: Some of the real sample chromatograms, between brackets are precursor ion/product ion 
 
In conclusion, the methanolic method is capable of extracting most basic drugs in 
hair samples but only part of the total incorporated drug. Therefore, these results 
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suggest that a combination of both methods (methanolic and alkaline extractions) in 
hair sample processing for the detection of basic and weak basic drugs seems to 
provide better extraction yield than either method alone. However, not all basic 
drugs are stable to alkaline digestion. A further study with more real samples was 
needed and preferably in comparison with other hair extraction techniques, such as 
powdering the hair and other digestion methods.         
Limitations 
Ideally, the method should be applied to more samples especially from subjects 
taking the same drugs as the drugs used in the method development. Unfortunately, 
only those patients who were studied agreed to participate. Also, the access time on 
the LC-MS/MS was very limited and optimization of every variable was not feasible. 
Moreover, the method is intended to analyse basic drugs in general and basic drugs 
are very common so it is almost impossible to include all of them. Alkaline digestion 
has limited application to only analytes stable under basic conditions, while 
methanolic extraction showed partial extraction ability even after 18 hours of 
incubation. Also due to limited access time to LC-MS/MS analysis of hair washes 
could not be included in the study. Finally, in this study MS/MS data were based on 
only one product ion transition, which should be acceptable for clinical purposes, 
compared to that of forensic purposes, where a minimum of two is required.   In the 
clinic, the drug therapy will be known and hence, to monitor patient compliance, it 
may be argued that one major ion transition will suffice, simplifying data analysis, 
especially for those not so skilled in mass spectrometry.  By contrast, in forensic 
toxicology, whether a particular drug has been administered or not, is often 
unknown, and once a drug (or its metabolites) is detected in a biological matrix, 
confirmatory analysis is required so that the results can withstand the scrutiny of a 
legal challenge, necessitating the use of several ion transitions (or full scan).
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3. Chapter 3 - Dose/concentration 
relationships in hair, blood and oral fluids 
from patients under controlled 
psychoactive drug administration 
3.1. Introduction 
As mentioned in the hair analysis review given in chapter 1, this bioanalytical tool is 
getting more interest and attention by the toxicology(ists) community particularly as 
it has shown proven histories of single and chronic drug consumption (Kintz 2007a). 
However, this bio-monitoring tool lacks some features such as the ability of its 
results to reflect or estimate the relative amount of drug consumption or a clear 
association with blood drug concentration. This in fact is due to a number of 
reasons, one of them is the lack of extensive research in this area, principally 
controlled administration studies. Other reasons/factors are the effects of hair 
treatments, hair colour, growth rate, external contamination and the heterogeneity of 
samples.  
However, in the case of the other biological matrices like, for example oral fluids, 
drug level correlation with blood does exist at least for some investigated drugs such 
as voriconazole (correlation, r=0.95), chloramphenicol (r=0.8), ampicillin (r=0.78), 
lacosamide (r=0.8), alcohol (r=0.88), salicylic acid (r=0.94), theophylline (r=0.86) 
(Michael et al. 2010, Koup et al. 1979, Akimoto et al. 1985, Greenaway et al. 2010, 
Degutis et al. 2004, Levy et al. 1980, Tewthanom et al. 2005). On the other hand, in 
case of urine it is a completely different story as the drug concentration there is 
significantly affected by a number of variables; pH of the urine, creatinine clearance, 
frequency of bladder voiding, water consumption, diabetes, etc (Jones, Karlsson 
2005). Therefore, drug concentration in urine would possibly have low correlation 
with blood concentration and mostly used as an indication of recent drug use.  
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From the limitations mentioned earlier not all drugs are suitable for detection by hair 
testing although the majority is. The more basic and lipophilic the drug the higher the 
concentration will be found in hair. Also the darker the hair the more of the basic 
drug will be incorporated (Pragst, Balikova 2006). All these characteristics have 
been taken into consideration in this study as most of the patients have very dark 
hair and the consumed drugs are basic drugs. In addition to that this study has the 
advantage of having closely monitored administration of the drugs unlike other 
published studies which relied on possibly inaccurate self-reported administration. 
The choice of specimen type for the present study (whole blood, oral fluids and hair) 
was based on the following facts: 
Whole blood rather than plasma or serum because in a fairly recent bioanalytical 
meeting scientists highlighted that it could be more accurate to measure drug 
concentrations in all blood components (whole blood) as most drugs do not solely 
bind to plasma proteins. In addition, the advances in analytical techniques and the 
instrumentation ruled out the need to separate the plasma to get cleaner samples or 
reduce the noise level. Moreover, when measuring plasma it is important to relate it 
back to blood drug concentration as well as all the pharmacokinetic parameters, 
whereas in whole blood this is not the case (Beaumont 2010). 
Oral fluids and hair are non-invasive promising alternative matrices. Oral fluids have 
several advantages over the conventional samples (blood and urine), such as the 
ease of collection and multiple sampling especially with the new collection 
kits/devices available, providing less risk of infection compared to blood 
venipuncture, less prone to tampering, much cleaner sample than blood and urine 
and so may require a shorter extraction time.  
Results of some of the previous hair to dose or hair to blood correlation investigation 
studies in controlled administration settings showed that generally the correlations 
found were weaker in case of dose to hair and slightly better with hair to 
blood/plasma concentration. In France, Kintz et al for example found dose/hair 
correlation coefficients for heroin, 6-MAM and morphine to be r=0.12, 0.25 and 0.64, 
respectively, in 20 patients receiving controlled heroin doses in a heroin 
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maintenance programme (Kintz et al. 1998), whereas the total opiate correlation 
was r=0.346. Kintz’s study was repeated in 2005 by a German group on a larger 
number of subjects (n=46) in a very similar controlled program and they found much 
better correlation (r=0.66) between total opiates in hair and the given dose. 
Plasma/hair concentration correlation coefficients for each analyte were r=0.42, 0.58 
and 0.69 for heroin, 6-MAM and morphine, respectively (Musshoff et al. 2005). Two 
other groups have investigated the correlation for methadone between hair 
concentration and the given dose and they found no significant relationship exists 
(r=0.1 and r=0.34) (Paterson et al. 2003, Girod, Staub 2001), respectively. Although 
Girod et al found the correlation very weak between dose and hair level they 
remarkably found it strong between blood and hair (r=0.8). Moreover, the dose of 
the anti-psychotic drug clozapine was found to correlate with hair drug concentration 
at r=0.54 (Cirimele et al. 2000). Three years earlier Pragst and his group suggested 
that there was no way to estimate the dose or steady state concentration from hair 
for amitriptyline, clomipramine, doxepine, imipramine and maprotiline (Pragst et al. 
1997). In contrast, the antiepileptic phenytoin was found to have a good dose to hair 
concentration relationship (r=0.88) and dose to plasma (r=0.78) as well, while 
valproic acid and carbamazepine showed a lower relationship coefficient (r=0.72 
and r=0.46, respectively) and this was even lower with plasma (r=0.13 and r=0.14, 
respectively) (Mieczkowski et al. 2001).    
These conflicting results bring up many questions such as were the subjects taking 
any illicit heroin while in the heroin maintenance program? Was the hair extraction 
method efficient enough with real samples? Was the number of patients 
participating enough to draw conclusion from their results? Was the length of hair 
appropriate or representative of the drug administration period? Answering these 
questions maybe quite difficult but these things need to be taken into consideration 
particularly when interpreting results and drawing conclusions, especially if needed 
or requested by court or any judicial authorities. There are as well inter-individual 
variations in metabolism which might have contributed also to those inconsistent 
results.  
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Procyclidine (Kemadrin – brand name) is a synthetic antagonist for muscarinic and 
nicotinic cholinergic receptors. It is been used as an anti-dyskinetic, anti-epileptic 
and anti-Parkinson agent. Currently procyclidine is used widely with psychiatric 
patients especially those on anti-schizophrenic medications as it has a 
neuroprotective characteristic that controls the extrapyramidal side effects caused 
by those medications. It has a half-life of 12.6 hours and a normal dosage regimen 
of 2.5 or 5mg two to four times a day. Published therapeutic plasma levels ranged 
from 0.116 to 0.650µg/mL and toxicity level >4µg/mL. Procyclidine is a 
phenylpropylamine with a tertiary amine group responsible for its basic 
characteristics (Mehta, Royal Pharmaceutical Society of Great Britain 2000, Ettinger 
et al. 2003, Hadidi 2004, Kim et al. 2002, Whiteman et al. 1985, Brocks 1999). 
Due to its basic nature, extensive prescribing, reported abuse potential and lack of 
appearance in analytical publications, procyclidine was chosen for this study (El-Haj, 
Al-Amri & Ali 2011).   
Quetiapine (Seroquel) is a clozapine-like dibenzothiazepine compound, an atypical 
anti-psychotic used for treatment of schizophrenia, schizoaffective disorders, acute 
mania and depression. Pharmacokinetic data show that it has a half-life ranging 
between 5 and 7 hours and steady state level is achieved after 48 hours. Normal 
quetiapine doses range from 100 and up to 800mg per day, while therapeutic serum 
levels are reported between 70 and 170ng/mL with a toxicity level above 1.8µg/mL. 
The abuse of this drug has been found to be related to its anxiolytic and sedative 
properties. (Gerlach et al. 2007, Khazaal et al. 2007, Schulz, Schmoldt 2003, 
PIERRE et al. 2004, DeVane, Nemeroff 2001a, Winter et al. 2008). 
Risperidone (Risperdal), is an atypical anti-psychotic drug belonging to the chemical 
class of benzisoxazole derivatives. It is commonly used in the treatment of 
psychoses connected with schizophrenia, Alzheimer's disease, bipolar disorders 
and irritability in people with autism. It has both selective serotonin 5-HT2 and a 
dopamine D2 receptor antagonism activity. Wide inter-individual pharmacokinetic 
variability for risperidone is quite normal.  Its average half-life is 20±3 hours. Normal 
doses range from 2 and up to 8mg per day, while therapeutic serum levels are 
reported between 10 and 30ng/mL with a toxicity level above 90ng/mL. Paliperidone 
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(9-OH-risperidone) therapeutic serum level is from 15 and 60ng/mL and its toxicity 
level is above 80ng/mL. Some papers suggest that most patients taking oral 
risperidone have 5–10 times more paliperidone in their blood than the parent drug 
(Schulz, Schmoldt 2003, Xiang et al. 2010, Leon, Wynn & Sandson 2010, Huang et 
al. 1993, Scordo et al. 1999, Heykants et al. 1994). 
Chlorprothixene is a thioxanthene compound from the earlier generation of anti-
psychotics still commonly used in some countries for the treatment of schizophrenia, 
senile dementia and bipolar disorders. It has good sedative properties as well. A 
recent study showed that it was associated with higher mortality rates in long term 
treatment behind haloperidol compared to other anti-psychotic medications. The 
half-life of chlorprothixene is between 8 and 12 hours. The clinical oral dosage range 
is 50 to 400mg/day. The therapeutic serum level is reported between 30 and 
300ng/mL and the toxicity level is above 400ng/mL, while the lethal concentration is 
reported at 800ng/mL. (Schulz, Schmoldt 2003, Bagli et al. 1999, Raaflaub 1975, 
Lehman, Steinwachs 1998, Gjerden, Slørdal & Bramness 2010, Di Giovanni, Di Matteo & 
Esposito 2008). 
Haloperidol is a butyrophenone compound and a member of the typical anti-
psychotic drugs. It is a potent antidopaminergic and narcoleptic drug very active 
against severe psychosis symptoms such as delusions, hallucinations and agitation. 
It possesses a good sedative effect as well on patients and was found to have the 
highest association with mortality risk among a list of anti-psychotics investigated in 
Norway. The official recommended dosage is from 1 up to 30mg/day in cases of 
severe schizophrenia. It has a half-life of 10-30 hours and a therapeutic serum level 
reported between 4 and 25ng/mL, a toxicity level above 50ng/mL and a lethal level 
of 500ng/mL (Schulz, Schmoldt 2003, Gjerden, Slørdal & Bramness 2010, Di Giovanni, Di 
Matteo & Esposito 2008, Hugenholtz et al. 2006, Froemming et al. 1989, Desai et al. 2003). 
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      Procyclidine       Quetiapine    Risperidone 
 
    9-OH-risperidone         Chlorprothixene   Haloperidol 
 
Figure 11: Chemical structures of the analytes (ChemSpider 2011, Baselt 2004) 
 
3.1.1. Patients’ compliance and hair analysis 
Many factors can play roles in patients’ non-adherence to their medication such as 
alcohol or drug abuse, unawareness of possible health consequences, fear of 
medication side effects, etc. However, the results of non-compliance can be serious 
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in some occasions particularly cases like psychiatry where patients have potential of 
violent behaviour. Recent study showed also that anti-psychotic therapy compliance 
lower the risk of death by 25% in addition to the management of schizophrenic 
symptoms (Cullen 2012). Therefore observing compliance with the use of hair 
analysis can have a great potential if studies carried out and showed significant 
correlations between doses, blood and hair concentrations of the given medications. 
3.1.2. Hydrophilic interaction liquid chromatography 
Hydrophilic interaction liquid chromatography (HILIC) is an alternative high-
performance liquid chromatography (HPLC) mode for separating polar compounds. 
It is based on a mixed mode retention mechanisms and it has been reported that 
HILIC is a modified normal phase liquid chromatography NP-LC, but the separation 
mechanism used in HILIC is more complicated than that in NP-LC. Like NP-LC, 
HILIC employs conventional polar stationary phases such as silica, amino or cyano, 
however the mobile phase used is like those used in the reversed phase RP-LC 
mode, aqueous-organic (Buszewski, Noga 2012). The retention, unlike traditional 
RP materials, is based on the formation of a stagnant aqueous layer on the surface 
of the stationary phase. Analytes of a hydrophilic nature will then partition between 
the eluent and the aqueous phase, with subsequent phase interactions would be 
dipole–dipole, ion exchange and/or hydrogen bonding (Dejaegher, Mangelings & 
Vander Heyden 2008). This separation technique will be employed in this study as 
its usage with the study’s analytes has not been found in literature.                
3.2. Aim of the study 
The main aim is to investigate drug incorporation rate into hair and to look into the 
correlation pattern, if it exists between the daily dose, plateau in blood, plateau in 
oral fluids and plateau in hair. Clinical/forensic bioanalysts/toxicologists would 
interpret their results more efficiently and more confidently if more data of this kind 
were available. 
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3.3. Research subjects and drug administration 
The population of the study were middle-eastern male patients (17 for procyclidine, 
17 for quetiapine, 14 for risperidone, 14 for chlorprothixene and 10 for haloperidol) 
aged between 18 and 68 years from the psychology hospital and the addiction 
treatment centre in Kuwait. Almost all were receiving long term management of their 
psychological conditions with oral doses of medication. A minimum of 2 weeks 
treatment with a constant dose was a pre-inclusion condition for hair samples. 
However, almost all of the patients received the same dose for months. Therefore, 
the concentration of the drug in their hair should have reached a constant or steady-
state level in the near root hair segment. Ethical approval was granted by the 
research ethics committee at the ministry of health in Kuwait and all the consent 
forms were signed by the patients both in Arabic and English, copies are shown in 
Appendix 8.1 and 8.2. Doses of the drugs were different from one patient to another 
as shown and detailed in Tables 24, 27, 30, 35 and 38. Almost all the patients gave 
all three samples; hair, blood and oral fluids, except some special cases. Data 
treatment was carried out anonymously and patients were given total freedom of 
choice to participate or not and many declined participation. 
 
3.4. Materials and reagents 
All chemicals were of HPLC or analytical grade. Procyclidine, risperidone, 9-OH-
risperidone, chlorprothixene and haloperidol were purchased from Sigma-Aldrich 
Co. UK. Quetiapine was purchased from Kinesis UK. Deuterated internal standards 
haloperidol-D4 and nortriptyline-D3, were purchased from LGC standards, 
Middlesex UK. Deionised water was prepared on site (ELGA Limited). All 
consumables (tubes, etc) are from VWR UK. The rest of chemicals used in the 
solutions below are from Sigma-Aldrich Co. UK. 
Other solutions used in this chapter have been mentioned in section  2.2.2.2.  
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Standard solutions 
1000µg/mL or 100µg/mL working standards were prepared with MS grade methanol 
for procyclidine, quetiapine, risperidone, 9-OH-risperidone, chlorprothixene, 
haloperidol, nortriptyline-D3 and haloperidol-D4, respectively. All were stored at -
20⁰C. 
Quality control samples (QCs) 
QCs were prepared in two concentrations, medium 0.5µg/mL and low 0.05µg/mL. 
The medium QC samples were prepared by dissolving 50µL of 50µg/mL stock 
standard of the analyte in 4.95mL pooled drug free blood/oral fluids. The low QCs 
were prepared by diluting 0.5mL of the medium QC mixture into 4.5mL pooled drug 
free blood/oral fluids. All the mixtures were thoroughly mixed and divided into 150µL 
aliquots stored in 0.5mL Eppendorf tubes and kept at -80°C until analysis.  
1M phosphoric acid 
6.5mL of concentrated 14.7M phosphoric acid (85/100) was mixed with 93.5mL of 
deionized water, mixed well and stored at room temperature. 
Hair extraction solution (MAF) 
80mL of 1% formic acid methanol, 10mL of acetonitrile and 10mL of deionized water 
were measured in a measuring cylinder, mixed well and stored at room temperature. 
1M Sodium sulfide solution 
24g of Na2S*9H2O (MW 240g/mol) pellets were measured into a 100ml volumetric 
flask and made up to the 100ml mark with deionized water. This was mixed 
thoroughly and stored at room temperature. 
Proteinase K extraction solution (Lucas et al. 2000)  
The working solution was based on mixing 25µL of 20mg/mL proteinase K solution 
with 0.475mL of 5mg/mL dithiothreitol prepared in 10mM Tris buffer pH9 
(readymade solution) to make a final concentration of 1mg/ml. 
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Mobile phase 
(A) 999mL de-ionised water and 1mL formic acid (98/100). 
(B) 999mL acetonitrile and 1mL formic acid (98/100). 
 
3.5. Samples and data collected 
Blank (drug free) hair, blood and oral fluids samples were obtained from laboratory 
personnel and friends not taking any medication that interfered with the study.  
Patients’ hair samples were taken from the occipital area of the scalp where hair is 
strongly and constantly growing even in bald subjects. Colours of the hair were 
black, dark brown or grey and none of the patients had any kind of hair treatment. 
Each sample was cut as close as possible from the scalp with a targeted amount of 
around 100mg hair of at least 0.5cm in length. This study focused mainly on the first 
hair segment (proximal end 0-0.6cm), and should represent roughly drug 
consumption in the last 2 weeks. All blood and oral fluids samples collected from 
patients were taken just before their next dose (trough level), in most cases at 6-
7am in the morning.  Oral fluids samples were taken without stimulation 
simultaneously with blood samples. The amounts of blood and oral fluids samples 
were a minimum of 2mL collected in sodium fluoride/potassium oxalate vacutainer 
and frozen at -20°C for few days then in -80°C until analysis. All the samples were 
collected in the hospitals by the researcher himself with some help from the nursing 
staff. Other information such as age, dose and duration of therapy are listed in 
Tables 24, 27, 30, 35 and 38.  
 
3.6. LC-MS method 
Mass spectrometry was chosen for the detection and quantitation in this study as it 
can provide a very sensitive and very low detection limit (ng/mL and pg/mg) 
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compared to other analyte detection instruments. The LC-MS analysis was carried 
out with an HPLC system consisting of a Thermo Scientific Accela 600 pump, 
autosampler and column compartment. The MS part was an Orbitrab Exactive Mass 
Spectrometer (ThermoElectron UK) equipped with an electrospray interface set in 
the positive mode. The ion spray needle was set to 4500 voltage. The heated 
capillary temperature was set on 320°C, sheath gas flow of 50 arbitrary units and 
auxiliary gas flow of 17 arbitrary units. The Exactive mass spectrometer is a high 
resolution instrument with mass accuracy less than 5ppm and capable of running 
negative and positive scans simultaneously (Moulard et al. 2011). 
Chromatography was achieved using a ZIC-HILIC column (150 x 4.6mm 5µm 
particle size, Hichrom UK) preceded by a guard ZIC-HILIC column (20 x 4.6mm 
5µm). The mobile phase consisted of: (A) 999mL de-ionised water and 1mL formic 
acid (98/100) and (B) 999mL acetonitrile and 1mL formic acid (98/100). The running 
of the system was isocratic and the percentage of A and B of the mobile phase was 
40% of (A) and was pumped at 0.5mL/min. The column oven was off and auto-
sampler tray set on 4°C.  The volume of injection was 10μL and on no waste mode. 
Total run time was 7 min. 
The high resolution Exactive MS instrument was running on full scan, range from 75 
to 1200 amu. Extracted ion chromatograms were based on less than 5 ppm mass 
deviation window. Chromatographic qualitative and quantitative data acquisition and 
processing was carried out using Xcalibur 2.2 software (Thermo Fisher Scientific, 
UK).  
 
3.6.1. Identification of ions results 
Table 10 shows the analytes’ molecular formula, accurate masses, retention times 
and mass accuracies. Mass accuracy with Exactive MS was generally below 1ppm, 
except on some occasions below 2ppm, which means that the potential for 
interference from other components was very little. Figure 12 shows the mass 
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spectra of each analyte ion after extraction from full scan (75-1200 amu) at the 
retention time. Retention chromatograms are shown in patients’ results, section  0. 
Table 10: Extracted ions of target analytes, internal standards and their relevant data. 
Analyte Formula (+H) Accurate mass (M+H) 
Retention 
time Mass accuracy 
Procyclidine C19H30NO 288.2323 4.5 0.109 ppm 
Quetiapine C21H26O2N3S 384.1724 5.2 -1.624 ppm 
Risperidone C23H28FN4O2  411.2193 5.7 0.219 ppm 
9-OH-
risperidone C23H28FN4O3  427.2141 5.0 0.105 ppm 
Chlorprothixene C18H19ClNS  316.0922 4.4 0.065 ppm 
Haloperidol C21H24ClFNO2 376.1476 4.4 0.229 ppm 
Haloperidol-D4 C21H20D4ClFNO2 380.1727 4.4 0.182 ppm 
Nortriptyline-D3 C19H19D3N  267.1936 4.5 0.093 ppm 
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Chlorprothixene and Nortriptyline-D3 
 
Haloperidol
 
Haloperidol-D4 
 
Figure 12: Extracted mass spectra of each analyte and internal standard ion 
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3.7. Blood and oral fluids analysis 
3.7.1. Method development 
Methods 1, 2, 3 (0.01, 1M NaOH, Tris Buffer pH9) 
Three types of extraction solutions were tested on spiked blood and oral fluids 
samples in three triplicates. The general extraction procedure was based on placing 
100µL of blood/oral fluids samples spiked with 1µg/mL of the analyte (10µL of 
blood/oral fluids sample was replaced with 10µL of 10µg/mL standard in deionized 
water and mixed properly) in 4mL polypropylene tubes. Two hundred fifty µL of 
extraction solution (0.01, 1M NaOH or Tris buffer pH 9) plus 2mL MTBE were added 
to the samples, mixed on a rotary mixer for 30 min and then centrifuged for 10 min. 
The solvent layer was transferred to tubes containing 200µL 0.1M phosphoric acid 
and shaken again for 15 min and centrifuged. Finally, the solvent layer was removed 
or aspirated, 150µL of 0.01, 1M NaOH or Tris buffer was added plus 0.3mL MTBE, 
vortex mixed for 2 min and centrifuged. Solvent layers were transferred to 0.3mL 
auto-sampler vials, evaporated to dryness under nitrogen and reconstituted in 
120µL of acetonitrile and then 10µL was injected into the LC-MS system. At the 
same time, two replicates of unextracted 100µL of calibrators containing 1µg/mL of 
analytes in methanol were placed in two vials, evaporated to dryness and 
reconstituted in 120µL of acetonitrile and injected alongside the samples. 
Method 4 (Protein crash) 
Three replicates of 100µL of blood/oral fluids samples spiked with 1µg/mL of the 
analyte (10µL of blood/oral fluids sample was replaced with 10µL of 10µg/mL 
standard in deionized water and mixed properly) placed in 2mL Eppendorf tubes. 
Acetonitrile (350µL) was added and vortex mixed for 20 min and centrifuged for 30 
min. Solvent layers were transferred to vials, evaporated and reconstituted in 120µL 
acetonitrile. 10µL was injected into the LC-MS system. At the same time, two 
replicates of unextracted 100µL of calibrators containing 1µg/mL of analytes in 
methanol were placed in two vials, evaporated to dryness and reconstituted in 
120µL of acetonitrile and injected alongside the samples. 
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3.7.1.1. Results 
Extraction with 1M NaOH (Method 2) showed the highest extraction recovery with 
mean percentages ranging between 58 and 110 for all the analytes. Next was the 
protein crash method with a percentage of recovery ranging from 46 to 96, while the 
other two methods (1 and 3) failed to produce any acceptable recoveries as shown 
in Table 11.  
 
Table 11: Percent of recoveries with four different extraction conditions for 1µg/mL of analytes spiked 
in blood and oral fluids (n=3) 
Method 1 Method 2 Method 3 Method 4 
Analyte 0.01M NaOH %CV 
1M 
NaOH %CV 
Tris 
buffer %CV 
Protein 
crash %CV 
Procyclidine 0.4 6 110 6 1.4 46 49 8 
Quetiapine 0.1 132 90 6 0.2 88 86 2 
Risperidone 0.1 87 103 5 0.2 68 77 11 
9-OH-risperidone 0.1 140 85 2 0.2 95 96 11 
Chlorprothixene 4.8 19 58 11 10.6 51 46 20 
Haloperidol 2.4 27 93 6 8.2 27 61 7 
Mean 1.3 69 90 6 3.4 63 69 10 
 
3.7.2. Method validation 
3.7.2.1. Linearity 
Linearity was defined in section  2.2.7.3. It was attained by spiking blank blood and 
oral fluids samples with a range from 0, 10, 100, 1000 and 10,000ng/mL of each 
analyte. One µg/mL deuterated internal standard was used. The resulting ratio of 
peak areas of standards/internal standard was plotted versus the spiked analyte 
concentrations and linear correlation coefficient (r2) was calculated. The correlation 
coefficient (r2) values indicate the degree of linearity (r2 should be >0.99). 
3.7.2.2. Recovery 
Recoveries were estimated by measuring peak areas obtained when the drugs were 
spiked into blank blood/oral fluids at three concentrations 0.1, 0.5, and 2µg/mL (n=3) 
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against unextracted/unfiltered standards. This recovery takes into account all the 
extraction steps including cleaning and matrix effect (absolute). The recovery was 
calculated as a percentage by dividing the average peak area of the extracted 
standards over the average peak area of the duplicate unextracted standards and 
multiplied by 100.  
3.7.2.3. Intra-day precision 
Precision is the closeness of agreement between a series of tests results obtained 
under a set of prescribed conditions (Peters, Drummer & Musshoff 2007). The intra-
day precision was calculated by spiking blank blood/oral fluids samples with three 
levels of concentration (low, medium and high, 0.1, 0.5 and 2µg/mL) in five 
replicates. After extraction, precision was measured by calculating the coefficient of 
the variation expressed as a percentage (CV %). 
3.7.2.4. Inter-day precision 
The inter-day precision experiment was a replicate of the intra-day experiment over 
5 days and the coefficient of the variation percentage (CV %) was calculated 
between concentrations of each analyte over these 5 days. 
3.7.2.5. LOD and LLOQ 
Limit of detection (LOD) and lower limit of quantification (LLOQ) were assessed by 
spiking blank blood/oral fluids with the analytes in decreasing concentrations. LOD 
is defined as the lowest detectable concentration of the analyte that differentiates it 
from the background noise, whereas LLOQ is lowest quantitative concentration that 
fulfils the required accuracy and precision. The spiked concentrations were 0, 1, 2.5, 
5, 10 and 25ng/mL of each analyte and 1µg/mL deuterated internal standard. Ten 
microliters of the final extracts were injected into the LC-MS system. LOD and LLOQ 
signal-to-noise cut-offs ratios were 3 and 10, respectively. 
LODs were calculated using Equations 2 and 3 (Alfazil, Anderson 2008).  
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Equation 2 
               YLOD = YB+3SB                     
Equation 3 
               LOD = (YLOD-YB)/m              
where YB is the intercept, SB is the standard error of the regression line and m is the 
gradient.  
LOQs were calculated using Equations 4 and 5. 
Equation 4 
               YLOQ = YB+10SB                   
Equation 5       
               LOQ = (YLOQ-YB)/m              
3.7.2.6. Method validation results 
Linearity results showed a good regression with r2>0.99 for all analytes over the 
calibration line ranging from LOQ to 10,000ng/mL in spiked blood and oral fluids 
samples as listed in Table 12. LOD and LLOQ were 0.3-0.9 and 1-3.1ng/mL, 
respectively, for all analytes as summarized in Table 12. 
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Table 12: Linear correlation coefficients, LODs and LLOQs of analytes in blood and oral fluids 
Analyte 
Blood Oral fluids 
Linear 
correlation 
coefficient 
(r2) 
LOD 
ng/mL 
LLOQ 
ng/mL 
Linear 
correlation 
coefficient 
(r2) 
LOD 
ng/mL 
LLOQ 
ng/mL 
Procyclidine 0.999 0.8 2.7 0.999 0.5 1.6 
Quetiapine 0.999 0.3 1.1 0.999 0.4 1.2 
Risperidone 0.998 0.3 1.0 0.998 0.3 1.0 
9-OH-risperidone 0.998 0.8 2.7 0.998 0.8 2.7 
Chlorprothixene 0.999 0.6 2.0 0.999 0.3 1.0 
Haloperidol 0.999 0.7 2.3 0.999 0.3 1.0 
 
When the absolute recovery experiment was carried out taking into account all the 
extraction steps and the matrix effect it gave a lower recovery with spiked blood than 
with oral fluids. Blood recovery results were between 48-75% with CVs from 3-19% 
for the means of all the three concentrations (0.1, 0.5 and 2µg/mL), while oral fluids 
recoveries ranged from 57 to 93% with CVs from 6-26% for the means of the three 
levels. The results are summarized in Tables 13 and 14. 
Table 13: Absolute recovery (RE%) results for 0.1, 0.5 and 2µg/mL of analytes spiked in blood (n=4) 
Analyte 100ng/mL (RE%)   %CV 
500ng/mL 
(RE%)  %CV 
200ng/mL 
(RE%) %CV 
Mean 
RE 
(CV) 
Procyclidine 46 4 48 4 49 4 48 (3) 
Quetiapine 65 5 72 3 87 4 75 (15) 
Risperidone 60 6 80 1 75 5 72 (15) 
9-OH-risperidone 48 9 68 2 65 4 60 (18) 
Chlorprothixene 44 4 53 4 64 5 54 (19) 
Haloperidol 62 1 75 1 70 4 69 (10) 
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Table 14: Absolute recovery (RE%) results for 0.1, 0.5 and 2µg/mL of analytes spiked in oral fluids 
(n=4) 
Analyte 100ng/mL (RE%)   %CV 
500ng/mL 
(RE%)  %CV 
200ng/mL 
(RE%) %CV 
Mean 
RE 
(CV) 
Procyclidine 72 4 90 8 79 2 80 (11) 
Quetiapine 51 3 85 3 84 3 73 (26) 
Risperidone 87 4 97 2 95 3 93 (6) 
9-OH-risperidone 81 3 97 4 87 2 88 (9) 
Chlorprothixene 44 2 64 3 62 1 57 (19) 
Haloperidol 97 1 97 1 86 1 93 (7) 
 
Over three concentrations, 100, 500 and 2000ng/mL, intra- and inter-day precision 
results for blood QC samples showed acceptable CV percentages of ≤17% for all 
analytes except only the set of 500ng/mL for inter-day results where the precision 
was between 9-38% as shown in Table 15. Similarly, with oral fluids QC intra- and 
inter-day precision results showed good precision (≤12%) with all samples apart 
from only three occurrences as listed in Table 16.   
Table 15: Inter-day and intra-day precision results in blood 
Analyte 
Inter-day mean (CV%) n=4 Intra-day mean (CV%) n=4 
100ng/mL 500ng/mL 2000ng/mL 100ng/mL 500ng/mL 2000ng/mL 
Procyclidine 92 (17) 502 (9) 1995 (6) 87 (7) 515 (4) 2030 (9) 
Quetiapine 82 (10) 374 (38) 1992 (7) 89 (7) 430 (3) 1942 (6) 
Risperidone 90 (10) 444 (26) 1926 (12) 95 (15) 502 (8) 2152 (7) 
9-OH-
risperidone 
93 (15) 411 (29) 1987 (7) 100 (8) 498 (4) 2053 (8) 
Chlorprothixene 93 (13) 469 (32) 2029 (7) 92 (11) 526 (7) 2052 (5) 
Haloperidol 99 (8) 451 (27) 1945 (8) 95 (7) 508 (9) 1941 (8) 
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Table 16: Inter-day and intra-day precision results in oral fluids 
Analyte 
Inter-day mean (CV%) n=4 Intra-day mean (CV%) n=4 
100ng/mL 500ng/mL 2000ng/mL 100ng/mL 500ng/mL 2000ng/mL 
Procyclidine 94 (12) 459 (10) 1870 (6) 90 (5) 466 (10) 1813 (2) 
Quetiapine 95 (28) 501 (8) 2205 (5) 104 (6) 525 (5) 2135 (6) 
Risperidone 97 (10) 489 (9) 2034 (6) 98 (6) 453 (5) 2115 (3) 
9-OH-
risperidone 101 (7) 469 (5) 1932 (4) 99 (4) 470 (4) 1916 (5) 
Chlorprothixene 96 (30) 394 (33) 2014 (6) 111 (3) 500 (6) 2081 (4) 
Haloperidol 100 (10) 493 (12) 2177 (5) 98 (7) 522 (5) 2249 (2) 
 
3.8. Hair analysis 
3.8.1. Sample preparation 
3.8.1.1. Decontamination 
The decontamination process was achieved by using three washing steps with three 
solvents and one aqueous solution: 0.01M phosphate solution (pH6), 
dichloromethane and propanol/acetone (1:1). The uncut hair was put in a 6ml glass 
tube, then 2mL of the first solvent added, followed by 1 min vortexing. After that the 
solvent was decanted into a separate tube where all the following washing waste 
solvents were collected for the same sample. The decanting process was done with 
the use of a plastic pipette or in case of short hair where the hair was scattered in 
the tube, a piece of fabric or textile was used to hold the hair inside the tube and 
filter the washing solution out. After the last washing step (2mL propanol/acetone) 
the hair was left to dry at room temperature. This decontamination method was 
found to be the quickest and most efficient by the researcher, as there is no 
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agreement or consensus on specific decontamination method among hair analysts 
or in literature (Kintz 2007a).  
3.8.1.2. Segmentation 
After the hair dried segments of 0-0.5cm each were cut in small pieces (1–2mm) 
with scissors onto a piece of paper and weighed directly. Mostly to ease the 
calculation 25 or 30mg of hair was taken but, if not, any available weight was 
considered, and then segment snippets were placed into a 2ml Chromacol glass vial 
with a screw cap. 
3.8.2. Optimization of extraction 
Four extraction methods have been tested by applying them on authentic patient 
samples reduced into 1-2mm snippets and mixed thoroughly after washing. These 
patients’ hair samples were chosen based on their availability in large amount, being 
darker in colour and being from patients taking high doses of the analytes. The 
recovery of the following four extraction methods was measured by the use of five 
50µL unextracted calibrators 0.01, 0.02, 0.05, 0.1, 0.5, 1, 2µg/mL (~ng/mg) with 
50µL of 1µg/mL IS (nortriptyline-D3) prepared at the same time as the samples but 
kept in the fridge during sample incubation and then evaporated with the samples 
and reconstituted in 160µL of acetonitrile and run simultaneously with the samples. 
Extraction method 1 (1M NaOH) 
Twenty five mg of washed blank(drug free)/patient hair was incubated in triplicate 
with 0.5mL of 1M NaOH for 6 hours in a water bath (45°C) to allow for 
homogenization of the hair. Homogenates were then extracted with 2mL MTBE by 
30min rotary mixing and 10 min centrifugation (3.5krpm). Solvent layers were 
transferred into new tubes containing 200µL 0.1M phosphoric acid then mixed on a 
rotary mixer for 15min and the solvent layer was removed afterward. 100µL of 1M 
NaOH and 300µL of MTBE were added and vortex mixed for 1 min and centrifuged. 
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The solvent layer evaporated and the residue reconstituted in 100µL of acetonitrile. 
10µL was injected to the LC-MS system. 
Extraction method 2 (1M Na2S) 
Similar to method 1, 25mg of washed blank/patient hair was incubated in triplicate 
with 0.5mL of 1M Na2S for 6 hours in a water bath (45°C) to allow for 
homogenization of the hair. Homogenates were then extracted with 2mL MTBE by 
30min rotary mixing and 10 min centrifugation. Solvent layers were transferred into 
new tubes containing 200µL 0.1M phosphoric acid, then mixed on rotary mixer for 
15min and the solvent layer was removed afterwards. 100µL of 1M NaOH and 
300µL of MTBE were added and vortex mixed for 1 min and centrifuged. The 
solvent layer evaporated and the residue reconstituted in 100µL of acetonitrile. 10µL 
was injected to the LC-MS system. 
Extraction method 3 (MAF) 
After weighing 25mg of washed blank/patient hair, samples were incubated in three 
replicates in 1mL of extraction solution (0.1% formic acid 
methanol:acetonitrile:deionized water/80:10:10) for 6 hours at 45°C. After 
centrifugation at 3.5krpm for 10 min the extraction solutions were dried out and 
reconstituted in 300µL 0.1M NaOH and 300µL MTBE were added and vortex mixed 
for 1 min and centrifuged. The solvent layer was evaporated and the residue 
reconstituted in 100µL of acetonitrile. 10µL was injected to the LC-MS system. 
Extraction method 4 (Proteinase K) 
Twenty five milligrams of washed blank/patient hair was incubated in triplicate with 
0.5mL of Proteinase K extraction solution (described in section  3.4) for 6 hours in a 
water bath (45°C) to allow for homogenization of the hair. Homogenates were then 
extracted with 2mL MTBE by 30min rotary mixing and 10 min centrifugation 
(3.5krpm). Solvent layers were transferred into new tubes containing 200µL 0.1M 
phosphoric acid, then mixed on a rotary mixer for 15min and the solvent layer was 
removed afterwards. 100µL of 1M NaOH and 300µL of MTBE were added and 
vortex mixed for 1 min and centrifuged. The solvent layer evaporated and the 
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residue reconstituted in 100µL of acetonitrile. 10µL was injected into the LC-MS 
system. 
3.8.2.1. Extraction optimization results 
Comparison between the four methods revealed that method 3 (MAF) gave the 
highest recoveries from the authentic hair samples for procyclidine, chlorprothixene 
and haloperidol, 982, 368 and 61pg/mg, respectively. Method 1 (1M NaOH) gave 
the highest recoveries for quetiapine and risperidone, 3125 and 1192pg/mg, 
respectively. Method 4 showed superiority only with 9-OH-risperidone (22pg/mg), 
while method 2 (1M Na2S) showed no lead in recovery of any of the analytes as 
shown in Table 17 and Figure 13. Accordingly, a combination of method 1 and 3 
was considered for the analysis of the analytes as described below. 
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Developed extraction method (Combined methods 1 and 3) 
Incubation with 1mL MAF solution (16hr/40°C) 
 
Centrifugation 7min 
 
         supernatant transferred to                                                        to remaining residue  
      new tubes (1st extraction tubes)                     0.4mL 1M NaOH added 
                                                                incubated (3hr/50°C)Centrifuge 
             dried under nitrogen and                   
         reconstituted in 0.4mL deionized water     ←            liquid layer transferred to 
1st extraction tubes                       
                                     
2mL MTBE added 
windmill mixed 20mincentrifuged 
solvent transferred to tubes containing 0.2mL 0.1M phosphoric acid 
windmill mixed 15mincentrifuged solvent removed 0.1mL 1M NaOH 
and 0.3mL MTBE added vortex mixed 1mincentrifuged 
solvent transferred to 0.3mL vials  dried  
reconstituted in 100µL acetonitrile 
10µL injected into LC-MS 
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Table 17: Extraction optimization results from authentic/patient hair samples in pg/mg of analytes 
(n=3) 
Method 1 Method 2 Method 3 Method 4 
Analyte 1M NaOH 
% 
CV 1M Na2S 
% 
CV MAF 
% 
CV 
Proteinase 
K 
% 
CV 
Procyclidine 457 16 132 40 982 4 635 15 
Quetiapine 3125 6 1461 17 655 3 871 13 
Risperidone 1192 5 206 18 235 3 592 9 
9-OH-risperidone 0 0 0 0 12 11 22 4 
Chlorprothixene 355 13 117 32 368 10 36 21 
Haloperidol 40 15 26 5 61 13 9 9 
 
 
Figure 13: Extraction optimization results from authentic/patient hair samples 
 
3.8.3. Method validation 
Essential method validation experiments were carried out for the combined method 
and achieved by following the industrial guidelines for bioanalysis method validation 
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stated by the FDA and other sources (Peters, Drummer & Musshoff 2007, FDA 
2001, Shah et al. 2000).   
3.8.3.1. Linearity 
Linearity was described in section  2.2.7.3. It was assessed by spiking blank hair 
samples with 0, 10, 50, 100, 500, 1000, 10000, 40000pg/mg of each analyte and 
1ng/mg deuterated internal standard. The resulting ratio of peak areas of 
standards/internal standard was plotted versus the spiked analyte concentrations 
and linear correlation coefficient (r2) calculated. The correlation coefficient (r2) value 
indicates the degree of linearity (r2 should be >0.99).  
3.8.3.2. Stability 
Two experiments testing the stability of the analytes were been done, stability with 
method 1 (NaOH) and stability during the whole extraction/incubation process with 
the selected optimized extraction method (combined 1 and 3). Both were assessed 
by preparing matrix-free QC samples at a concentration of 0.5ng/mg in triplicate. 
Deuterated external standards were added at the end of the extraction procedure 
and samples were run together with unextracted standards spiked at the same 
concentrations.  
3.8.3.3. Recovery 
Recoveries were estimated by measuring peak areas obtained when the drugs were 
spiked into blank hair (in extraction solution) at three concentrations 0.1, 0.5, and 
2ng/mg (n=3) against unextracted/unincubated standards. This recovery takes into 
account all the extraction steps including clean up, incubation and matrix effect 
(absolute). The recovery was calculated as a percentage by dividing the average 
peak area ratio of the extracted standards by the average peak area ratio of the 
duplicate unextracted standards and multiplied by 100.  
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3.8.3.4. Matrix effect 
The matrix effect is principally the ion suppression or enhancement of analyte 
ionisation caused by co-eluting compounds from the biological matrix (urine, blood, 
hair, etc). The aim of this experiment was to acquire more accurate data on the 
extent of matrix influence on the results when matrices come from different 
individuals or different types of hair. As proposed by Matuszewski et al the matrix 
effect was assessed by comparing the mean peak area ratio of product ion/internal 
standard of extracted blank hair samples from three different sources (dark brown, 
baby-brown and white) spiked with 0.1ng/mg low standard solution following 
filtration (i.e. after extraction) with the mean peak area ratio of product ion/internal 
standard of unextracted standards prepared in mobile phase at equivalent 
concentrations (Matuszewski et al., 2003). The samples were decontaminated, 
segmented and extracted according to the procedures described in sections 3.8.1.1 
and 3.8.1.2. The percentage of the matrix effect was calculated by dividing the mean 
of the extracted samples by the mean of unextracted ones according to Equation 1 
(page 59). 
This percentage represents the absolute ME taking into account ion suppression 
and ion enhancement. It shows the difference in response between a standard 
present in the sample of hair extract and the same standard present in a neat 
solution without the presence of the matrix. A 100% value indicates that the 
standard’s MS response from the neat solution was the same as the standard 
response from the hair extracts and no matrix effect was observed. Accordingly 
<100% value indicates ion suppression while >100% value indicates ion 
enhancement. Because hair was from different types of hair, they may contain 
different amounst of endogenous compounds that maybe undetected and co-elute 
with the analytes of interest. Therefore the ionisation of the analytes of interest could 
be affected, resulting in a decreased or increased MS response. 
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3.8.3.5. Intra-day precision 
Precision was described in section  3.7.2.3. However, the intra-day precision for hair 
analysis was made by spiking the blank hair samples with three levels of 
concentration (low, medium and high) in five replicates. After extraction, precision 
was measured by calculating the coefficient of variation expressed as a percentage 
(CV%). 
3.8.3.6. Inter-day precision 
The inter-day precision experiment was a replicate of intra-day experiment over 5 
days and the coefficient of variation percentage (CV%) was calculated between 
concentrations of each analyte over these 5 days. 
3.8.3.7. LOD and LLOQ 
Limit of detection (LOD) and lower limit of quantification (LLOQ) were assessed by 
spiking blank hair with the analytes in decreasing concentrations. LOD is defined as 
the lowest detectable concentration of the analyte that differentiates it from the 
background noise, whereas LLOQ is lowest quantitative concentration that fulfills the 
required accuracy and precision. The spiked concentrations were 1, 2.5, 5, 10, 25, 
50 and 100pg/mg of each analyte and 1ng/mg deuterated internal standard. All were 
mixed with 25mg of washed blank hair, incubated and extracted according to the 
selected method. Ten µL were injected into the LC-MS system. Signal-to-noise ratio 
was considered to calculate LOD and LLOQ, and 3 and 10, respectively, were used 
as cut-offs. LODs and LLOQs were calculated using  
Equation 2-5 (page 91).  
3.8.3.8. Method validation results 
Linearity results showed a good regression with r2>0.99 for all analytes over the 
calibration line ranging from LLOQ to 40,000pg/mg in spiked hair samples as listed 
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in Table 18. LOD and LLOQ were 1.4-5.8 and 4.7-19.5pg/mg, respectively, for all 
analytes as summarized in Table 18. Lower calibrants graphs are listed in appendix 
8.6.  
Table 18: Linear correlation coefficients, LODs and LLOQs of analytes in hair 
Analyte 
Linear 
correlation 
coefficient 
(r2) 
LOD 
pg/mg 
LLOQ 
pg/mg 
Procyclidine 0.998 2.0 6.6 
Quetiapine 0.994 1.4 4.7 
Risperidone 0.999 2.5 8.6 
9-OH-risperidone 0.996 1.9 6.4 
Chlorprothixene 0.997 5.8 19.5 
Haloperidol 0.998 4.4 14.7 
 
Three QC concentrations, 100, 500 and 2000pg/mg were analysed in five replicates 
for intra- and inter-day precision from spiked hair and revealed acceptable CV 
percentages of <20% for all analytes excluding three samples (≤26%) as shown in 
Table 19.   
 
Table 19: Inter-day and intra-day precision results in hair 
Analyte 
Interday mean (CV%) n=5 Intraday mean (CV%) n=5 
100pg/mg 500pg/mg 2000pg/mg 100pg/mg 500pg/mg 2000pg/mg 
Procyclidine 105 (24) 516 (9) 1808 (7) 99 (1) 563 (3) 1752 (2) 
Quetiapine 76 (10) 465 (10) 2280 (3) 99 (2) 510 (4) 2013 (2) 
Risperidone 64 (26) 506 (7) 1966 (2) 121 (21) 444 (5) 1855 (2) 
9-OH-
risperidone 88 (14) 552 (1) 1889 (5) 110 (2) 572 (1) 2152 (6) 
Chlorprothixene 102 (8) 617 (19) 2049 (7) 95 (3) 556 (4) 2258 (2) 
Haloperidol 102 (11) 480 (3) 2041 (3) 102 (7) 467 (6) 2186 (2) 
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Results of stability during incubation/extraction with method 1 (NaOH) showed that 
all analytes were stable under the alkaline conditions with stability of >52% except 
OH-risperidone (~30% stability) as illustrated in Table 20. However, stability of the 
selected combined method gave >78% recovery for all analytes as shown in Table 
21. 
Table 20: Analytes stability during 1M NaOH incubation (n=3) 
Analyte 0.5ng/mg (%) %CV 
Procyclidine 0.30 (60) 20 
Quetiapine 0.47 (94) 10 
Risperidone 0.49 (98) 11 
9-OH-risperidone 0.16 (32) 21 
Chlorprothixene 0.26 (52) 17 
Haloperidol 0.44 (88) 8 
 
Table 21: Analytes stability during optimized analysis method (n=3) 
Analyte 0.5ng/mg (%)  %CV 
Procyclidine 0.39 (78) 5.5 
Quetiapine 0.49 (98) 5.9 
Risperidone 0.53 (106) 3.5 
9-OH-risperidone 0.52 (104) 3.4 
Chlorprothixene 0.39 (78) 9.0 
Haloperidol 0.39 (78) 4.9 
 
The mean absolute recovery results of the combined method after spiking hair 
samples with three different concentrations in triplicate were between 71 and 101% 
and 6-13 CV%, details shown in Table 22. 
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Table 22: Combined method absolute recovery (RE%) results for 0.1, 0.5 and 2ng/mg of analytes 
spiked in hair (n=3) 
Analyte 0.1ng/mg (RE%)   %CV 
0.5ng/mg 
(RE%)  %CV 
2ng/mg 
(RE%) %CV 
Mean RE 
(CV) 
Procyclidine 67 5 77 6 69 4 71 (7) 
Quetiapine 83 2 98 6 80 16 87 (11) 
Risperidone 104 3 106 4 94 12 101 (6) 
9-OH-
risperidone 92 6 104 3 92 6 96 (7) 
Chlorprothixene 62 10 77 9 80 11 73 (13) 
Haloperidol 74 21 78 5 63 9 72 (11) 
 
Some ion suppression was shown during the matrix effect study with procyclidine 
results only, 85% (7%CV). However, other analytes showed no effect of matrix with 
98 to 104% recovery and 1-4%CV as illustrated in Table 23. 
Table 23: Matrix effect (ME) results for 0.1ng/mg spiked hair samples (n=3) 
Analyte % of ME % CV 
Procyclidine 85 7 
Quetiapine 98 3 
Risperidone 104 3 
9-OH-Risperidone 104 4 
Chlorprothixene 98 1 
Haloperidol 99 2 
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3.9. Patients’ results 
3.9.1. Procyclidine 
Blood results from the 17 patients receiving procyclidine were all positive with 
concentrations ranging from 30 to 357ng/mL. However, the corresponding oral fluids 
samples were short of two samples not given by those patients. Oral fluids samples 
were generally within relatively similar pre-dose concentration range as blood, from 
7 to 395ng/mL. As for hair, all patients were positive except one and drug levels 
were between 118 and 5624pg/mg as shown in Table 24. Some chromatograms of 
patients’ results and calibrators are shown in Figure 14. 
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Table 24: Procyclidine patients’ hair, blood and oral fluids trough levels 
Proximal (0-0.6 cm) Pre-dose levels 
Subject Age (years) 
Daily 
dose 
Duration of 
therapy 
Hair 
colour 
Hair conc. 
pg/mg 
Blood conc. 
ng/mL 
Oral fluids 
conc. ng/mL 
1  46 15mg (5X3) >Month Black 1101 67.7 9.6 
2   53 15mg (5X3) >Month Grey 2959 245.6 32.9 
3  32 15mg (5X3) >Month Black 1295 164.6 34.3 
4   48 15mg (5X3) >Month Grey 3521 119.8 52.9 
5   68 10mg (5X2) >Month Grey 1062 48.9 144.8 
6   58 5mg (5X1) >Month Grey 1450 61.5 8.2 
7  38 10mg (5X2) >Month Black 5624 356.7 125.3 
8   52 10mg (5X2) >Month Black 4790 246.9 NA 
9  47 5mg (5X1) >Month 
Dark 
Grey 939 30.2 6.7 
10  41 5mg (5X1) >Month Black 118 45 12.5 
11  48 10mg (5X2) >Month Black 1962 73.4 13.6 
12  28 15mg (5X3) >Month Black 2024 187.2 19 
13  46 5mg (2.5X2) 29 days black 395 63.2 NA 
14  44 15mg (5X3) >Month Black 271 138.8 57.8 
15  33 15mg (5X3) >Month Black 2722 165 395.2 
16  56 10mg (5X2) >Month Grey 2441 38.9 34.1 
17  50 10mg (5X2) >Month 
Dark 
brown 4446 274.6 9.2 
 NA: Sample not available. NF: Drug not found. 
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Figure 14: Chromatograms of extracted procyclidine and IS from low calibrators and patient’s oral 
fluids, blood and hair samples 
The Pearson correlation coefficient (r) test used for calculating the correlations 
between results showed that procyclidine’s dose and blood level has r=0.38 with 
p=0.125 , dose/oral fluids level has r=0.28 with p=0.307 and dose/hair level has 
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r=0.22 with p=0.391 . However, hair and blood levels revealed significant correlation 
with r=0.83 and p=<0.001, while, hair/oral fluids levels and blood/oral fluids levels 
did not show good correlation with r=0.21 (p=0.446) and r=0.19 (p=0.491), 
respectively. All the details are shown in Figure 15, Tables 25 and 26.     
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - Dose/concentration relationships in hair, blood and oral fluids 
Page 110 of 255 
 
1512.5107.55
1000
100
10
1
Dose (mg/day)
S
al
iv
a 
C
o
n
c.
 (
n
g
/m
L)
S 0.471086
R-Sq 24.2%
R-Sq(adj) 18.4%
Regression
95% CI
Procyclidine
log10(Saliva) =  0.0602 + 1.384 log10(Dose)
1512.5107.55
1000
100
10
Dose (mg/day)
B
lo
o
d
 C
o
n
c.
 (
n
g
/m
L)
S 0.280843
R-Sq 33.4%
R-Sq(adj) 28.9%
Regression
95% CI
Procyclidine
log10(Blood) =  1.011 + 1.011 log10(Dose)
 
1512.5107.55
10000
1000
100
Dose (mg/day)
H
ai
r 
C
o
n
c.
 (
p
g
/m
g
)
S 0.429265
R-Sq 18.0%
R-Sq(adj) 12.5%
Regression
95% CI
Procyclidine
log10(Hair) =  2.147 + 1.023 log10(Dose)
100010010
10000
1000
100
10
Blood Conc. (ng/mL)
H
ai
r 
C
o
n
c.
 (
p
g
/m
g
)
S 0.384112
R-Sq 55.7%
R-Sq(adj) 52.9%
Regression
95% CI
Procyclidine
log10(Hair) =  1.201 + 0.9670 log10(Blood)
 
100001000100
1000
100
10
1
Hair Conc. (pg/mg)
S
al
iv
a 
C
o
n
c.
 (
n
g
/m
L)
S 0.526133
R-Sq 5.5%
R-Sq(adj) 0.0%
Regression
95% CI
Procyclidine
log10(Saliva) =  0.603 + 0.2743 log10(Hair)
1000100
1000
100
10
Blood Conc. (ng/mL)
S
al
iv
a 
C
o
n
c.
 (
n
g
/m
L)
S 0.505389
R-Sq 12.8%
R-Sq(adj) 6.1%
Regression
95% CI
Procyclidine
log10(Saliva) =  0.3592 + 0.5540 log10(Blood)
 
Figure 15: Relationship plots between procyclidine concentrations in hair, blood, oral fluids and daily 
dose 
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Table 25: Procyclidine 
Procyclidine 
Pearson 
correlation 
coefficient 
(r) 
P-value 
(r) n 
Regression equation Slope (Log) Regr. 
Log(y) = Log(c) + mLog(x) CI 95% (m) P value 
Hair vs Dose 0.215 0.391 17 log10(Hair)=  2.15 + 1.023 log10(Dose) (-0.172 - 2.218) 0.090 
Blood vs Dose 0.375 0.125 17 log10(Blood)=  1.01 + 1.011 log10(Dose) (0.229 - 1.793) 0.015 
Oral fluids vs 
Dose 0.283 0.307 15 
log10(Oral fluids)=  0.06 + 1.384 
log10(Dose) (-0.072 - 2.840) 
0.062 
Hair vs Blood 0.825 0.000 17 log10(Hair)=  1.20 + 0.9670 log10(Blood) (0.512 - 1.422) 0.000 
Oral fluids vs 
Hair 0.213 0.446 15 
log10(Oral fluids)=  0.60 + 0.2743 
log10(Hair) (-0.402 - 0.951) 
0.400 
Oral fluids vs 
Blood 0.193 0.491 15 
log10(Oral fluids)=  0.36 + 0.5540 
log10(Blood) (-0.306 - 1.414) 
0.190 
 
Table 26: Correlation coefficient (r) and P-value for log transformed procyclidine results 
(r) 
Log(Dose) Log(Hair) Log(Blood) Log(Oral fluids) P-value 
Log(Dose)   
 0.424 0.578 0.492 
0.090 0.015 0.062 
Log(Hair) 
0.424  0.746 0.234 
0.090 0.000 0.400 
Log(Blood) 
0.578 0.746  0.358 
0.015 0.000 0.190 
Log(Oral 
fluids) 
0.492 0.234 0.358  
0.062 0.400 0.190 
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3.9.2. Quetiapine 
The results from blood samples of the 17 patients taking quetiapine were all positive 
with concentrations ranging from 1.2 to 955ng/mL, except two unavailable samples 
and one undetected. Likewise, oral fluids samples were all positives except one 
negative and two unavailable. Concentrations varied between 5 and 212ng/mL and 
were markedly lower than in blood. With regard to hair results, they were all positive 
and ranged from 2.4 to 22ng/mg as shown in Table 27. Selected samples calibrators 
and patients’ results chromatograms are shown in Figure 16.   
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Table 27: Quetiapine patients’ hair, blood and oral fluids trough levels 
Proximal (0-0.6 cm) Pre-dose levels 
Subject 
Age 
(yrs) 
Daily 
dose 
Duration of 
therapy 
Hair 
colour 
Hair conc. 
pg/mg 
Blood conc. 
ng/mL 
Oral fluids 
conc. ng/mL 
1   34 600mg (300X2) 19 days Black 5435 72 41 
2    54 500mg (250X2) >Month 
Dark-
grey 11362 15.4 8.7 
3   48 300mg (100X3) >Month Black 15399 270 56.1 
4    
37 
200mg 
(200X1) >Month Black 2371 23.8 22.3 
5   34 200mg (200X1) 4 weeks Black 14422 NF 5 
6  38 400mg (200X2) >Month Black 21998 337.4 76.7 
7   35 200mg (200X1) 19 days Black 2853 NA NA 
8  35 200mg (200X1) >3 weeks 
Dark 
brown 3183 7 5.2 
9   34 400mg (400X1) 17 days Black 6283 17.2 9.3 
10  25 200mg (200X1) >3 weeks Black 2437 1.2 NF 
11  28 200mg(200X1) >Month Black 7750 33.8 9.4 
12  32 200mg(200X1) 17 days Black 3009 18.2 14.8 
13  35 100mg (100X1) 2 weeks Black 5545 2.2 5.2 
14  38 200mg (200X1) >3 weeks Black 6852 NA NA 
15  35 200mg (200X1) 19 days Black 7207 13.8 211.7 
16  34 200mg (200X1) >2 weeks Black 13730 17.8 18.9 
17  52 200mg (200X1) >3 weeks 
Dark 
brown 7169 954.7 9.1 
 NA: Sample not available. NF: Drug not found. 
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Figure 16: Chromatograms of extracted quetiapine and IS from low calibrators and patient’s oral 
fluids, blood and hair samples 
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dose and hair level (r=0.29 with p=0.264). Correlations between hair and blood 
levels also revealed no significant correlation with r=0.28 and p=0.326. Also hair/oral 
fluids levels and blood/oral fluids levels did not show a correlation with r=0.16 
(p=0.576) and r=-0.05 (p=0.864), respectively. Only the log results revealed a 
correlation between hair and blood levels, r=0.56 and p=0.036. All the details are 
shown in Figure 17, Tables 28 and 29.       
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Figure 17: Relationship plots between quetiapine concentrations in hair, blood, oral fluids and daily 
dose 
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Table 28: Quetiapine 
Quetiapine 
Pearson 
correlation 
coefficient 
(r) 
P-value 
(r) n 
Regression equation Slope (Log) Regr. 
Log(y) = Log(c) + mLog(x) CI 95% (m) P value 
Hair vs Dose 0.287 0.264 17 log10(Hair)=  2.57 + 0.521 log10(Dose) (-0.290 – 1.332) 0.193 
Blood vs Dose -0.019 0.949 14 log10(Blood)=  -2.35 + 1.578 log10(Dose) (-0.632 – 3.788) 0.149 
Oral fluids vs 
Dose 0.025 0.933 14 
log10(Oral fluids)=  -0.57 + 0.753 
log10(Dose) (-0.656 – 2.162) 
0.271 
Blood vs Hair 0.284 0.326 14 log10(Blood)=  -4.29 + 1.501 log10(Hair) (0.132 – 2.870) 0.036 
Oral fluids vs 
Hair 0.164 0.576 14 
log10(Oral fluids)=  -0.36 + 0.415 
log10(Hair) (-0.617 – 1.447) 
0.402 
Blood vs Oral 
fluids -0.053 0.864 14 
log10(Blood)=  0.84 + 0.542 log10(Oral 
fluids) (-0.370 – 1.454) 
0.225 
 
Table 29: Correlation coefficient (r) and P-value for log transformed quetiapine results 
(r) 
Log(Dose) Log(Hair) Log(Blood) Log(Oral fluids) P-value 
Log(Dose)   
 0.332 0.407 0.316 
0.193 0.149 0.271 
Log(Hair) 
0.332  0.564 0.243 
0.193 0.036 0.402 
Log(Blood) 
0.407 0.564  0.361 
0.149 0.036 0.225 
Log(Oral 
fluids) 
0.316 0.243 0.361  
0.271 0.402 0.225 
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3.9.3. Risperidone and OH-risperidone 
Blood results of the fourteen patients on risperidone were positive in all the samples 
for both the drug and its metabolite with concentrations ranging from of 1-68ng/mL 
and 4-44ng/mL, respectively. In the same way, results from oral fluids samples were 
all positive for both analytes and concentrations were found to be between 1 and 
31ng/mL for risperidone and 7.5 to 110ng/mL for OH-risperidone. With regard to hair 
results, they were all positive for risperidone ranging from 63 to 5318pg/mg whereas 
for OH-risperidone all samples were positive except one and concentrations ranged 
from 8 to 79pg/mg as shown in Table 30. Selective sample calibrators and patients’ 
results chromatograms are shown in Figures 18 and 19.  
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Table 30: Risperidone and OH-risperidone patients’ results  
 
Risperidone 9-OH-risperidone 
Proximal 
0-0.6cm Pre-dose levels 
Proximal 
0-0.6cm Pre-dose levels 
Subject 
Age 
(yrs) Daily dose 
Duration 
of 
therapy 
Hair 
colour 
Hair 
conc. 
pg/mg 
Blood 
conc. 
ng/mL 
Oral 
fluids 
conc. 
ng/mL 
Hair 
conc. 
pg/mg 
Blood 
conc. 
ng/mL 
Oral 
fluids 
conc. 
ng/mL 
1 48 7mg (3.5X2) >Month Black 1462 10.1 31.1 16.5 44.4 110 
2 32 6mg (2X3) >Month Black 955 9.6 8.9 71 21.8 61.7 
3 48 6mg (2X3) >Month Grey 1195 1.7 10 54.7 17 60.8 
4 68 4mg (2X2) >Month Grey 105 1.6 9.2 49.8 40.8 36.1 
5 18 3mg(1.5X2) >Month Black 85 0.3 1 13.1 4.7 12 
6 38 4mg (2X2) 24 days Grey 110 0.3 1.4 50.3 3.9 31.4 
7 24 6mg (2X3) 22 days Black 198 1.4 2.9 NF 8.7 14.3 
8 48 4mg (2X2) >Month Black 1469 5 10.6 79.4 26.3 49.1 
9 28 6mg (2X3) >Month Black 849 5.8 10.7 10 15.8 21.9 
10 46 4mg (2X2) 25 days Black 99 5.2 NA 24 25.2 NA 
11 44 3mg(1.5X2) >Month Black 651 1.4 5.4 57.7 17.7 43.3 
12 51 4mg (2X2) >Month Black 63 1 8.8 0.7 10.8 90.1 
13 30 6mg (2X3) >Month Dark brown 468 1.6 6 7.9 7.6 41.3 
14 50 8mg (4X2) >Month Dark brown 5318 68.4 23.4 23.5 15.9 7.5 
NA: Sample not available. NF: Drug not found. 
Chapter 3 - Dose/concentration relationships in hair, blood and oral fluids 
Page 120 of 255 
 
 
 
 
Figure 18: Chromatograms of extracted risperidone and IS from low calibrators and patient’s oral 
fluids, blood and hair samples 
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Figure 19: Chromatograms of extracted OH-risperidone and IS from low calibrators and patient’s oral 
fluids, blood and hair samples 
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Risperidone results showed good correlations between the dose and all the sample 
matrices. Correlation coefficients for dose/blood concentration, dose/oral fluids 
concentration and dose/hair concentration were r=0.62 with p=0.009, r=0.67 with 
p=0.012 and r=0.67 with p=0.017, respectively. The strongest correlation was 
between blood and hair concentrations, r=0.96 with p=0.000, followed by oral fluids 
concentration/hair concentration with r=0.66 and p=0.013, while the weakest but still 
significant was between blood and oral fluids concentrations, r=0.59 and p=0.035. 
Unlike its parent drug OH-risperidone did not show any correlation between the 
dose and any matrix level as correlation coefficients were r=0.15 with p=0.610 , 
r=0.06 with p=0.838 and r=-0.20 with p=0.515 for dose/blood concentration, 
dose/oral fluids concentration, dose/hair concentration, respectively. Also no 
significant correlations were found between blood concentration/hair concentration, 
oral fluids concentration/hair concentration and blood concentration/oral fluids 
concentration as coefficients results were r=0.24 with p=0.437, r=-0.03 with p=0.937 
and r=0.51 with p=0.075, respectively. All the details are shown in Figures 20 and 
21, Tables 31-34.      
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Figure 20: Relationship plots between risperidone concentrations in hair, blood, oral fluids and daily 
dose 
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Figure 21: Relationship plots between OH-risperidone concentrations in hair, blood, oral fluids and 
daily dose 
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Table 31: Risperidone 
Quetiapine 
Pearson 
correlation 
coefficient 
(r) 
P-value 
(r) n 
Regression equation Slope (Log) Regr. 
Log(y) = Log(c) + mLog(x) CI 95% (m) P value 
Hair vs Dose 0.668 0.009 14 log10(Hair)=  0.64 + 2.879 log10(Dose) (0.790 - 4.968) 0.012 
Blood vs Dose 0.624 0.017 14 log10(Blood)=  -1.79 + 3.215 log10(Dose) (1.088 - 5.343) 0.007 
Oral fluids vs 
Dose 0.673 0.012 13 
log10(Oral fluids)=  -0.53 + 1.967 
log10(Dose) (0.360 - 3.574) 
0.022 
Blood vs Hair 0.955 0.000 14 log10(Blood)=  -1.73 + 0.8217 log10(Hair) (0.403 - 1.241) 0.001 
Oral fluids vs 
Hair 0.664 0.013 13 
log10(Hair)=  1.86 + 0.9576 log10(Oral 
fluids) (0.318 - 1.597) 
0.008 
Blood vs Oral 
fluids 0.586 0.035 13 
log10(Blood)=  -0.65 + 1.253 log10(Oral 
fluids) (0.707 - 1.799) 
0.000 
 
Table 32: OH-risperidone 
Quetiapine 
Pearson 
correlation 
coefficient 
(r) 
P-value 
(r) n 
Regression equation Slope (Log) Regr. 
Log(y) = Log(c) + mLog(x) CI 95% (m) P value 
Hair vs Dose -0.199 0.515 13 log10(Hair)=  1.43 - 0.120 log10(Dose) (-2.794 - 2.554) 0.924 
Blood vs Dose 0.149 0.610 14 log10(Blood)=  0.80 + 0.5434 log10(Dose) (-0.886 -1.972) 0.427 
Oral fluids vs 
Dose 0.063 0.838 13 
log10(Oral fluids)=  1.65 - 0.1528 
log10(Dose) (-1.788 - 1.482) 
0.842 
Hair vs Blood 0.236 0.437 13 log10(Hair)=  0.76 + 0.4888 log10(Blood) (-0.604 - 1.582) 0.351 
Oral fluids vs 
Hair -0.026 0.937 13 
log10(Oral fluids)=  1.65 - 0.0595 
log10(Hair) (-0.457 - 0.338) 
0.751 
Oral fluids vs 
Blood 0.510 0.075 13 
log10(Oral fluids)=  1.00 + 0.4660 
log10(Blood) (-0.163 - 1.095) 
0.135 
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Table 33: Correlation coefficient (r) and P-value for log transformed risperidone results 
(r) 
Log(Dose) Log(Hair) Log(Blood) Log(Oral fluids) P-Value 
Log(Dose)   
 0.652 0.686 0.627 
0.012 0.007 0.022 
Log(Hair) 
0.652  0.774 0.702 
0.012 0.001 0.008 
Log(Blood) 
0.686 0.774  0.833 
0.007 0.001 0.000 
Log(Oral 
fluids) 
0.627 0.702 0.833  
0.022 0.008 0.000 
 
Table 34: Correlation coefficient (r) and P-value for log transformed OH-risperidone results 
(r) 
Log(Dose) Log(Hair) Log(Blood) Log(Oral fluids) P-Value 
Log(Dose)   
 -0.029 0.231 -0.061 
0.924 0.427 0.842 
Log(Hair) 
-0.029  0.282 -0.103 
0.924 0.351 0.751 
Log(Blood) 
0.231 0.282  0.438 
0.427 0.351 0.135 
Log(Oral 
fluids) 
-0.061 -0.103 0.438  
0.842 0.751 0.135 
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3.9.4. Chlorprothixene 
Results from blood samples of the 14 patients on chlorprothixene were all positive 
except one negative and their trough concentrations were between 13 and 41ng/mL. 
Four oral fluids samples were negative and one was unavailable. The rest of the oral 
fluids samples gave results ranging between 16 and 22ng/mL. Only one hair sample 
was unavailable and the remaining 13 were positive and their concentrations range 
was from 0.3 to 25.3ng/mg as shown in Table 35. Selected sample calibrators and 
patients’ results chromatograms are shown in Figure 22.    
Table 35: Chlorprothixene patient results 
Proximal (0-0.6 cm) Pre-dose levels 
Subject 
Age 
(yrs) 
Daily 
dose 
Duration 
of 
therapy 
Hair 
colour 
Hair conc. 
pg/mg 
Blood conc. 
ng/mL 
Oral fluids 
conc. ng/mL 
1  46 50mg (50X1) >Month Black 13159 17.3 16.4 
2   53 100mg (100X1) >Month Grey 12196 32.4 18.2 
3   48 100mg (50X2) >Month Grey 11680 16.1 16.4 
4   58 100mg (100X1) >Month Grey 19457 25.5 17.6 
5  47 50mg (50X1) >Month 
Dark 
grey 25257 23.9 NF 
6   41 50mg (50X1) >Month Black 5114 NF NF 
7   34 50mg (50X1) 19 days Black 6731 17.3 16.7 
8    24 50mg (50X1) 3 days NA NA 40.6 18.8 
9   46 50mg (50X1) 12 days Black 981 29.4 NA 
10  32 65mg (65X1) >Month Black 7432 24.2 17.9 
11  54 150mg (75X2) >Month 
Dark-
grey 13095 35.5 21.8 
12  30 50mg (50X1) >Month 
Dark-
brown 6789 17.0 17.0 
13  56 50mg (50X1) >Month Grey 3561 15.8 NF 
14  32 50mg (50X1) 17 days Black 290 13.3 NF 
  NA: Sample not available. NF: Drug not found. 
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Figure 22: Chromatograms of extracted chlorprothixene and IS from low calibrator’s and patient’s oral 
fluids, blood and hair samples 
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No significant correlations have been found between chlorprothixene dose and 
blood or hair trough levels, r=0.37 with p=0.211 and r=0.40 with p=0.176, 
respectively. Conversely, dose/oral fluids concentration showed some significant 
correlation, r=0.68 and p=0.045. Also blood concentration/oral fluids concentration 
were correlated with r=0.79 and p=0.011. However, hair concentration/blood 
concentration and hair concentration/oral fluids concentration revealed insignificant 
relations, r=0.32 with p=0.319 and r=0.21 with p=0.625, respectively. All the details 
are shown in Figure 23, Tables 36 and 37. 
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Figure 23: Relationship plots between chlorprothixene concentrations in hair, blood, oral fluids and 
daily dose 
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Table 36: Chlorprothixene 
Quetiapine 
Pearson 
correlation 
coefficient 
(r) 
P-value 
(r) n 
Regression equation Slope (Log) Regr. 
Log(y) = Log(c) + mLog(x) CI 95% (m) P value 
Hair vs Dose 0.372 0.211 13 log10(Hair)=  1.23 + 1.414 log10(Dose) (-0.468 - 3.296) 0.130 
Dose vs Blood 0.400 0.176 13 log10(Dose)=  1.11 + 0.4269 log10(Blood) (-0.232 - 1.086) 0.186 
Dose vs Oral 
fluids 0.678 0.045 9 
log10(Dose)=  - 2.76 + 2.676 log10(Oral 
fluids) (-0.594 - 5.946) 
0.101 
Hair vs Blood 0.315 0.319 13 log10(Hair)=  1.38 + 1.491 log10(Blood) (-1.087 - 4.069) 0.236 
Oral fluids vs 
Hair 0.206 0.625 9 
log10(Hair)=  2.32 + 0.989 log10(Oral 
fluids) (-2.698-4.676) 
0.559 
Blood vs Oral 
fluids 0.792 0.011 9 
log10(Blood)=  - 3.92 + 3.236 log10(Oral 
fluids) (1.284 - 5.188) 
0.007 
 
Table 37: Correlation coefficient (r) and P-value for log transformed chlorprothixene results 
(r) 
Log(Dose) Log(Hair) Log(Blood) Log(Oral fluids) P-Value 
Log(Dose)   
 0.443 0.392 0.581 
0.130 0.186 0.101 
Log(Hair) 
0.443  0.370 0.245 
0.130 0.236 0.559 
Log(Blood) 
0.392 0.370  0.822 
0.186 0.236 0.007 
Log(Oral 
fluids) 
0.581 0.245 0.822  
0.101 0.559 0.007 
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3.9.5. Haloperidol 
All the blood samples analysed from patients on haloperidol were positive with pre-
dose levels ranging from 7 to 27ng/mL. Oral fluids samples as well were all positive 
except one undetected and one unavailable. Positive oral fluids results were in the 
range of 6-38ng/mL. Interestingly, hair samples, which were all positive, revealed 
relatively high levels of haloperidol ranging from 15.3 to 80.3ng/mg as shown in 
Table 38. Selected samples calibrators and patients’ results chromatograms are 
shown in Figure 24. 
 
Table 38: Haloperidol Patients 
Proximal (0-0.6 cm) Pre-dose levels 
Subject 
Age 
(yrs) 
Daily 
dose 
Duration of 
therapy 
Hair 
colour 
Hair conc. 
pg/mg 
Blood conc. 
ng/mL 
Oral fluids 
conc. ng/mL 
1  46 20mg (10X2) >Month Black 39645 11.8 7.3 
2   53 30mg (10X3) >Month Grey 52299 23.4 14 
3  32 30mg (10X3) >Month Black 38446 11.2 15 
4   48 20mg (10X2) >Month Grey 43451 9.5 12.2 
5  38 30mg (10X3) >Month Black 80314 27.7 37.9 
6   52 10mg (5X2) >Month Black 34250 14.6 NA 
7  47 10mg (10X1) >Month 
Dark 
grey 15284 6.6 NF 
8   41 10mg (10X1) >Month Black 15990 7 6.2 
9   56 30mg (10X3) >Month Grey 29310 11.3 18.4 
10  50 15mg (5X3) >Month 
Dark 
brown 36363 13.5 8.1 
  NA: Sample not available. NF: Drug not found. 
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Figure 24: Chromatograms of extracted haloperidol and IS from low calibrators and patient’s oral 
fluids, blood and hair samples 
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Haloperidol results showed weak correlations existed with dose/blood concentration 
and dose/oral fluids concentration with coefficients of r=0.58 with p=0.080 and 
r=0.66 with p=0.073, respectively. With regard to dose/hair concentration the 
correlation was similar (r=0.65) but with a better p-value (p=0.042). In the other 
hand, blood concentration/hair concentration showed very significant correlation, 
r=0.90 with p=0.000. The other two sets also showed significant correlations, oral 
fluids concentration/hair concentration r=0.83 with p=0.012 and oral fluids 
concentration/blood concentration r=0.76 with p=0.03. All the details are shown in 
Figure 25, Tables 39 and 40. 
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 Figure 25: Relationship plots between haloperidol concentrations in hair, blood, oral fluids and daily 
dose 
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Table 39: Haloperidol 
Quetiapine 
Pearson 
correlation 
coefficient 
(r) 
P-value 
(r) n 
Regression equation Slope (Log) Regr. 
Log(y) = Log(c) + mLog(x) CI 95% (m) P value 
Hair vs Dose 0.649 0.042 10 log10(Hair)=  3.60 + 0.7427 log10(Dose) (0.172 - 1.313) 0.019 
Blood vs Dose 0.578 0.080 10 log10(Blood)=  0.38 + 0.5636 log10(Dose) (-0.043 - 1.170) 0.069 
Oral fluids vs 
Dose 0.663 0.073 8 
log10(Oral fluids)=  - 0.42 + 1.137 
log10(Dose) (0.298 - 1.976) 
0.018 
Hair vs Blood 0.901 0.000 10 log10(Hair)=  3.48 + 0.9660 log10(Blood) (0.563 - 1.369) 0.001 
Oral fluids vs 
Hair 0.825 0.012 8 
log10(Oral fluids)=  - 3.08 + 0.9115 
log10(Hair) (0.066 - 1.757) 
0.043 
Blood vs Oral 
fluids 0.757 0.030 8 
log10(Oral fluids)=  0.10 + 0.8963 
log10(Blood) (0.008 - 1.785) 
0.054 
 
Table 40: Correlation coefficient (r) and P-value for log transformed haloperidol results 
(r) 
Log(Dose) Log(Hair) Log(Blood) Log(Oral fluids) P-Value 
Log(Dose)   
 0.721 0.596 0.795 
0.019 0.069 0.018 
Log(Hair) 
0.721  0.887 0.721 
0.019 0.001 0.043 
Log(Blood) 
0.596 0.887  0.698 
0.069 0.001 0.054 
Log(Oral 
fluids) 
0.795 0.721 0.698  
0.018 0.043 0.054 
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3.10. Discussion 
3.10.1. Aim and the subjects 
In this chapter the main aim was to investigate and evaluate the relationship 
between the given dose and the concentration detected in hair, blood and oral fluids 
of subjects under controlled drug administration (in-patients). Five drugs and one 
active metabolite have been studied (procyclidine, quetiapine, chlorprothixene, 
haloperidol, risperidone and OH-risperidone). These drugs were chosen because of 
their wide prescription to psychiatric patients, high potential of short and long term 
side effects and toxicity and also for their resemblance to some degree with the 
majority of drugs of abuse, which target mostly brain cells.  
Addressing and evaluating the research question should provide a better confidence 
or understanding when interpreting forensic and clinical toxicological case results. 
This is particularly true for hair and oral fluids results, as hair is the most suitable 
sample with a wide window for retrospective investigation of drug intake, while 
collection of oral fluids is non-invasive, easy to provide, easy to collect and easier to 
extract/process. However, few studies in the literature have dealt with these issues 
and most of them were based on animal models or based on self-reported drug 
history. Therefore, their results may not be categorical or conclusive. In contrast, in 
this study the main criteria were to have human subjects and under controlled drug 
administration. Nevertheless, the only issue was the population size for those who 
agreed to participate. The number of patients for procyclidine was 17, 17 for 
quetiapine, 14 for risperidone, 14 for chlorprothixene and 10 for haloperidol. These 
patients were chosen primarily for their long and constant treatment regimen, which 
should have provided a steady-state level of drug in their biological system. Blood 
and oral fluids samples have been taken at the trough levels (pre-dose), while hair 
ones were the first segment (<1cm proximal end of hair strands).     
Patients’ drug history, age, hair colour and other relevant information have been 
taken. However, their possible influence on the results was not investigated as it 
clearly require a larger sample size to observe their real effect.  
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3.10.2. LC-MS 
Table 10 shows the accurate masses of the targeted analytes and internal 
standards extracted from the full scan (75-1200amu) run on the LC-MS system. The 
mass accuracy for all the analytes was less than 2ppm due to the high resolution 
(+50,000) of the Exactive (Orbitrap) system have provided a great selectivity, 
sensitivity and confidence in the results. On the other hand, the chromatography 
separation which was achieved by the HILIC condition is considered relatively 
unique as no paper was found in literature reporting analysis of these drugs with 
these conditions. The HILIC method showed good separation of the peaks with a 
short run time (7 min). In fact one of the advantages of HILIC is the low back 
pressure which allows for increasing the flow rate (0.5mL/min) making the run 
relatively fast without compromising the results as the resolution is very high. The 
isocratic mobile phase with high acetonitrile content has also contributed to the 
quick separation without the need of re-equilibrating the column as in a gradient run.          
3.10.3.  Blood and oral fluids analysis 
Blood and oral fluids samples were treated in the same way throughout the method 
development and validation as these matrices are composed mainly of water. 
Method development results showed that low strength NaOH solution (0.01M) could 
not provide enough alkalinisation to extract analytes from the aqueous phase into 
the solvent phase. Therefore, a very low recovery was seen, as shown in Table 11. 
Similarly, Tris buffer pH 9 did not produce any recovery except only 11% and 8% for 
chlorprothixene and haloperidol, respectively. However, 1M NaOH solution has 
provided the required pH to give the highest extraction yield for all analytes. The 
analytes have pKa ranging from 8.2-10.7 except Quetiapine (6.8) and 1M NaOH 
solution has pH of 14 so enough alkalinisation to ensure all analytes are non-
ionization in order to be extracted by the MTBE solvent.     
On the other hand, the fourth method of extraction, the protein crash, did show good 
recovery for four analytes (>60%) but procyclidine and chlorprothixene were not as 
good (<50%). One explanation could be a possible effect from ion suppression by 
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co-eluting endogenous compounds or metabolites as the crashing solvent dissolves 
many impurities alongside the targeted analytes. Unluckily, there was no possibility 
to investigate that effect further and the 1M NaOH showed enough recovery to be 
chosen as the successful extraction method. 
With regard to method validation for the successful method, linearity for blood and 
oral fluids calibrators was very good and showed r2=>0.998 for all analytes. LOD 
and LOQ were low enough for this type of study (below the drugs’ therapeutic 
concentrations range). They were found to be between 0.3 - 0.9ng/mL and 1 - 
2.7ng/mL, respectively for all analytes as shown in Table 12. They were calculated 
with the Equations 2-5 (page 91). Absolute recovery results for analytes in spiked 
oral fluids samples showed an acceptable level of >60% for all the analytes except 
in two cases with the low calibrator (0.1ng/mL) where quetiapine and 
chlorprothixene showed 51 and 44% recovery. In blood the absolute recoveries for 
all the analytes were generally lower, especially for procyclidine (80% in oral fluids 
and 48% in blood). Precision results for intra-day as shown in Table 15 were good 
with a CV below 15% for all analytes. However, inter-day precision was not as good. 
On some occasions (8 out of 72 results’ means) at the 0.1 and 0.5ng/mL 
concentrations the CV reached up to 38%. 
3.10.4. Hair analysis 
Conducting a hair analysis always starts with a decontamination step to reduce the 
interference from external contaminants, especially if the analysed drug presents in 
sebum or sweat. A very quick and effective decontamination step was applied to all 
samples as described in section  3.8.1.1 and discussed as well earlier in chapter 2. 
Following decontamination and reduction into 1-2mm snippets (25mg), authentic 
hair samples taken from patients on high chronic doses of procyclidine, quetiapine, 
risperidone, chlorprothixene and haloperidol were used for method optimization. 
Four different extraction methods were tested in triplicate on these authentic 
samples as described in the methods section. Method 3 (MAF) gave highest 
recoveries for procyclidine, chlorprothixene and haloperidol and second highest for 
OH-risperidone while method 1 (1M NaOH) gave highest recoveries for quetiapine 
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and risperidone. Therefore, these two methods combined got almost all the highest 
recoveries for the compounds of interest and the other two tested methods showed 
lower recoveries. Similar findings for similar drugs have been reported in the 
literature for the alkaline method (0.1M NaOH) (Shen et al. 2002a). MAF solution 
seems to be able to swell the hair and attract the basic drugs with its slightly acidic 
composition while NaOH dissolves the hair and frees the entrapped compounds. 
Summary of the findings can be seen in Figure 13. Combining methods 1 and 3 was 
chosen to ensure most if not all the amount of drugs present in hair were extracted.          
As the combined method (NaOH/MAF) was chosen validation was carried out and 
showed acceptable results. All analytes’ calibration lines were linear (r2>0.99). LOD 
and LOQ were 1.4-5.8 and 4.7-19.5pg/mg which were low enough for the purpose of 
this study. Intra- and inter-day precision from spiked hair revealed acceptable CV 
percentages of <20% for all analytes excluding 3 samples (≤26%). As for accuracy it 
can be seen clearly from Table19 that QC concentrations are within 80-120% except 
two results at low QC. Absolute recoveries were between 71 and 101% (CV<15%) 
which considered within acceptable ranges. Also no matrix effect was shown (98-
104%) and could only be seen slightly with procyclidine (85%).        
Analytes showed 78-106% (CV<10%) stability under the combined method 
extraction conditions. However, stability of the analytes under the alkaline conditions 
only was not great but that does not matter so much as these conditions are applied 
after the samples have been extracted initially with MAF incubation. 
3.10.5. Patients’ results 
Patients’ whole blood trough levels (pre-dose) of procyclidine results ranged from 30 
to 357ng/mL (dose 5-15mg/day). No whole blood range could be found in the 
literature for procyclidine. The reported therapeutic range in the literature, 80 to 
650ng/mL, is based on plasma levels (Hadidi 2004, Schulz et al. 2012). However, 
procyclidine is roughly 100% protein bound and plasma normally constitutes 
approximately 50% of the whole blood (Wishart et al. 2008). Therefore, the present 
study’s whole blood results should represent a 50% of the actual plasma 
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concentrations and consequently correspond very well with the literature plasma 
procyclidine range. Based on that almost all the patients are within the therapeutic 
drug level. With regard to oral fluids results, procyclidine pre-dose levels ranged 
from 7 to 395ng/mL and no procyclidine oral fluids data could be found in the 
literature. Analysis of procyclidine in patients’ hair revealed a concentration range 
from 0.12 to 5.62ng/mg and also no published procyclidine levels in hair were found.  
Blood trough levels of quetiapine (dose 100-600mg/day) for the studied subjects 
were between 1.2 and 337ng/mL except one patient with a high result (955ng/mL). 
However, nine of the patients had quetiapine concentrations <25ng/mL. Considering 
the published therapeutic serum level which is between 70 and 500ng/mL, these 
nine patients are possibly below the therapeutic target level even though quetiapine 
is mainly in the serum with reported protein binding of approximately 83% (Gerlach 
et al. 2007, Schulz et al. 2012), (DeVane, Nemeroff 2001b). As to subjects’ oral 
fluids quetiapine, the range was between 5 and 212ng/mL and no oral fluids data 
were found in the literature with regard to this drug. Hair results showed that 
quetiapine presence in relatively high amount in patients’ hair with a concentration 
range from 2.4 to 22ng/mL. Comparable results were reported in a previous study 
(Al Jaber, Holt & Johnston 2012). 
Risperidone (dose 3-8mg/day) and its active metabolite OH-risperidone  blood 
results were found to be in the range of 1 to 10ng/mL, except for one subject 
(68ng/mL) who was on the highest daily dose (8mg), and 4 to 44ng/mL, 
respectively. No whole blood results were found in literature except one study 
measuring the drug in plasma and in red blood cells (RBC) separately (Aymard et al. 
2002). The ranges they found for risperidone were 1-23 and 1-8ng/mL in plasma 
and RBC respectively, whereas for OH-risperidone they were 8-70 and 2.6-
22.5ng/mL for plasma and RBC, respectively. The reference therapeutic plasma 
levels are 2-20ng/mL and 10-100ng/mL for risperidone and OH-risperidone, 
respectively (Schulz et al. 2012). Results from oral fluids samples for both analytes 
were found to be between 1 and 31ng/mL for risperidone and 7.5 to 110ng/mL for 
OH-risperidone. Comparable results were found in published studies (Mandrioli et 
al. 2011, Saracino et al. 2010). With regard to hair results, they were ranging from 
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63 to 5318pg/mg and from 8 to 79pg/mg for both risperidone and its metabolite, 
respectively. Very similar ranges were reported in published studies (Al Jaber, Holt 
& Johnston 2012, Schneider et al. 2009). These results indicate that OH-risperidone 
has a much lower incorporation rate into hair than its parent drug and also the 
second alkaline extraction might have some effect on its results. A previous study 
showed that OH-risperidone gave similar recoveries from positive hair samples 
when extracted firstly with MAF (~50%) and secondly with NaOH digestion (~50%) 
(Al Jaber, Holt & Johnston 2012). It is also known that polar compounds show lower 
incorporation, compared to their less polar homologues (Nakahara, Kikura 1996). 
The focus in this research was mainly on parent drugs as they incorporate in hair 
more than their water-soluble metabolites. 
Trough concentrations (dose 50-150mg/day) for chlorprothixene in blood samples 
were between 13 and 41ng/mL. Only a serum and plasma therapeutic reference 
range was reported in the literature and was between 20 to 300ng/mL (Hiemke et al. 
2011). As chlorprothixene is known to bind to plasma protein to the extent of 90 to 
95% it would be normal to see lower concentrations with whole blood analysis 
(Ebadi 2007). Results from oral fluids samples ranged from 16 to 22ng/mL and no 
oral fluids range or data could be found in the literature. Hair results were between 
0.3 and 25ng/mg for the subjects and a slightly higher result (30ng/mg) has been 
reported in one publication (Shen et al. 2002b).  
Haloperidol trough blood concentrations (dose 10-30mg/day) were between 7 and 
27ng/mL. The clinically recommended therapeutic window is between 4 and 
26ng/mL in plasma or serum (Oliveira et al. 1996). Only one study was found 
reporting whole blood haloperidol levels and was 2.7ng/mL for a patient on a 
3mg/day dose (Seno et al. 1993). However, the present study’s subjects had an 
average of a 20mg/day dose. It is worth mentioning that haloperidol is around 90% 
bound to protein and therapeutic drug monitoring (TDM) is highly recommended for 
patients on it (Wishart et al. 2008, Hiemke et al. 2011). Subjects’ oral fluids 
haloperidol levels were between 6 and 38ng/mL. Similar oral fluids levels were 
found in the literature (Jain et al. 2011). Haloperidol seems to have the highest 
accumulation in hair among the studied drugs as patients’ results were between 15 
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and 80ng/mg. A published case has a concentration within the present study range 
(Shen et al. 2002b). Some published results were as high as 242ng/mg (Couper, 
McIntyre & Drummer 1995a). 
3.10.6. Correlation between blood, oral fluids, hair and 
dose 
As mentioned earlier the relationships between the given dose and the steady-state 
concentrations in hair, blood and oral fluids of subjects under controlled drug 
administration were investigated. Blood and oral fluids were pre-dose samples 
whereas hair samples were the proximal end (near the scalp) 0-0.6cm segments 
which should represent roughly drug consumption within the last two weeks. Starting 
with procyclidine, the only clear significant relationship found with this drug was 
between trough blood and hair concentrations (Pearson r=0.825, p=<0.001). 
Correlation between blood level and daily dose was weak (r=0.375, p=0.125), 
however, the logarithmically transformed results showed significant correlation with 
r=0.578, p=0.015 and slope of 1.011 (95% CI, 0.229-1.793). All the other 
procyclidine correlations were very weak and insignificant, between blood and oral 
fluids trough levels r=0.193 (p=0.491), oral fluids and dose r=0.283 (p=0.307), oral 
fluids and hair r=0.213 (p=0.446), and hair and dose r=0.215 (p=0.391). The clearly 
significant correlation between blood and hair levels indicates that procyclidine 
incorporation into hair is mainly through blood and the other ways of incorporation 
like sebum and sweat must be minimal. Inter-individual pharmacokinetic and 
pharmacodynamic variations are possibly the cause of the insignificant correlations 
found in the other specimens.         
Quetiapine on the other hand showed no correlations among all the types of 
matrices and daily dose with normal data. Correlations coefficients were r=-0.019 
(p=0.949) for dose and blood level, r=0.025 (p=0.933) for dose and oral fluids levels, 
r=0.287 (p=0.264) for dose and hair level, r=0.284 (p=0.326) for hair and blood 
levels, r=0.164 (p=0.576) for hair and oral fluids levels and r=-0.053 (p=0.864) for 
blood and oral fluids levels. However, when logarithmically transformed a significant 
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correlation appeared between blood and hair concentrations r=0.564 (p=0.036) and 
slope of 1.501 (95% CI, 0.132-2.870).  These results also could be due to inter-
individual variations. 
Contrary to quetiapine, risperidone results have shown remarkable and significant 
correlations among concentrations in all types of matrices tested and daily dose, 
both in normal data and in the logarithmically transformed data. Correlation 
coefficients for dose/blood level, dose/oral fluids level and dose/hair level were 
r=0.62 with p=0.009, r=0.67 with p=0.012 and r=0.67 with p=0.017, respectively. 
The strongest correlation was between blood and hair levels, r=0.96 (p=<0.001), 
followed by oral fluids and hair levels with r=0.66 (p=0.013), whereas the weakest, 
but still significant, was between blood and oral fluids concentrations, r=0.59 
(p=0.035). 
Unlike its parent drug, OH-risperidone did not show any correlation between the 
dose and any matrix level as correlation coefficients were r=0.15 (p=0.610), r=0.06 
(p=0.838) and r=-0.20 (p=0.515) for dose/blood level, dose/oral fluids level, 
dose/hair level, respectively. Also no significant correlations were found between 
blood with hair levels and oral fluids with hair levels as coefficients results were 
r=0.24 (p=0.437) and r=-0.03 (p=0.937), respectively. Only weak correlation was 
observed between blood and oral fluids levels, r=0.51 (p=0.075). 
Chlorprothixene correlation results were significant only between dose and oral 
fluids level (r=0.678, p=0.045) and between blood and oral fluids levels (r=0.792, 
p=0.011). Correlation coefficients between chlorprothixene dose and blood or hair 
trough levels were r=0.37 (p=0.211) and r=0.40 (p=0.176), respectively. 
Chlorprothixene hair and blood levels had an insignificant correlation (r=0.32, 
p=0.319). Similarly, hair and oral fluids drug levels showed a correlation coefficient 
of r=0.21 with p=0.625. One of the possible reasons would be the limited number of 
participants which were not enough to soften the pharmacokinetic/dynamic 
variations between subjects. 
Haloperidol correlation results were similar to those of risperidone. Significant 
correlations existed between blood and oral fluids trough drug levels (r=0.76, 
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p=0.03), oral fluids with hair levels (r=0.83, p=0.012) and daily dose with hair drug 
level (r=0.65, p=0.042). An even stronger correlation was found between blood and 
hair concentrations, r=0.90 with p=<0.001. However, between the daily dose and 
blood and oral fluids drug levels the correlations were slightly weaker, r=0.58 with 
p=0.080 and r=0.66 with p=0.073, respectively. Correlation results significantly 
increased when they were logarithmically transformed e.g. dose and oral fluids gave 
r=0.795 with p=0.018. Matsuno et al conducted a similar study and found significant 
correlations as well between both haloperidol hair concentration and daily dose 
(r=0.682, p=<0.001) and with plasma concentration (r=0.558, p=<0.001) (Matsuno, 
Uematsu & Nakashima 1990). However, they did not find a significant correlation 
between plasma drug level and daily dose. 
Regardless of pharmacokinetic and hair growth inter-individual variations and the 
risperidone metabolite, in this study four out of the five investigated drugs showed 
significant correlation between hair and blood concentrations. Therefore this study 
supports that the bloodstream must be playing a major role in hair drug 
incorporation. Similarly with oral fluids four out of the six compounds (including OH-
risperidone) showed correlation between blood and oral fluids. Therefore, compiling 
data from such studies could be used to establish therapeutic limits for the 
alternative matrices, as alternative samples have many advantages.  
The lack of a correlation between the dosage of the drugs given to the patients and 
the blood concentrations should be taken into great consideration as it showed 
clearly that the assigned therapeutic levels should remain tentative due to the great 
inter-individual variations observed with these drugs.    
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Table 41: Summary of all Pearson correlation coefficients and their P-values 
r Pearson correlation coefficient  (P-value) 
Drug Blood/Dose Oral fluids/Dose Hair/Dose 
Blood/Oral 
fluids 
Oral 
fluids/Hair Hair/Blood 
Procyclidine 0.38 (0.13) 0.28 (0.31) 0.22 (0.39) 0.19 (0.49) 0.21 (0.45) 0.83 (0.001) 
Quetiapine -0.02 (0.95) 0.03 (0.93) 0.29 (0.26) -0.05 (0.86) 0.16 (0.58) 0.28 (0.33) 
Risperidone 0.62 (0.02) 0.67 (0.01) 0.67 (0.01) 0.59 (0.04) 0.66 (0.01) 0.96 (0.001) 
OH-risperidone 0.15 (0.61) 0.06 (0.84) -0.20 (0.52) 0.51 (0.08) -0.03 (0.94) 0.24(0.44) 
Chlorprothixene 0.40 (0.18) 0.68 (<0.05) 
0.37 (0.21) 0.79 (0.01) 0.21 (0.63) 0.32 (0.32) 
Haloperidol 0.58 (0.08) 0.66 (0.07) 0.65 (0.04) 0.76 (0.03) 0.83 (0.01) 0.90 (0.001) 
Green: significant correlations. Yellow: weak correlations or significant when Log transformed.  
3.10.7. Effect of t ½ on drug incorporation into hair 
It is known that a number of factors contribute to drug incorporation into hair such as 
basicity and lipophilicity of the drug and the melanin content of the hair (Pragst, 
Balikova 2006). In the present study another factor has been looked at which is the 
drug half-life in blood and its effect on drug incorporation into hair. Kintz et al 
mentioned that when drug plasma half-life increases the correlation between hair 
concentration and dose increases (Kintz et al. 1998). However, they did not look at 
the hair incorporation effect. When the ratios of hair concentration over daily dose of 
the investigated drugs were plotted against their blood half-lives it showed a very 
remarkable and significant correlation (r2=0.96, p≤0.003) as seen in Figure 26. 
Procyclidine, quetiapine, risperidone, chlorprothixene and haloperidol half-lives were 
12, 6, 8.5, 10 and 36 hours, respectively (Whiteman et al. 1985, DeVane, Nemeroff 
2001a, Raaflaub 1975, de Leon et al. 2004, Feng et al. 2008).  
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Figure 26: The correlation between concentration in hair over dose ratio and the elimination half-life 
of the drugs (r2 = 0.96, p ≤ 0.003) 
 
3.11. Conclusion 
After development and validation of the LLE-LC-MS method for the analysis of anti-
psychotics in blood, oral fluids and hair, an investigation was carried out on the 
correlation pattern between trough levels in those three matrices. The most 
significant correlation coefficients (r) found were those between blood and hair 
concentrations, procyclidine r=0.83 (18 subjects p=<0.001), risperidone r=0.96 (14 
subjects p=<0.001), haloperidol r=0.90 (10 subjects p=<0.001), OH-risperidone 
r=0.24 (13 subjects p=>0.44), quetiapine r=0.28 (14 subjects p=>0.33) and 
chlorprothixene r=0.32 (13 subjects p=>0.32). Among the interesting results is the 
strong correlation found between drug half-lives and the mean ratio of hair 
concentration/dose (r= 0.96, p≤0.003).
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4. Chapter 4 - Stability of some 
psychoactive drugs in dried blood spots 
from real patients’ samples 
4.1. Introduction 
Dried blood spot (DBS) sample collection is a well-established practice for the 
identification of metabolic errors or congenital disorders of metabolism for neonates 
since almost half a century. This technique was published in the sixties by Dr Robert 
Guthrie, and the filter paper cards used for blood collection are named after him 
(Guthrie, Susi 1963). Dr Guthrie used the cards for the collection of newborn blood 
to detect phenylalanine. Subsequently, a number of screening tests for different 
metabolic disorders in the newborn have emerged using the DBS technique (Mei et 
al. 2001). In recent years the applications of DBS have been expanded further to 
include drugs and their metabolites in pharmacokinetic studies and therapeutic drug 
monitoring (AbuRuz, Millership & McElnay 2006, Edelbroek, Heijden & Stolk 2009). 
Furthermore giant pharmaceutical companies are adapting this technique for clinical 
drug development particularly in their toxicokinetics and pharmacokinetics studies 
(Spooner, Lad & Barfield 2009), as DBS sampling has many advantages over the 
traditional way of venipuncturing or cannula sampling.  DBS require only a drop of 
blood from a finger, toe or heel pricking whereas in conventional sampling normally 
≥ 0.5mL is needed. DBS decreases the risk of infections with blood-borne viruses. 
Moreover, transportation of DBS samples is predominantly easier than liquid 
biological samples (e.g. plasma, blood, etc) since the analytes are generally much 
more stable and do not require dry ice or refrigeration; they can even be posted by 
mail (La Marca et al. 2009). Sample stability is of paramount importance in order to 
ensure accurate results. Degradation of analytes in the sample is usually caused by 
three possible reactions: hydrolysis, oxidation and reduction (Drummer 2004). The 
commonest among them is the hydrolysis of amide and ester groups within drugs’ 
structures (Waterman, Adami 2005). For instance, it has been found that 
Chapter 4 - Stability of some psychoactive drugs in dried blood spots 
Page 149 of 255 
 
hydrolytically labile drugs were much more stable in DBS compared to liquid 
samples after 1 year in different storage temperatures (Alfazil, Anderson 2008). In 
addition, the non-invasive DBS technique made it easier for volunteers to participate 
in clinical studies, particularly when paediatric patients are needed. Another great 
advantage of DBS analysis is the great potential for automation of sample 
processing. A number of companies have already launched machines that 
automatically punch the cards, do the extraction/cleaning and introduction/injection 
into the LC-MS/MS system as shown in Figure 27 and 28 below. 
 
  
Figure 27: Dried blood spot analysis automation (Karolia 2011, Camag AG 2011) 
 
  
Figure 28: Specially designed cards for microvolume DBS analysis (ichrom.com 2011, Whatman.com 
2009)  
Chapter 4 - Stability of some psychoactive drugs in dried blood spots 
Page 150 of 255 
 
4.1.1. Filter papers/cards 
Currently, there are a number of different types of DBS cards available on the 
market. For drugs and small molecules analysis Guthrie cards (Schleicher & Schuell 
903®) can be used, they are made of 100% pure cotton linters with no wet-strength 
additives (Li, Tse 2010).  They have been used widely for newborn screening and 
other uses. The other types such as FTA and FTA Elute are pre-treated cards with 
chemicals to denature proteins, lyse cells and protect samples from bacterial growth 
(http://www.whatman.com).   
4.1.2. Haematocrit 
Haematocrit is the proportion volume of red blood cells out of the total volume of 
whole blood (all components).  The percentage of haematocrit in blood varies with 
age, sex and general health (Jopling et al. 2009). The ranges are between 0.37 and 
0.51 among adults, 0.35 and 0.42 among children and 0.28 to 0.67 in neonates 
(Kayiran et al. 2003, Wilhelm et al. 2009). The importance of haematocrit effect lies 
on its effect on the pattern of distribution of the blood drop and its diffusion in the 
filter paper. Haematocrit has great impact on the viscosity of the blood. Thus, if the 
blood has a high haematocrit percentage it would result in a smaller and more 
concentrated spot on the filter paper and vice versa in the case of a low haematocrit 
sample. However, a number of studies have been conducted on evaluating the 
haematocrit effect on DBS samples and the conclusion is that it seems that the 
effect maybe case dependent as it not predominantly significant with most of the 
tested analytes (Li, Tse 2010).    
4.1.3. Spot volume 
Due to the advances in the sensitivity of mass spectrometry detectors, especially the 
tandem ones, it became no longer necessary to have a large volume of samples 
(e.g. 1mL) for extraction of analytes. Some new DBS methods use only 10µL blood 
spot (micro-whole blood analysis) (AbuRuz, Millership & McElnay 2006, Déglon et al. 
2010, Déglon et al. 2009).  
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Unlike the recent trend in the published DBS studies, where they punch the filter 
cards with a 3mm punch in the centre of the spot after drying out, in this study the 
whole spot was taken and precise and consistent amount of blood (50µL) has been 
used/spotted for each sample. The reason behind the adoption of this method is to 
prevent the possible inaccuracy in the results when an uneven distribution of blood 
on the paper occurs. Therefore, this way will reduce the effect of haematocrit 
difference between samples.      
 
4.2. Dried blood spot analysis 
4.2.1. Aim of the study 
The first aim of this study was to develop and validate a method to enable the use of 
the DBS technique for the analysis and quantification of some of the common 
psychoactive drugs used in psychiatric clinics in Kuwait. Secondly, to investigate the 
stability of these drugs in 50µL of whole blood spotted, dried and stored for 6 
months in freezers (-20 and -80⁰C), refrigerator (4⁰C) and at room temperature 
(25⁰C). Another objective was to see the effect of impregnating the cards with 
sodium fluoride prior to spotting on the stability of the drugs. 
4.2.2. Study analytes  
The analytes of interest in this study are the same as those covered in the previous 
chapter. The structures and brief information about each analyte are found in 
chapter 3. These analytes were procyclidine, quetiapine, risperidone, 9-OH-
risperidone, chlorprothixene and haloperidol. 
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4.2.3. Source of samples 
Blank blood (drug free) was collected from laboratory personnel. The source of 
blood positive samples used in this study was a selection of patients’ samples with 
the highest drug concentrations found in the previous study (chapter 3) for which 
consent and ethical approval had been already granted. The reason behind that 
selection is to empower the study’s results with authentic patients’ samples and 
avoid building conclusions based on spiked samples even though they are generally 
and widely accepted. More than one patient sample has been selected for each 
drug with the highest concentrations as illustrated in results’ tables (section  4.5.5). 
Forty spots from each patient sample were spotted on the cards to cover the 
different storage time/temperature regimens. 
4.2.4. Materials and reagents 
All chemicals were of HPLC or analytical grade. All consumables (tubes, etc) are 
from VWR UK. Whatman 903 neonatal Guthrie cards were purchased from 
Whatman USA. The rest of chemicals used in the solutions below are from Sigma-
Aldrich Co. UK. For drug and solvent standards see section  2.2.2 and  3.4.  
Other solutions used in this chapter have been mentioned in section  2.2.2.2.  
Standard solutions 
1000µg/mL or 100µg/mL working standards of procyclidine, quetiapine, risperidone, 
9-OH-risperidone, chlorprothixene, haloperidol, nortriptyline-D3 and haloperidol-D4 
were made with MS grade methanol. All were stored at -20⁰C. 
Quality control samples (QCs) 
QCs were prepared in two concentrations, lower 0.5µg/mL and higher 2µg/mL. The 
higher QC samples were prepared by dissolving 10µL of 1000µg/mL stock standard 
of the analyte in 4.990mL pooled drug free blood (containing fluoride/oxalate as 
preservative and anticoagulant). Whereas the lower QCs were prepared by diluting 
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1mL of the higher QC mixture with 3mL pooled drug free blood. All the mixtures 
were thoroughly mixed and divided into 150µL aliquots, stored in 0.5mL Eppendorf 
tubes and kept at -80°C until analysis. Prior to experiments QC aliquots were 
thawed at room temperature and 50µL was spotted on the filter paper 3-18 hours 
before extraction and analysis. 
DBS extraction solution MAF 
80mL of 0.1% formic acid methanol, 10mL of acetonitrile and 10mL of deionized 
water were measured in measuring cylinder, mixed well and stored at room 
temperature. 
NaF solution 0.5% (w/v) 
100mg of sodium fluoride salt was dissolved in 20mL of deionized water, mixed 
properly and stored in the fridge. (20µL was used for preserving a filter paper card 
spot). 
Calibration standards 
Calibration samples were prepared by dissolving 50µL of 1000µg/mL stock standard 
of the analyte in 4.95mL pooled drug free blood (containing fluoride/oxalate as 
preservative and anticoagulant) to produce 10µg/mL. A series of dilutions followed 
with blank blood to produce a range of 2.5 to 2000ng/mL. Fifty milliliters of the 
spiked blood were spotted on the cards. 
4.2.5. Blood spotting 
50µL of blank, spiked (calibrators/QCs) or patient blood samples were spotted on 
the Whatman 903 neonatal cards using a volumetric pipette after 30 minutes of 
proper mixing to ensure homogeneity and equal distribution of analytes in the 
samples. The cards were allowed to dry at room temperature for >3 hours. Each 
card then was packed in a sealable plastic bag containing a desiccant pad and 
packed again in a paper envelope and stored until the stability analysis due date. 
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The storage temperatures were varied for stability experiments (25, 4, -20 and -
80˚C). 
   
Figure 29: 50µl aliquots of spiked blood spotted on Guthrie cards, dried, and punched out 
4.2.6. Method development 
4.2.6.1. Extraction optimization 
Four liquid-liquid extraction solutions were used and their extraction efficiencies for 
the analytes were evaluated. 2mL blank blood was spiked with 1µg/mL of analytes 
and mixed thoroughly, then spotted on the cards (50µL for each spot) and allowed 
to dry at ambient temperature on a drying rack. After drying, dried blood spots were 
then punched out with 1.3cm diameter punch. Each disc was placed in an 8mL tube, 
60µL of internal standard mixture (1µg/mL of haloperidol-D4 and nortriptyline-D3) 
was added and the following methods were applied in triplicate. 
DBS extraction method 1 and 2 
One and a half mL of either MAF (method 1) solution (0.1% formic acid 
methanol/acetonitrile/deionized water - 8:1:1) or MTBE (method 2) was added to the 
tubes containing 60µL of internal standard with the discs and vortex mixed for 15 
minutes and then sonicated for 1 hour at 40˚C. The discs were then removed and 
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the remaining solution was evaporated under nitrogen. The extracts were then 
reconstituted in 0.3mL of 0.1M NaOH solution, followed with 0.3mL MTBE and 
vortex mixed for 2 minutes, centrifuged and then the solvent layer were transferred 
into 0.3mL auto-sampler vials. The solvent then was evaporated under nitrogen and 
finally reconstituted in 120µL of acetonitrile and 10µL was injected into the LC-MS 
system.   
DBS extraction method 3 and 4 
One and half mL of 0.1M or 0.05M phosphate buffer (extraction method 3 or 4, 
respectively) was added to the tube containing 60µL internal standard with the disc 
and vortex mixed for 15 minutes and then sonicated for 1 hour at 40˚C. The disc 
was then removed and to the remaining solution 0.5mL of 1M NaOH was added, 
vortex mixed for 30 seconds, followed with 2mL MTBE and mixing on a rotary mixer 
for 30 minutes, centrifuged thereafter and the solvent layer was transferred into new 
tubes and evaporated/reduced under nitrogen to ~0.25mL and transferred finally to 
0.3 mL auto-sampler vials. The solvent then was evaporated completely under 
nitrogen and reconstituted in 120µL of acetonitrile and 10µL was injected into the 
LC-MS system.   
4.2.6.2. Extraction optimization results 
Following the application of the four methods, results showed that method 1 (MAF) 
produced the highest recoveries for most of the analytes with recoveries ranging 
from 79 to 106% except chlorprothixene (54%). Method 2 (MTBE) also showed 
good recoveries for most the analytes ranging from 61 to 122% except for 
risperidone and its metabolite, 47 and 26% respectively. The other methods, 3 and 
4, gave generally poor recoveries with mean recoveries for all analytes of 37 and 
41% respectively. Details are shown in Table 42. 
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Table 42: Recovery of (1µg/mL) drugs from DBS using four different solutions (n=3) 
Analytes 
Mean recovery %              (CV %) 
Method 1 
MAF 
Method 2 
MTBE 
Method 3 
Phos 0.1M 
Method 4 
Phos 0.05M 
Procyclidine 106  (7) 122  (12) 59  (5) 63  (3) 
Quetiapine 83  (20) 61  (9) 31  (5) 33  (8) 
Risperidone 79  (16) 47  (5) 47  (6) 54  (2) 
9-OH-risperidone 79  (4) 26  (10) 32  (15) 40  (15) 
Chlorprothixene 54  (12) 76  (14) 8  (6) 9  (7) 
Haloperidol 84  (14) 92  (5) 43  (7) 47  (7) 
Mean 81 71 37 41 
 
4.2.6.3. Successful method 
Method 1 (MAF) showed the best general recoveries compared to the other 
methods and also better reproducibility. MAF solution also showed the ability to 
partially extract/release haemoglobin from the spots unlike MTBE. In addition 
methods 1 and 2 were simpler and faster than methods 3 and 4. Therefore, method 
1 was chosen for the rest of this project.  
4.2.7. LC-MS method 
The LC-MS method is described in section  3.6. 
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4.2.7.1. Ion identification results 
 
Table 43 shows the molecular formula of the analytes, accurate masses, retention 
times and mass accuracies. Mass accuracy with Exactive MS was <1ppm which 
means that the potential for interference from unknown components was very little. 
Figure 30 shows extracted ion chromatograms for spiked analytes at 10ng/mL, 
while, Figure 31 shows the mass spectra of each analyte ion after extraction from 
full scan (75-1200 amu) at retention time. Retention chromatograms are shown in 
stability results, section  4.4. 
 
Table 43: Target analytes plus internal standards and their relevant data 
Analyte Formula (+H) 
Accurate 
mass (M+H) 
Retention 
time Mass accuracy 
Procyclidine C19H30NO 288.2322 4.5 0.066 ppm 
Quetiapine C21H26O2N3S 384.1739 5.2 -0.115 ppm 
Risperidone C23H28FN4O2  411.2190 5.7 -0.148 ppm 
9-OH-
risperidone C23H28FN4O3  427.2141 5.0 0.155 ppm 
Chlorprothixene C18H19ClNS  316.0921 4.4 0.017 ppm 
Haloperidol C21H24ClFNO2 376.1476 4.4 0.448 ppm 
Haloperidol-D4 C21H20D4ClFNO2 380.1722 4.4 -0.732 ppm 
Nortriptyline-D3 C19H19D3N  267.1934 4.5 -0.324 ppm 
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Figure 30 : Set of extracted ion chromatograms, sample spiked with 10ng/mL analytes and 1µg/mL 
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Figure 31: Mass spectra for analytes (1µg/mL) at their mass and retention range 
 
4.2.8. Method validation 
4.2.8.1. Linearity 
Linearity was attained from spotting 50µL of blank blood samples spiked with 
concentrations ranging from 2.5, 5, 10, 25, 100, 500, 1000 and 2000ng/mL of each 
analyte. Deuterated internal standards were 1µg/mL. The resulting ratio of peak 
areas of analytes/internal standard plotted versus the spiked analyte concentrations 
were plotted and linear correlation coefficients (r2) calculated. The correlation 
coefficient (r2) value indicate the degree of linearity (r2 should be >0.99). 
4.2.8.2. Recovery 
Recoveries were estimated by measuring peak areas obtained when the drugs were 
spiked into blank blood at three concentrations 100, 500, and 2000µg/mL (n=3) 
before spotting them on cards against unextracted neat standards dissolved in 
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acetonitrile. This recovery takes into account all the extraction steps including matrix 
effect (absolute recovery). The recovery was calculated as a percentage by dividing 
the average peak area of the extracted standards by the average peak area of the 
duplicate unextracted standards and multiplied by 100.  
4.2.8.3. Intra-day precision 
The intra-day precision was made by spiking blank blood samples with two 
concentrations (medium and high) in five replicates, then spotting them on cards. 
After extraction and analysis, precision was measured by calculating the coefficient 
of variation expressed as a percentage (CV %). 
4.2.8.4. Inter-day precision 
Inter-day precision experiment was done through replicate analysis of intra-day 
experiments over 5 days and the coefficient of variation percentage (CV %) was 
calculated between concentrations of each analyte over these five days. 
4.2.8.5. LOD and LLOQ 
Limit of detection (LOD) and lower limit of quantification (LLOQ) was assessed by 
spiking blank blood with the analytes in decreasing concentrations before spotting 
them on cards. LOD is defined as the lowest detectable concentration of the analyte 
that differentiates it from the background noise by three fold, whereas LLOQ is 
lowest quantitative concentration that fulfils the required accuracy and precision (10 
fold higher than the noise). The spiked concentrations were 1, 2.5, 5, 10 and 
25ng/mL of each analyte and 1000ng/mL was the concentration of deuterated 
internal standard. Ten µL of final extract was injected into the LC-MS system. 
Signal-to-noise ratio is the method that has been used to calculate LOD and LLOQ, 
and 3 and 10 respectively were the cut-offs. LODs and LLOQs were calculated 
using 
Equation 2 to Equation 5 (page 91). 
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4.2.8.6. Method validation results 
The relationship between analyte concentrations and peak area ratios was linear 
over the range of 2.5 to 2000ng/mL and the linear correlation coefficients (r2) were 
better than 0.99 for all analytes as shown in Table 44 and Figure 32. LOD and 
LLOQ were calculated using Equations 2-5 and also from the chromatograms. LOD 
values for all analytes were 0.1-1.5ng/mL and LLOQ values were 0.4-4.5ng/mL. The 
details presented in Tables 44 and 45. 
Table 44: Linear correlation coefficients, LODs and LLOQs for analytes in DBS calculated using 
Equations 2-5 
Analyte 
Linear 
correlation 
coefficient 
(r2) 
LOD 
ng/mL 
LLOQ 
ng/mL 
Procyclidine 0.9938 0.1 0.4 
Quetiapine 0.9979 0.7 2.4 
Risperidone 0.9977 1.0 3.4 
9-OH-risperidone 0.9967 1.1 3.7 
Chlorprothixene 0.9924 0.6 1.9 
Haloperidol 0.9992 0.2 0.7 
 
Table 45: Linear correlation coefficients, LODs and LLOQs for analytes in DBS calculated from the 
chromatograms 
Analyte 
Linear 
correlation 
coefficient 
(r2) 
LOD 
ng/mL 
LLOQ 
ng/mL 
Procyclidine 0.9938 1.5 4.5 
Quetiapine 0.9979 0.5 1.5 
Risperidone 0.9977 0.2 0.6 
9-OH-risperidone 0.9967 0.3 1.0 
Chlorprothixene 0.9924 0.5 1.5 
Haloperidol 0.9992 0.7 2.0 
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Figure 32: DBS calibration lines for all analytes 
 
As shown in Table 46 the method revealed good precision and the coefficient of 
variation (CV%) for intra- and inter-day precision was in the range 2-15 and 2-12% 
respectively, which are considered to be acceptable. 
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Table 46: Inter-day and intra-day precision results in DBS 
Analyte 
Inter-day mean (CV%) 
n=5 
Intra-day mean (CV%) 
n=5 
0.5µg/mL 2µg/mL 0.5µg/mL 2µg/mL 
Procyclidine 0.506 (3) 2.142 (2) 0.536 (2) 2.174 (5) 
Quetiapine 0.456 (5) 1.901 (2) 0.448 (6) 2.106 (9) 
Risperidone 0.463 (8) 2.084 (3) 0.492 (3) 2.107 (7) 
9-OH-Risperidone 0.491 (10) 1.925 (3) 0.457 (15) 2.132 (8) 
Chlorprothixene 0.476 (12) 2.077 (5) 0.473 (13) 2.152 (3) 
Haloperidol 0.442 (7) 1.924 (5) 0.525 (5) 2.139 (7) 
 
The overall means of absolute recoveries for all analytes at the three concentrations 
were in the range of 64 to 94% as shown and detailed in Table 47.   
Table 47: Absolute recovery (RE%) results for 0.1, 0.5 and 2µg/mL of analytes spiked in DBS (n=3) 
Analyte 0.1µg/mL (RE%)   %CV 
0.5µg/mL 
(RE%)  %CV 
2µg/mL 
(RE%) %CV 
Mean 
(%CV) for 
3 Conc. 
Procyclidine 63 3 65 8 63 3 64 (2) 
Quetiapine 46 4 77 4 70 2 64 (25) 
Risperidone 59 5 91 2 85 2 78 (22) 
9-OH-risperidone 62 2 86 3 75 4 74 (16) 
Chlorprothixene 69 4 66 10 67 6 67 (2) 
Haloperidol 102 3 98 1 83 2 94 (11) 
4.3. Impregnation/pre-treatment with sodium fluoride 
In order to look at the efficacy of pre-treating Guthrie cards with preservative such 
as sodium fluoride, half of the stability study spots/circles were pre-treated with 20µL 
of 5mg/mL NaF solution. This amount was enough to spread all over the spot 
(13mm). The pre-treated cards/spots were allowed to dry completely before 
applying/spotting patients’ blood samples. Data analysis was performed using 
Microsoft Excel 2010. A t-test was done to test whether the analyte concentrations 
from patients’ blood spotted on NaF treated cards and the corresponding untreated 
cards were significantly different. The threshold chosen for statistical significance 
was p=<0.05. 
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4.4. Stability results  
4.4.1. Procyclidine 
Table 48: Stability of procyclidine in DBS from patient 1 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 260.7 268.7 260.7 268.7 260.7 268.7 260.7 268.7 
45 180.1 177.5 206.1 240.4 272.8 284.2 257.1 272.5 
90 185.3 223.3 229.5 241.5 225.4 210.2 197.5 201.4 
180 198.6 216.2 223.4 209.0 222.1 218.0 231.7 227.5 
Table 49: Stability of procyclidine in DBS from patient 2 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 97.8 119.1 97.8 119.1 97.8 119.1 NA NA 
45 117.3 96.5 105.5 98.7 112.9 105.4 NA NA 
90 119.3 102.3 120.2 116.1 112.8 112.1 NA NA 
180 125.4 124.5 139.1 120.4 139.5 139.3 NA NA 
   NA, not available (amount of the patient sample was not enough to cover all conditions) 
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Figure 33: Procyclidine and IS chromatograms from low calibrator and patient 2 DBS samples 
4.4.2. Quetiapine 
Table 50: Stability of quetiapine in DBS from patient 1 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 324.5 331.8 324.5 331.8 324.5 331.8 324.5 331.8 
45 221.6 194.7 299.6 276.1 272.3 268.4 273.1 276.0 
90 230.3 187.5 178.7 208.4 194.4 239.7 249.4 218.5 
180 215.1 227.1 242.1 204.9 264.9 212.8 248.8 245.6 
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Table 51: Stability of quetiapine in DBS from patient 2 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 164.0 166.4 164.0 166.4 164.0 166.4 164.0 166.4 
45 133.6 138.4 152.3 154.1 153.6 140.2 157.5 150.9 
90 150.6 151.3 123.2 152.4 126.7 159.5 141.5 144.2 
180 148.1 149.5 168.5 156.2 135.7 144.9 142.4 146.5 
 
 
Figure 34: Quetiapine and IS chromatograms from low calibrator and patient 2 DBS samples 
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4.4.3. Risperidone 
Table 52: Stability of risperidone in DBS from patient 1 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 3.9 3.7 3.9 3.7 3.9 3.7 3.9 3.7 
45 4.3 4.5 5.4 5.5 5.2 4.2 3.7 4.5 
90 3.5 3.6 3.2 3.6 3.7 3.5 3.5 3.3 
180 4.0 4.2 4.7 4.5 3.4 4.4 3.9 4.0 
 
Table 53: Stability of risperidone in DBS from patient 2 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 48.8 45.5 48.8 45.5 48.8 45.5 NA NA 
45 50.6 51.1 42.6 46.4 43.2 45.3 NA NA 
90 42.7 44.6 42.3 46.0 40.4 42.1 NA NA 
180 45.3 39.7 43.4 40.6 40.9 43.3 NA NA 
    NA, not available (amount of the patient sample was not enough to cover all conditions) 
Chapter 4 - Stability of some psychoactive drugs in dried blood spots 
Page 168 of 255 
 
 
Figure 35: Risperidone and IS chromatograms from low calibrator and patient 2 DBS samples 
4.4.4. OH-risperidone 
Table 54: Stability of OH-risperidone in DBS from patient 1 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 17.6 16.0 17.6 16.0 17.6 16.0 17.6 16.0 
45 17.8 16.1 14.7 14.5 18.1 18.4 18.6 16.9 
90 21.1 18.1 19.0 19.9 17.0 19.9 NF 20.3 
180 24.7 21.7 27.9 22.8 23.3 20.5 22.9 22.2 
    *NF (not found). 
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Table 55: Stability of OH-risperidone in DBS from patient 2 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 40.3 42.2 40.3 42.2 40.3 42.2 40.3 42.2 
45 39.2 33.4 42.4 42.8 38.6 38.9 43.4 41.1 
90 35.0 35.7 24.3 34.1 28.6 34.6 32.7 27.6 
180 39.2 38.1 41.4 40.4 32.9 36.3 37.1 37.3 
 
Table 56: Stability of OH-risperidone in DBS from patient 3 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 23.0 20.1 23.0 20.1 23.0 20.1 NA NA 
45 17.3 19.0 16.9 16.6 15.2 14.2 NA NA 
90 13.5 15.5 18.2 13.4 12.8 12.2 NA NA 
180 16.1 13.4 14.3 13.5 14.3 14.9 NA NA 
   NA, not available (amount of the patient sample was not enough to cover all conditions) 
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Figure 36: OH-risperidone and IS chromatograms from low calibrator and patient 2 DBS samples 
4.4.5. Chlorprothixene 
Table 57: Stability of chlorprothixene in real patient DBS sample 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 8.1 8.9 8.1 8.9 8.1 8.9 8.1 8.9 
45 3.7 7.4 7.4 5.7 6.9 8.6 7.1 7.7 
90 8.3 9.5 8.4 9.2 8.1 7.5 NF 7.2 
180 11.7 11.2 14.6 13.0 12.9 14.7 12.0 12.4 
   *NF (not found). 
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Figure 37: Chlorprothixene and IS chromatograms from low calibrator and patient DBS samples 
4.4.6. Haloperidol 
Table 58: Stability of haloperidol in DBS from patient 1 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 30.7 31.4 30.7 31.4 30.7 31.4 30.7 31.4 
45 27.3 26.0 32.6 27.8 29.5 30.4 33.9 31.0 
90 28.6 29.5 27.1 27.7 29.9 29.0 29.3 30.7 
180 28.5 27.7 26.4 23.3 31.2 25.7 27.8 28.7 
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Table 59: Stability of haloperidol in DBS from patient 2 
Time 
(day) 
Storage condition 
Room 
temperature 
(25 °C) 
(ng/mL) 
Refrigerator 
(4 °C) 
(ng/mL) 
Freezer 
(-20 °C) 
(ng/mL) 
Freezer 
(-80 °C) 
(ng/mL) 
Pre-
Treated - NaF - NaF - NaF - NaF 
0 8.9 7.3 8.9 7.3 8.9 7.3 NA NA 
45 4.9 6.5 5.2 5.6 3.7 4.4 NA NA 
90 8.3 8.6 7.8 9.3 8.2 8.4 NA NA 
180 8.0 7.9 8.5 8.0 8.0 8.2 NA NA 
   NA, not available (amount of the patient sample was not enough to cover all conditions) 
 
Figure 38: Haloperidol and IS chromatograms from low calibrator and patient 1 DBS samples 
4.4.7. Stability results summary 
Analytes were found to be stable in dried blood spots stored at room temperature 
(25±2°C) over 180 days and the loss observed was minimal. Testing on day 45 
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showed analyte stability to be between 72 and 108% compared to initial 
concentrations, while testing on days 90 and 180 showed stabilities ranges from 80 
to 104% and 79 to 134%, respectively. Details are shown in Table 60.  
Table 60: Stability of analytes in DBS stored at 25ºC 
Analyte 
Percentage of stability for all patients (CV%) 
Day 0 Day 45 Day 90 Day 180 
DBS  DBS DBS DBS 
Procyclidine 100 72 (11) 80 (10) 87 (17) 
Quetiapine 100 78 (10) 85 (14) 79 (17) 
Risperidone 100 108 (4) 93 (6) 99 (12) 
9-OH-risperidone 100 91 (12) 96 (19) 81 (19) 
Chlorprothixene 100 64 (40) 104 (2) 134 (11) 
Haloperidol 100 79 (21) 100 (12) 95 (9) 
 
Analysis of patients’ dried blood spots after 6 months of storage in the refrigerator 
(4±1°C) revealed similar stability results to those of ambient temperature storage. 
Analysis of days 45, 90 and 180 showed stability ranging from 90-96%, 77-104% 
and 82-142%, respectively, as shown in Table 61. 
Table 61: Stability of analytes in DBS stored at 4ºC 
Analyte 
Percentage of stability for all patients (CV%) 
Day 0 Day 45 Day 90 Day 180 
DBS  DBS DBS DBS 
Procyclidine 100 90 (14) 100 (16) 88 (13) 
Quetiapine 100 90 (5) 77 (19) 91 (16) 
Risperidone 100 96 (11) 92 (10) 106 (17) 
9-OH-risperidone 100 90 (14) 84 (21) 82 (25) 
Chlorprothixene 100 91 104 142 
Haloperidol 100 91 (16) 98 (20) 92 (16) 
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No change in results was observed when analysing patients DBS stored in -20°C 
freezer from the previous ones. The percent of stability for the analytes at day 45 
was between 86 and 104% while for day 90 and day 180 it was 82-100% and 81-
97%, respectively. Chlorprothixene gave an outlier result for day 180 which was 
161% and other details are shown in Table 62. 
Table 62: Stability of analytes in DBS stored at -20ºC 
Analyte 
Percentage of stability for all patients (CV%) 
Day 0 Day 45 Day 90 Day 180 
DBS  DBS DBS DBS 
Procyclidine 100 104 (11) 94 (17) 95 (21) 
Quetiapine 100 86 (6) 82 (15) 84 (4) 
Risperidone 100 101 (12) 92 (6) 97 (16) 
9-OH-risperidone 100 91 (15) 83 (15) 81 (7) 
Chlorprothixene 100 90 (1) 92 (8) 161 (13) 
Haloperidol 100 97 (1) 100 (10) 97 (13) 
 
Also similar stability results were seen for analytes from patients’ DBS stored at -
80°C for 180 days. Testing on day 45 indicated analyte stability to be between 87 
and 108% compared to starting concentrations whereas testing on days 90 and 180 
showed stabilities ranges of 76 to 104% and 82 to 144%, respectively. Details are 
shown in Table 63. 
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Table 63: Stability of analytes in DBS stored at -80ºC 
Analyte 
Percentage of stability for all patients (CV%) 
Day 0 Day 45 Day 90 Day 180 
DBS  DBS DBS DBS 
Procyclidine 100 100 (2) 76 (1) 87 (3) 
Quetiapine 100 89 (7) 83 (7) 82 (9) 
Risperidone 100 108 (17) 89 (0) 104 (6) 
9-OH-risperidone 100 104 (4) 104 (31) 104 (22) 
Chlorprothixene 100 87 (1) 81 144 (4) 
Haloperidol 100 106 (8) 98 (2) 92 (1) 
 
 
Figure 39: Analyte stability after 180 days over different storage temperatures 
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Figure 40: Stability of the analytes overtime under four different temperatures (25, 4, -20 and -80°C) 
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Table 64: Paired t-test analysis results for the difference between analyte stability in NaF treated and 
untreated cards  
Analyte 
NaF treated versus untreated 
P-values from paired 2 tailed t-test (all patients) 
25ºC  4ºC -20ºC -80ºC 
Procyclidine 0.463 0.560 0.702 0.253 
Quetiapine 0.473 0.970 0.750 0.557 
Risperidone 0.398 0.843 0.656 0.633 
9-OH-risperidone 0.093 0.785 0.492 0.158 
Chlorprothixene 0.235 0.590 0.195 0.035 
Haloperidol 0.927 0.304 0.410 0.981 
 
4.5. Discussion 
4.5.1. Introduction, aim and study design 
As covered in the introduction, storing DBS on paper has been used since at least 
the 1960s for the screening of metabolic disorders (Guthrie, Susi 1963). However, 
the usage of this technique has been expanded to cover other purposes such as 
therapeutic monitoring and clinical drug development (Spooner, Lad et al. 2009). 
DBS have many advantages over traditional blood samples as described in the 
introduction. Drug stability is one of the most important ones. Drugs can degrade 
easily in liquid samples especially if not kept frozen. One of the most common 
degradation processes is hydrolysis which uses water to split an amide or ester 
bond within drugs structures (Waterman, Adami 2005).  
In recent years, the prescribing of anti-psychotics has increased and their link to 
sudden cardiac death could explain their high prevalence in forensic cases (Ray et 
al. 2009). Stability of anti-psychotics in blood samples stored in different conditions 
have been studied and published reports disclosed that quetiapine, risperidone, OH-
risperidone, chlorprothixene and haloperidol showed significant losses after 140 
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days under at least one of the storage conditions (Saar et al. 2012). No DBS study 
could be found in the literature investigating these drugs. In the present study the 
stability of procyclidine, quetiapine, risperidone, OH-risperidone, chlorprothixene and 
haloperidol in DBS stored at different temperatures at a number of time intervals 
over a 6 months period was tested. The present study is distinct from other studies 
as well in the use of real patients’ blood samples. It is worth mentioning that stability 
studies in the literature are generally based only on spiked plasma (Saar et al. 
2012).  
4.5.2. Extraction optimization 
The development of a suitable method for the extraction of the investigated analytes 
from DBS was started with the use 50µL spiked blood. This amount of blood was 
used as it filled the marked circles in the cards and was very similar to the actual 
volume of a blood drop (Morita, Folkers 1993). Four liquid-liquid extraction solutions 
were tested and they were mainly based on initial incubation with four different 
solutions (MAF, MTBE, 0.1M or 0.05M phosphate buffer). MAF, which was 
successful in the previous chapter, and MTBE have shown superiority over the other 
two solutions for the extraction of the targeted analytes from DBS cards. However, 
MTBE showed lower recoveries with quetiapine, risperidone and its metabolite. 
Phosphate buffer 0.1M and 0.05M results were very similar and showed generally 
low recoveries between 8 and 63% for all analytes. Therefore the MAF solution was 
chosen for carrying out the rest of the study. It worth mentioning that all the solutions 
provided a clean extract as the DBS technique has the rarely mentioned advantage 
of removing many of the unwanted macromolecules which stick to the cards, so they 
are not extracted alongside the analytes. 
4.5.3. LC-MS 
Table 43 shows the accurate masses of the targeted analytes and internal 
standards extracted from the full scan (75-1200amu) run on the LC-MS system. The 
mass accuracy for all the analytes was less than 1ppm which due to the high 
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resolution (+50,000) of the Exactive (Orbitrap) system provided great sensitivity and 
confidence in the results. Detection and quantitation with 1ppm mass window using 
high resolution mass spectrometry are adequate to generate a high selectivity equal 
or sometimes superior to that produced by MRM or SRM acquisition at unit mass 
resolution (Kaufmann et al. 2011). On the other hand, the chromatography 
separation which was achieved by HILIC conditions is considered rare as no paper 
has been found in the literature reporting analysis of these drugs under these 
conditions. The HILIC method showed good separation of the peaks with short run 
time (7 minutes), in fact one of the advantages of HILIC is the low back pressure 
which allows for increasing the flow rate (0.5mL/min) making the run relatively fast 
without compromising the results as the resolution is very high. The isocratic mobile 
phase with high acetonitrile content has also contributed to the quick separation 
without the need of re-equilibrating the column as in a gradient run.          
4.5.4. Validation 
Generally method validation for this optimized method was very successful. Linearity 
for DBS calibrators was very good and showed r2=>0.99 for all analytes over the 
range of 2.5 to 2000ng/mL. LOD values for all analytes were 0.1-1.5ng/mL and 
LLOQ values were 0.4-4.5ng/mL. Similar range was reported for risperidone and its 
metabolite (Jantos, Skopp 2011). Overall absolute recovery results for analytes in 
spiked DBS have been found to be >64% for all the analytes. Only at low calibrators 
(0.1ng/mL), quetiapine showed reduced recovery (47%). Intra- and inter-day 
precision from spiked DBS revealed acceptable CV percentages of <15% for all 
analytes. With regard to accuracy it can be seen clearly from Table 46 that QC 
concentrations are within 90-110%. 
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4.5.5. Stability results 
4.5.5.1. Procyclidine 
From two different patients who were on procyclidine, whole blood with 
concentrations of 265 and 110ng/mL were spotted on Whatman neonatal cards and 
stored in conditions described earlier and analysed over a specified time scale in 
order to assess their stability. Combined results from the two procyclidine patients’ 
DBS showed that mean losses of drug after 180 days under all the storage 
conditions (25, 4, -20 and -80ºC) were ≤13%. This result also could be due to 
analytical errors rather than a real loss or degradation of the drug, as at day 45 in 
the room temperature group, procyclidine concentration had dropped to 72% 
compared to day 0, while at day 180 it was 87%. Similar patterns have been noticed 
in literature (Saar et al. 2012, Heller et al. 2004). Other explanation would be the low 
concentrations of the patients’ samples, as small changes in concentration can lead 
to large differences in the calculated stability results. Nevertheless, these results 
indicate that there is no need for refrigerating or freezing DBS samples for the 
analysis of procyclidine for at least 6 months. Unfortunately, no procyclidine stability 
studies in biological samples were found in literature to be compared with the 
present findings. However, dehydration of the samples on the cards should 
generally improve the stability by minimizing the hydrolysis of the compounds.     
4.5.5.2. Quetiapine 
As for quetiapine, two patients were involved with initial blood concentrations of 328 
and 165ng/mL. After the spotting of 50µL patients’ blood aliquots onto DBS cards 
and storing them under the assigned conditions, combined results of both patients 
showed a mean quetiapine concentration loss of 21% for those stored at room 
temperature after 180 days. However, the 4ºC batch showed only 9% loss, while -20 
and -80ºC had a 16 and 18% reduction, respectively. Analytical and data processing 
variations could possibly have caused slight deviation in these findings, as normally 
the lowest storage temperature should have the lowest loss. According to these 
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findings refrigeration only is enough to retain 90% quetiapine in DBS for at least 6 
months if not more. It has been reported that after only 14 days 50% of quetiapine 
was lost in plasma samples kept at room temperature (Peters 2007). No DBS 
published study could be found for quetiapine. 
4.5.5.3.  Risperidone 
The initial blood levels for the two risperidone patients’ samples were 4 and 
47ng/mL. Following 180 days of storage in different temperatures DBS were 
analysed and risperidone maintained a stability of ≥89% throughout all the tests 
days and all the storage conditions. At day 180 test stability was 99% for the room 
temperature batch and 106% for the refrigerated batch. Likewise the freezing at -20 
and -80ºC batches showed 97 and 104% stabilities, respectively.  Accordingly, 
these results indicate that there is no need for refrigerating or freezing DBS samples 
for the analysis of risperidone within at least 6 months. One study has reported 
risperidone loss of 15-35% in whole blood spiked samples from the starting 
concentration after 20 weeks of storage under all the range of conditions, 20 to -
60ºC (Saar et al. 2012). The only DBS study found in literature for risperidone was 
focused on the reliability of DBS results and they found the ratio between blood/DBS 
results to be very close to 1 which means almost equal (Jantos, Skopp 2011).    
4.5.5.4. OH-risperidone 
Results for OH-risperidone, also known as paliperidone, were from three patients 
and the starting concentrations were 17, 41 and 21ng/mL. Analysis of DBS after the 
6 months study period revealed that the mean losses of OH-risperidone were ≤19% 
for those stored at ambient (25±2ºC) temperature, refrigerator (4±1ºC) and freezer (-
20±1ºC), while the -80ºC freezer batch maintained a constant level of 104% stability 
throughout the 6 months evaluation. However, day 90 analysis for the ambient 
temperature batch showed a mean stability of 96%. Such discrepancy has been 
reported in the literature and one of the suggested explanations would be the 
method not maintaining a high enough level of accuracy. By and large -80ºC 
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freezers provide the highest stability but are costly and thus uncommon. A published 
study has reported that between 15-30% losses have been seen with OH-
risperidone stored at 20ºC for 10 weeks whereas at ≤4ºC the loss was ≤15% (Saar 
et al. 2012). One DBS study for OH-risperidone investigating the reliability of DBS 
results found the concentration ratio between blood/DBS to be 1.04 which means 
almost equal (Jantos, Skopp 2011).   
4.5.5.5. Chlorprothixene 
Samples included in the chlorprothixene DBS stability study were from one patient 
with a starting concentration of 9ng/mL. Subsequent to 180 days of storage in 
different temperatures DBS were analysed. On all the tested dates (day 45, 90 and 
180) and under all the storage conditions chlorprothixene showed a stability of not 
less than 81%. However, due to the low concentration of the chlorprothixene 
originally in the patient sample small variations in the quantitation can lead to 
outliers in the stability results. This was seen clearly with the day 180 test which 
showed stabilities between 134 and 161% for all the storage temperatures. This 
phenomena was seen in some publications (Saar et al. 2012, Heller et al. 2004). In 
view of this, these results can indicate that there is no need for refrigerating or 
freezing DBS samples for the analysis of chlorprothixene within at least 6 months. A 
published study pointed out that chlorprothixene in whole blood lost 55% after 140 
weeks of storage at 20ºC and 50 and 40% after storage in 4ºC and -20ºC, 
respectively (Saar et al. 2012). No DBS published study could be found for 
chlorprothixene. 
4.5.5.6. Haloperidol 
With regard to haloperidol, two patients were involved with initial concentrations of 
31 and 8ng/mL. After spotting the patients’ blood samples onto the DBS cards and 
storing them at the different temperatures, the combined results of both patients 
showed that mean haloperidol stabilities were more than 91% for all the storage 
conditions and all the tests days except day 45 ambient temperature results (79%), 
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which could be considered as an outlier. According to these results haloperidol is 
stable within DBS for as long as 6 months without refrigerating or freezing. In 
literature haloperidol concentrations in blood samples stored at room temperature 
(20±2ºC) for 140 days were found to drop by 25% of their original level, while at the 
lower temperatures (4, -20 and -60ºC) the loss was generally below 16% (Saar et al. 
2012). No haloperidol DBS study was found in the literature. 
4.5.6. Sodium fluoride impregnation 
Sodium fluoride is widely used for preserving drugs in samples in both clinical and 
forensic toxicology. It helps in the inhibition of bacterial growth and subsequently 
reduction in the rate of sample decomposition (Rees et al. 2011). Half of the stability 
study DBS cards were pre-treated with 5mg/mL NaF solution to see whether it has 
any stability enhancement effect on the drugs’ concentrations. A paired t-test was 
used to determine whether a difference between mean values determined from DBS 
on treated and untreated cards exists or not. Results showed that no significant 
difference was found between the two groups at all the storage conditions and with 
all the investigated drugs as seen on Table 64. Therefore, addition of a preservative 
showed no effect in terms of stability as the drugs were already stable even at room 
temperature. This could also mean that a much longer storage period might be 
needed in order to see the long term effect. The limited amount of samples, time 
and access to the mass spectrometry hindered the long term investigation.   
 
4.6. Conclusion 
A validated method has been developed which can be used for the extraction and 
quantitative analysis of drugs in small volumes of blood spotted and dried on filter 
papers or Guthrie cards. The DBS technique provides a suitable procedure for the 
storage and analysis of samples in therapeutic drug monitoring and forensic 
toxicology because they are easy and safer to handle, transport and store in the 
laboratory, even in the absence of refrigeration. The stability of antipyschotics in 
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DBS from real patients’ samples was assessed by storing them at four different 
temperatures (25, 4, -20 and -80°C) with and without prior impregnation of the DBS 
cards with sodium fluoride. After the development and validation of a LLE-LC-MS 
method, samples were analysed at days 0, 45, 90 and 180. Results showed a 
significant stability of all the compounds (procyclidine, quetiapine, risperidone, OH-
risperidone, chlorprothixene and haloperidol) in all the different storage conditions 
and no significant increase or decrease in drug concentrations with sodium fluoride 
impregnation. Possibly a much longer period than 6 months is needed to see if NaF 
has an effect on drug stability. 
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5. Chapter 5 - Prevalence of alcohol use 
among Kuwaiti patients undergoing drug 
rehab revealed by hair analysis 
5.1. Introduction 
Alcohol misuse is a worldwide issue affecting most countries including those where 
alcohol is considered as a controlled and illegal substance such as Kuwait and 
Saudi Arabia for instance. Alcohol can be smuggled or produced at home by 
fermenting sugars in the fruits in these countries. Therefore, they are not in a 
complete safe haven from alcohol problems. Globally, alcohol related mortality is 
about 2.5 million each year (WHO 2011). With regards to the Western world, it is 
estimated that in Western Europe, where extensive alcohol studies have been 
carried out, 20% of the population are considered alcohol abusers (Rehm et al. 
2003). Heavy drinking can lead to several physical and mental health problems in 
addition to the social problems it can create (Derauf, Katz & Easa 2003), namely, 
road accidents, violence, abuse of family members, child neglect, absenteeism in 
workplaces, etc. In fact, the second largest risk factor for disease burden in Europe 
is alcohol (WHO 2011). In a Scandinavian study they found that the majority of 
sexually assaulted females had been drinking alcohol (Jones et al. 2008). Therefore, 
it is not surprising that alcohol has strongly drawn the attention of the scientific 
community to tackle or minimize its burden.  
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Table 65: Prevalence of common drugs of abuse in the United States (Abudu 2008) 
Drug of misuse Prevalence (%) 
Alcohol 75 - 80 
Cannabis 20 – 26 
Cocaine 5 – 13 
Benzodiazepines 1 - 5 
Barbiturates  0.5 - 5 
Opiates 0.1 - 2 
Phencyclidine 0.1 - 2 
Amphetamines 0.1 - 1 
Other stimulants 0.8 - 2 
Other sedatives 0.6 - 2 
 
In the last two decades alcohol biomarker research was and still is very active. The 
research is aiming to find reliable markers in human biological matrices. The first 
generation or traditional markers are mainly detected in urine and blood, such as 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl-
transferase (γGT), mean corpuscular volume (MCV) and carbohydrate-deficient 
transferrin (CDT) (Bearer, Bailey & Hoek 2010). These generally serve as qualitative 
indicators and require several weeks or more to be elevated. Moreover, their values 
can be raised by several other non-alcoholic disorders which render their sensitivity 
and specificity to be quite low or limited which sometimes leads to false positive 
results. On the other hand, the new biomarkers such as the 5-hydroxytryptophol (5-
HTOL) and the metabolites of ethanol; ethyl glucuronide (EtG), ethyl sulfate (EtS) 
and fatty acid ethyl esters (FAEEs) are generally more specific and more sensitive 
(Litten, Bradley & Moss 2010). The main focus in the latest publications is on EtG 
specifically as it seems more robust, sensitive and reflective of actual alcohol 
consumption. It allows a flexible window of detection from hours after consumption 
(14 to 24 hours in blood) to several days (up to 102 hours in urine) (Kissack, Bishop 
& Roper 2008). EtS has similar advantages and window of detection as EtG, 
however the latter was found recently to have roughly twice the level of EtS in urine 
and serum (Lostia, Vicente & Cowan 2013). Also EtS detection in hair could not be 
retrieved from literature.  
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The detection of ethanol itself in urine has only a short window of 12 to 14 hours. 
Also ethanol can be formed in urine through fermentation especially in diabetic 
patients, whereas EtG is only produced after alcohol passage through liver where it 
is exposed to hepatic enzymes.  
 
 
Figure 41: Alcohol metabolic pathways (oxidative, non-oxidative) and blood markers (Abudu 2008) 
 
In fact, the EtG window of detection has been expanded into several months after 
the introduction of its detection in hair (Skopp et al. 2000, Alt et al. 2000). To be 
more impartial, hair alcohol analysis studies were not only focused on EtG but also 
on FAEEs. However, FAEEs are lipid soluble and incorporate into hair from the 
sebum, so segmentation, for instance, will be of no use because their incorporation 
is not associated with the growth rate of the hair and consequently may not help in 
estimating the time or amount of consumption and they also can be found in the hair 
of strict teetotallers (Auwarter et al. 2001). Thus, generally they can be classified as 
co-indicators of general drinking behaviour if detected in abnormal levels. In view of 
that,  EtG attracted attention because it is water soluble and incorporated from 
blood, but although less than 0.1% of ingested alcohol is eliminated as EtG, it can 
indicate alcohol abuse (Pragst, Yegles 2006). According to a recent paper EtG in 
hair is not significantly influenced by gender, body mass index, age, or hair colour 
(Kharbouche et al. 2011, Kintz 2010). One of the other reasons is that EtG has been 
found to reflect to some extent the actual daily consumption of alcohol (Kharbouche 
et al. 2010, Appenzeller et al. 2007). As a matter of fact, the society of hair testing 
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(SoHT) has set a cut-off value for the detection of EtG in hair (Kintz 2010). The 
proposed cut-off is that detection of >30pg/mg is reflective of chronic 
heavy/excessive drinking (>60g ethanol/day) and <30pg/mg reflective of social 
drinking (<60g ethanol/day). Another group has added another threshold of 7pg/mg 
to differentiate between teetotalers and social drinkers (Liniger et al. 2010). More 
recently, Kharbouche et al conducted a prospective self-monitoring study on 125 
subjects in order to investigate more accurately the thresholds limits and the 
reliability of EtG as a diagnostic test (Kharbouche et al. 2011). They found that EtG 
diagnostic performance was significantly better (P<0.05) than any of the traditional 
biomarkers alone and had a stronger or similar diagnostic performance in detecting 
at-risk (>20/30g/day) or heavy drinkers (>60g/day), respectively, than the best 
combination of traditional biomarkers (CDT and γGT). They also suggested a 
25pg/mg detection threshold for heavy drinkers and 9pg/mg for at-risk drinkers. On 
the other hand, a Swedish group concluded their controlled alcohol administration 
study with the fact that EtG detection in hair cannot completely exclude minor daily 
alcohol ingestion and lacks sensitivity for the purpose of monitoring complete 
abstinence (Kronstrand, Brinkhagen & Nyström 2011a). In this context of mentioning 
weak points of EtG power or reliability, it is worth noting that EtG is formed by a 
conjugation reaction of alcohol with glucuronic acid in the presence of the enzyme 
uridine diphosphate glucuronyl transferase (UGT) (Wurst, Skipper & Weinmann 
2003). However, there are 16 functional human genes of UGT, raising the possibility 
that the formation rate of EtG may vary by genotype (Litten, Bradley & Moss 2010). 
The last, but maybe not least, weak point is cosmetic hair treatment which may 
cause some reduction of the EtG level in hair (Pascal 2011). Nonetheless, an 
interesting study showed that EtG is not significantly washed out in the distal 
segments longer than 3cm (Agius, Ferreira & Yegles 2011). 
 
Figure 42: Structure of ethyl glucuronide (Janda, Alt 2001) 
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Solid phase extraction (SPE) 
As EtG is a minor metabolite of ethanol (<0.1%), its concentration in body fluids is 
mostly measured in ng/mL or ppb and in hair as pg/mg which is a very minute 
amount. Therefore, EtG extraction maybe better achieved with SPE as it provides a 
cleaner sample upon concentration than liquid-liquid extraction (LLE). Hence, it 
should apparently increase the sensitivity.  
The SPE technique first appeared in the seventies of last century as an alternative 
to the traditional liquid-liquid extraction, which is labour and solvent intensive plus 
not very environmentally friendly (Thurman, Snavely 2000). Thurman et al define 
SPE as “a method of sample preparation that concentrates and puriﬁes analytes 
from solution by sorption onto a disposable solid-phase cartridge, followed by elution 
of the analyte with a solvent appropriate for instrumental analysis” (Thurman, Mills 
1998). Therefore, SPE essentially is based on binary on and off separation strategy 
(Svec 2006).  
In the present study an EtG specific SPE column (Clean-Screen® EtG) has been 
tested. This column is made of proprietary carbon blend sorbent of a porous 
immobilised graphitic carbon in which the graphite is immobilised on a silica 
structure with a high attraction for organic polar compounds from both polar and 
non-polar matrices (Lamoureux et al. 2009). It has microporous surface areas 
holding polar groups primarily appropriate for the extraction of phenolic-polar 
compounds such as EtG from the biological matrices such as hair and urine. 
Precisely, the retention of the EtG on the sorbent is achieved by the attraction that 
takes place between the functional groups and the EtG through the carbon–
hydrogen bonds when the EtG is carried by a polar solution (Lamoureux et al. 
2009). Also, Waters Oasis Max (mixed-mode anion exchange) SPE cartridges have 
been used and compared to the Clean-Screen® EtG cartridges. Oasis Max is a 
mixed mode polymeric sorbent that combines reversed phase and ion exchange 
interaction (Fontanals, Marcé & Borrull 2007).    
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5.2. Ethyl glucuronide (EtG) analysis 
5.2.1. Aim of the study 
There are several objectives behind this study. Firstly, to determine the alcohol 
prevalence or consumption behaviour among Kuwaiti addicts and to draw a picture 
of addiction trends starting with this alcohol focused study. Also to possibly analyse 
the data statistically to look for any patterns or correlations between alcohol 
consumption, age and other drugs of abuse. Availability of these kinds of data or 
studies will facilitate the work of other departments in the country dealing with drugs 
and addiction. However, as yet no similar study has been conducted covering these 
issues in Kuwait. 
Secondly, to develop and validate a sensitive and specific method for EtG detection 
and quantitation in hair from samples based on comparing different extraction 
methods (LLE and SPE) and also different separation columns (hydrophilic 
interaction liquid chromatography HILIC and reversed phase column C18). 
Thirdly, to compare the results with self-reports received from addicts and see if they 
are in agreement, in other words, to investigate if addicts tend to reveal their alcohol 
consumption or they try not to.  
5.2.2. Sample and data collection 
Hair samples were collected from middle-eastern male drug addicts aged between 
24 and 54 years attending for treatment or rehabilitation in the addiction treatment 
centre. Collection permission was granted from the permanent committee of health 
research ethics at the ministry of health in Kuwait to which the centre belongs. 
Participants were given an explanation of the study and total freedom of choice to 
participate or not. Out of almost 120 attending the centre who were interviewed, 59 
agreed to participate and signed the consent forms. Information on present and past 
drug history, age, sex, hair colour and sample collection date were recorded during 
interviews and can be found in the appendix. Data treatment was carried out 
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anonymously. All samples were tied with string and kept inside folded tin foil and 
placed in paper envelope. Blank samples were collected from alcohol abstinent 
volunteers.  
Subjects’ hair samples were taken from the occipital area of the scalp where hair is 
strongly and constantly growing even in bald subjects. Colours of the hair were 
black, dark brown or grey and none of the subjects had any kind of hair treatment, 
except one who had a henna (herbal) dye. The minimum amount of collection was 
about 50mg hair and at least ~1cm in length. However, in 3 cases lesser amounts 
have been considered.   
5.2.3. Materials and reagents 
All chemicals were of HPLC or analytical grade. UK. Ethyl β-D-glucuronide and 
deuterated internal standard ethyl β-D-glucuronide-D5 were purchased from Kinesis 
UK. Clean Screen EtG extraction columns were purchased from United Chemical 
Technologies through Presearch, UK. Oasis MAX cartridges were purchased from 
Waters Limited (Hertfordshire, UK). The rest of chemicals and consumables are 
mentioned in sections  2.2.2 and  3.4. 
Other solutions used in this chapter were mentioned in sections  2.2.2.2 and  3.4. 
Standard solutions 
100µg/mL stock standards were made with MS grade methanol for ethyl β-D-
glucuronide and ethyl β-D-glucuronide-D5 and stored at -20⁰C.     
Mobile phases 
0.1% formic acid in water 
1mL of concentrated formic acid (98/100) was mixed with 999mL of deionized water, 
mixed well and sonicated. 
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0.1% formic acid in acetonitrile 
1mL of concentrated formic acid (98/100) was mixed with 999mL of acetonitrile, 
mixed well and sonicated. 
20mM ammonium acetate 
1mL of concentrated 2M ammonium acetate stock solution was mixed with 999mL 
of deionized water, mixed well and sonicated. 
20mM Ammonium carbonate 
This solution was provided by a collaborative laboratory.  
5.2.4. LC-MS(MS) method development 
5.2.4.1. Exactive Orbitrap LC-MS method 
The extracts were analysed initially by using Exactive Mass Spectrometer (Thermo 
Electron UK) operated in negative ion ESI mode interface with a needle voltage of 
4.5kV, a heated capillary temperature of 320°C, sheath gas flow of 50 arbitrary units 
and auxiliary gas flow of 17 arbitrary units. Scanning was from 75-1200 amu. 
Chromatography was carried out using a HPLC system consisting of a Thermo 
Scientific Accela 600 pump, autosampler and column compartment fitted with either 
ZIC-pHILIC column (150 x 4.6mm 5µm particle size, Hichrom UK) plus guard ZIC-
pHILIC column (20 x 2.1mm 5µm) or ZIC-HILIC column (150 x 4.6mm 5µm particle 
size, Hichrom UK) plus guard ZIC-HILIC column (20 x 4.6mm 5µm). These two were 
tested in two different isocratic mobile phases with a flow rate of 0.5 mL/min. The 
mobile phase for pHILIC was of (A) 20mM ammonium carbonate in water and (B) 
acetonitrile, while HILIC was (A) 0.1% formic acid in water and (B) 0.1% formic acid 
in acetonitrile. A summary of the LC-MS(MS) methods is shown in Table 68.  Data 
analysis was carried out using Thermo Xcalibur 2.2 SP1 software (Thermo Electron, 
UK). 
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 Table 66: Extracted ions of EtG and internal standard and their mass spectrometry data 
Analyte Formula (-H) Accurate Mass (M-H) 
Retention 
Time Mass Accuracy 
Ethyl 
glucuronide C8H13O7 221.0668 2.8 5.749 ppm 
Ethyl 
glucuronide-D5 C8H8D5O7 226.0983 2.8 5.825 ppm 
 
 
Figure 43: Mass spectrum for EtG and EtG-D5 on Exactive Orbitrap 
5.2.4.2. TSQ Vantage triple quad LC-MS/MS method 
The other instrument which was tried for this study was of triple quadrupole mass 
spectrometer TSQ Vantage (Thermo Fisher Scientific, USA) equipped with an 
electrospray interface (Turbo Ion Spray) set on the negative mode. The ion spray 
voltage was set to 3500 V. The sheath/auxiliary gas was nitrogen. The sheath gas 
pressure was 35 arbitrary units and auxiliary gas pressure was 10 arbitrary units. 
The ion transfer capillary temperature was 270°C and the vaporizer temperature 
150°C. The collision gas was argon with a pressure of 1.5 mTorr. 
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Table 67: Ethyl glucuronide and ethyl glucuronide-D5 SRM scans conditions  
Analyte Parent Product Width Time CE Q1 PW Q3 PW S-Lens 
EtG 221.114 
75.042 1.200 0.100 16 0.70 0.70 87 
85.060 1.200 0.100 19 0.70 0.70 87 
EtG-D5 226.133 
75.052 1.200 0.100 18 0.70 0.70 84 
85.101 1.200 0.100 20 0.70 0.70 84 
   * PW (peak width), CE (collision energy), Q (quadrupole), S-Lens (stacked-ring ion guide lens) 
The TSQ Vantage analyser was coupled with an Accela 1250 U-HPLC system. 
Extract separation was compared between three different LC columns. The first 
tested column was Ascentis Express (10cm x 4.6mm x 2.7µm, from Sigma-Aldrich 
Co. UK) with a mobile phase started with 95% (A) 0.1% formic acid in water (B, 
0.1% formic acid in acetonitrile) to 5% (A) in 3 min linear gradient, held for 2 min 
before returning to original conditions of 95% in 0.1 min followed by 2.9 min 
equilibration time to make a total run time of 8 min pumped at 0.5mL/min.  The 
second column was a Kinetex HILIC (50mm x 2.1mm x 1.7µm, from Phenomenex 
Inc. CA, USA) tested with mobile phase (A) 20mM ammonium acetate and (B) 
acetonitrile. The column was tried on several isocratic runs ranging from 1% to 60% 
(A) pumped at 0.5mL/min. The last column was an Acquity BEH C18 (50mm x 
2.1mm x 1.7µm, Waters Ltd, Hertfordshire UK) with gradient run mobile phase (A) 
0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile. The gradient run 
was started with 99% of (A) held for 1 min, followed by linear gradient to 20% (A) in 
2 min and held again for 1 min before returning back to the initial conditions at 99% 
(A) and kept for 2.5 min for equilibration. The total run time was 6.5 min with a flow 
rate of 0.25mL/min. The injection was set on no waste mode with an injection 
volume of 20μL. A list of all mobile phases and LC columns are summarized in 
Table 68. 
The five methods were compared through the injection of 10, 100 and 1000ng/mL 
EtG standard dissolved in acetonitrile in the case of HILIC/pHILIC columns and in 
water in the case of C18 columns. The system producing the highest peak area 
response for EtG was recorded as being 100 % and the peak area responses for the 
other systems were calculated as a percentage of the optimum system response. 
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5.2.4.3. Results 
As shown in Table 68 the combination of an Acquity BEH C18 column with TSQ 
Vantage LC-MS/MS provided the highest peak area responses for EtG detection 
compared to the other combinations. This column and instrument combination was 
therefore selected for the further EtG method development.  
Table 68: Instrument methods evaluated by relative % peak area response for optimal determination 
of EtG from neat standards 
Instrument Exactive Orbitrap Triple Quad TSQ Vantage 
Column ZIC-pHILIC ZIC-HILIC Acquity BEH C18 Kinetex HILIC 
Ascentis 
Express C18 
Mobile 
phase 
(60%) 20mM 
ACB 
(40%) ACN 
(60%) 0.1%FA 
(40%) 0.1%FA in 
ACN 
(99-20%) 0.1%FA 
(1-80%) 0.1%FA in 
ACN 
(gradient) 
(40%) 20mM 
ACT 
(60%) ACN 
(95-5%) 
0.1%FA 
(5-95%) 
0.1%FA in ACN 
(gradient) 
Injection 25µL 
Full loop 
25µL 
Full loop 
20µL 
No waste 
20µL 
No waste 
10µL 
No waste 
Relative % Peak Area Response 
Retention 2.8 2.8 1 0.3* 3 
10ng/mL 64.6 33.3 100.0 20.4 4.9 
100ng/mL 37.7 - 100.0 77.0 - 
1000ng/mL 45.8 25.3 100.0 94.0 - 
ACB: ammonium carbonate, ACT: ammonium acetate, ACN: acetonitrile, FA: formic acid  
* No retention was achieved between 1-95% ACN 
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Figure 44: Chromatograms of 10ng/mL EtG standards analysed by the 5 different systems 
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5.2.5. Sample preparation 
5.2.5.1. Decontamination 
Morini et al found that washing uncut EtG hair samples with dichloromethane 
followed by methanol (10 minutes sonication and 30 seconds vortex mixing, 
respectively) resulted in negligible amount of EtG loss ( <2.5% ) and significantly 
reduced matrix interference by removing external contaminants (Morini et al. 2006).  
However, the 2011 SoHT proficiency testing scheme for EtG did not recommend 
sonication during washing steps. Besides that, there is no agreement or consensus 
on a specific decontamination method among hair analysts. Accordingly, the 
decontamination process was achieved by using three washing steps with three 
solvents and one aqueous solution: dichloromethane, 0.01M phosphate buffer and 
propanol/acetone (1:1). The uncut hair was put in a 6ml glass tube and then 2mL of 
the first solvent was added, followed by 30 seconds vortexing. After that the solvent 
was decanted. The decanting process can be done with the use of plastic pipette or 
in the case of short hair where the hair are scattered in the tube a piece of 
disposable fabric or textile has been used to hold the hair inside the tube and filter 
the washing solution out. After the last washing step (2mL propanol/acetone) the 
hair was left to dry at room temperature in a fume hood or speeded up with the 
speed-vac in low temperature mode. This decontamination method was found to be 
the quickest and most efficient by the researcher. 
5.2.5.2. Segmentation 
Segmentation was performed only if hair was longer than 3 centimetres, as the 
recommendation by the SoHT consensus was that the cut-off concentration should 
be used when analysing a 3 cm segment (Pascal 2011).  After the hair became dry, 
segments were cut in small pieces (1–3mm) with scissors and weighed directly. To 
ease the calculation later, 60mg hair was usually taken, if not, any available weight 
was considered, and then each segment snippets were placed into a 2ml chromacol 
glass vial with a screw cap. 
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5.2.6. Optimization of extraction 
The main extraction method was based on incubation in water followed by SPE 
suggested by United Chemical Technology, Inc. (UCT) and recommended by SoHT 
EtG proficiency scheme and number of papers (Kronstrand, Brinkhagen & Nyström 
2011a, Kharbouche et al. 2009, Yegles et al. 2004). The other extraction methods were 
Oasis Max SPE, LLE and a filtration method. Extraction methods have been tested 
by applying them on authentic samples from known heavy drinkers. These samples 
were reduced into 1-3mm snippets and mixed thoroughly after washing. The 
recoveries of the following three extraction methods were calculated by the use of 
five 60µL unextracted calibrators 0, 1, 10, 100, 1000ng/mL (~pg/mg) with 50µL of 
0.2µg/mL IS (ethyl β-D-glucuronide-D5) prepared at the same time as the samples 
but kept in the fridge during sample incubation and then evaporated with the 
samples and reconstituted in 60µL of mobile phase and run simultaneously with the 
samples. 
SPE method1 (CleanScreenEtG) 
As mentioned before, after reducing hair into 1-3mm lengths, 60mg of 
blank/authentic hair was incubated in triplicate with 1.2 mL of deionised water for 18 
hours in a water bath (35°C + darkness) including 1 hour of sonication and after the 
addition of the internal standard. Afterward, samples were centrifuged at 3000rpm 
for 5 min and the supernatant was loaded into SPE CleanScreenEtG cartridges after 
conditioning. Conditioning was achieved with 3mL of methanol containing 1% formic 
acid followed by 3mL of 1% formic acid in deionised water (aspiration < 3 inches Hg) 
according to protocol provided by the manufacturer. Samples were loaded at 1-
2mL/minute and washed with 3mL of deionized water and columns were left to dry 
for 10 minutes with ≥10 inches Hg aspiration. Finally, analytes were eluted with two 
2mL loads of 1% formic acid in methanol, evaporated to dryness under nitrogen 
(40ºC) and residues were reconstituted in 60μL of the mobile phase. 
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SPE method 2 (Oasis Max) 
Similar to the previous method, 60mg of blank or patient hair (1-3mm) was 
incubated in triplicate with 1.2mL of deionized water for 18 hours in a water bath 
(35°C + darkness) including 1 hour of sonication and after the addition of the internal 
standard. Afterward, samples were centrifuged at 3000rpm for 5 minutes and 
supernatant was loaded into SPE Oasis Max cartridges after conditioning. 
Conditioning was achieved with 2mL of methanol followed by 2mL of deionized 
water. Samples were loaded at 1-2mL/min and washed with 1mL of deionized water 
and 2mL of cyclohexane. Then columns were left to dry for 10 min with ≥10 inches 
Hg aspiration. Finally, analytes were eluted with 2mL of 2% formic acid in methanol, 
evaporated to dryness and residues were reconstituted in 60μL of the mobile phase.   
Method 3 (A:W:M incubation) 
In this method 60mg of blank or patient hair (1-3mm) was incubated in 1mL of a 
mixture of acetonitrile: deionized water: methanol (A:W:M, 5:4:1). The hair was 
incubated overnight in a water bath (35°C + darkness) including 1 hour of sonication 
and after the addition of the internal standard. After centrifugation the supernatant 
was dried under nitrogen to ~200μL and then filtered with Mini-UniPrep Syringeless 
filters. The filtrate was evaporated and reconstituted in 60μL of the mobile phase. 
Method 4 (A:M incubation) 
60mg of blank or patient hair (1-3mm) was incubated in 1mL of a mixture of 
acetonitrile: methanol (A:M, 1:1). It was incubated overnight in a water bath (35°C + 
darkness) including 1 hour of sonication and after the addition of internal standard. 
After centrifugation the supernatant was dried under nitrogen to ~100μL and 100μL 
of deionized water was added (to ensure complete EtG transfer) and then filtered 
with Mini-UniPrep Syringeless filters. The filtrate was evaporated and reconstituted 
in 60μL of the mobile phase. 
Optimization of extraction started with an efficiency comparison between the two 
SPE methods mentioned earlier. The two methods were applied to two sets of EtG 
standards, 100 and 1000ng/mL each in triplicate, and their responses were 
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compared against unextracted standards. Following this stage the highest efficiency 
SPE method was then compared to methods 3 and 4 by applying them to real 
samples as described earlier (section  5.2.6).   
5.2.6.1. Results 
Even though a number of improvements and changes were tried in order to get 
better results with the use of Clean-Screen®ETG cartridges only 5% recovery was 
achieved in both tested concentrations (100 and 1000ng/mL). This contrasted with 
the Oasis Max columns which maintained a good extraction efficiency at both low 
and high concentrations as shown in Table 69.  
Table 69: Extraction efficiency results using two different SPE cartridges (% of recovery, n=3) 
                   Recovery 
 
Analyte 
Oasis Max 
% 
CV EtG 
CleanScreen 
% 
CV 
Ethyl glucuronide 1000ng/mL 103% 7 5% 22 
Ethyl glucuronide 100ng/mL 86% 5 5% 23 
As method 1 was excluded, results between the other 3 methods when applied to 
real positive hair samples showed that method 2 (Oasis Max SPE) revealed the 
highest recovery (26pg/mg) while method 3 (A:W:M) showed 20% lower recovery 
(22pg/mg) and method 4 showed very low recovery, ~3pg/mg as shown in Table 70 
and Figure 45.  
Table 70: Extraction optimization results with authentic hair sample extracted in different methods (% 
of recovery, n=2) 
Method 2 Method 3 Method 4 
                   Recovery 
 
Analyte 
SPE 
Oaisis
Max 
% 
CV A:W:M 
% 
CV A:M 
% 
CV 
Ethyl glucuronide 
(pg/mg) 
26 31 22 9 3 42 
 A:W:M, acetonitrile:deionized water:methanol. A:M, acetonitrile:methanol 
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Figure 45: Chromatograms of extraction optimization results of methods 2, 3 and 4 using authentic 
hair samples 
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5.2.7. Method validation 
Method validation experiments were achieved by following the industrial guidelines 
for bioanalysis method validation stated by the FDA and other sources (Peters, 
Drummer & Musshoff 2007, FDA 2001, Shah et al. 2000). 
5.2.7.1. Linearity 
Linearity was assessed by spiking blank hair samples with 10, 30, 100, 300 and 
1000pg/mg of ethyl glucuronide and 0.25ng/mg EtG-D5. The resulting ratio of peak 
areas of standards/internal standard was plotted versus the spiked analyte 
concentrations and the linear correlation coefficient (r2) calculated. The correlation 
coefficient (r2) value indicates the degree of linearity (r2 should be >0.99). 
5.2.7.2. LOD and LLOQ 
Limit of detection (LOD) and lower limit of quantification (LLOQ) were assessed by 
spiking blank hair with the EtG in decreasing concentrations. LOD was defined as 
the lowest detectable concentration of the analyte that differentiated it from the 
background noise, whereas LLOQ is lowest quantitative concentration that fulfils the 
required accuracy and precision. The spiked concentrations were 1, 3, 10, 30, 100, 
300 and 1000pg/mg of the analyte and 250pg/mg IS (EtG-D5). Signal-to-noise ratio 
was the method that was used to calculate LOD and LLOQ, and 3 and 10, 
respectively, were the cut-offs. LODs and LLOQs were calculated using  
Equation 2-5 (page 91). 
5.2.7.3. Stability (no matrix) 
Stability during the whole extraction/incubation process of the analyte in the selected 
optimized extraction method was assessed by spiking the analyte in 3 different 
concentrations (100, 300 and 1000pg/mg). Deuterated external standards 
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(0.25ng/mg) were added at the end of the extraction procedure and samples were 
run together with unextracted standards made at the same concentrations. 
5.2.7.4. Recovery 
Recoveries were estimated by measuring peak areas obtained when the EtG spiked 
into blank hair (in extraction solution) at three concentrations 100, 300, and 
1000pg/mg (n=3) against unextracted/unincubated standards. Therefore this 
recovery takes into account all the extraction steps including incubation and matrix 
effect (absolute). The recovery was calculated as a percentage by dividing the 
average peak areas of the extracted standards over the average peak areas of the 
unextracted standards and multiplied by 100. 
5.2.7.5. Intra-day precision 
The intra-day precision was achieved by spiking the blank hair samples with three 
concentrations of analytes (low, medium and high) in five replicates. After extraction 
and analysis precision was measured by calculating the coefficient of the variation 
expressed as a percentage (CV %). 
5.2.7.6. Inter-day precision 
The inter-day precision experiment was a replicate of the intra-day experiment over 
5 days and the coefficient of the variation percentage (CV %) was calculated 
between concentrations of each analyte over these 5 days. 
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5.2.7.7. Method validation results 
Table 71: Linear correlation coefficients, LODs and LLOQs of EtG in hair 
Analyte Linear correlation 
coefficient (r2) 
LOD 
pg/mg 
LLOQ 
pg/mg 
Ethyl glucuronide 1.0 3.0 9.0 
 
 
Figure 46: Calibration line for EtG in hair 
 
Figure 47a: Magnified lower calibration line for EtG in hair 
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Figure 48: Chromatograms of extracted 1, 3 and 10pg/mg EtG 
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Table 72: EtG percentage of stability during optimized analysis method 
Analyte 100  pg/mg  
300 
pg/mg 
1000 
pg/mg 
Mean(CV) 
for 3 
Conc. 
Ethyl 
glucuronide 
94% 86% 91% 90% (4) 
 
Table 73: Absolute recovery (RE%) results for 100, 300 and 1000pg/mg of EtG spiked in hair (n=3) 
Analyte 100  pg/mg %CV 
300  
pg/mg %CV 
1000 
pg/mg %CV 
Mean(CV) 
for 3 
Conc. 
Ethyl 
glucuronide 
70% 9 60% 12 62% 18 64% (8) 
 
Table 74: Inter-day and intra-day precision results in hair 
Analyte 
Inter-day mean (CV%) n=5 Intra-day mean (CV%) n=5 
100   
pg/mg 
300  
pg/mg 
1000 
pg/mg 
100   
pg/mg 
300  
pg/mg 
1000 
pg/mg 
Ethyl 
glucuronide 
93 (6) 291 (6) 942 (5) 78 (4) 278 (3) 1051 (3) 
 
 
5.3. Subjects’ EtG results 
5.3.1. Comparisons of self-reports and hair analysis  
The analysis of patients’ hair samples revealed that 37 out of 59 were EtG positive 
with concentrations ranging from 9 to 339pg/mg, 8 were below the LLOQ and 14 
were negative. From these 37 positives, only 16 have clearly self-reported alcohol 
use or abuse, and 21 had denied alcohol use in their report. However, from the 14 
negative subjects 4 were teetotallers as they reported, 7 were unspecified and 3 
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were from the self-reported use group. Lastly, from the 8 samples with EtG below 
the LLOQ 5 were from denied use group and 3 from unspecified alcohol use group.  
Table 75: Subjects’ hair EtG results and alcohol use self-report  
Subject Age (years) 
Hair 
colour 
Hair 
segment  EtG pg/mg 
Self-reported   
alcohol use 
1  32 Black 0-3 cm NF Yes, poly-addict 
2   38 Grey 0-3 cm NF Yes, poly-addict 
3  32 Black 0-3 cm NF Yes, poly-addict 
4   24 Black 0-3 cm <LLOQ Yes, poly-addict 
5   25 Black 0-3 cm NF Yes, poly-addict 
6   34 Black 0-3 cm 13.9 Yes 
7  33 Black 0-3 cm 49.7 Yes 
8   28 Dark brown 0-3 cm 19.9 Yes 
9  42 Brown 0-3 cm NF No 
10  40 Black 0-3 cm 9.6 Yes 
11  46 Black 0-3 cm NF Yes, poly-addict 
12  35 Black 0-3 cm 75.4 Yes 
13  24 Black 0-3 cm NF Yes 
14  49 Grey 0-3 cm NF Yes, poly-addict 
15  34 Dark grey 0-3 cm 18.3 No 
16  32 Black 0-3 cm <LLOQ No 
17  33 Dark grey 0-3 cm 13.0 No 
18  36 Black 0-3 cm 53.7 No 
19 27 Black 0-3 cm 13.8 No 
20 30 Black 0-3 cm 9.3 No 
21 41 Grey/ henna 0-3 cm NF Yes, rarely 
22 54 Grey 0-3 cm 339.3 Yes 
23 32 Black 0-3 cm 9.1 Yes 
24 38 Dark brown 0-3 cm 12.6 Yes, poly-addict 
25 29 Black 0-3 cm 14.4 Yes, rarely 
26 35 Black 0-3 cm NF No 
27 26 Dark brown 0-3 cm 16.0 
Yes 
28 53 Grey 0-3 cm 31.0 Yes, poly-addict 
29 30 Black 0-3 cm 17.1 No 
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Subject Age (years) 
Hair 
colour 
Hair 
segment  EtG pg/mg 
Self-reported   
alcohol use 
30 32 Brown 0-3 cm NF No 
31 45 Dark grey 0-3 cm 23.6 
Yes 
32 25 Black 0-3 cm 38 Yes 
33 35 Black 0-3 cm 14.1 Yes, poly-addict 
34 25 Black 0-3 cm 57.6 Yes 
35 37 Black 0-3 cm NF Yes 
36 30 Black 0-3 cm 18.9 Yes, poly-addict 
37 33 Dark grey 0-3 cm <LLOQ Yes, poly-addict 
38 29 Black 0-3 cm 14.4 Yes, poly-addict 
39 36 Black 0-3 cm 28.5 Yes 
40 26 Black 0-3 cm 23.4 Yes 
41 38 Black 0-3 cm 32.8 Yes, poly-addict 
42 28 Black 0-3 cm <LLOQ No 
43 35 Black 0-3 cm NF No 
44 38 Black 0-3 cm 23.2 Yes, poly-addict 
45 45 Black 0-3 cm 81.5 Yes, poly-addict 
46 32 Black 0-3 cm 24.6 No 
47 34 Dark brown 0-3 cm 19.2 Yes 
48 44 Black 0-3 cm 24.1 No 
49 34 Black 0-3 cm NF Yes, poly-addict 
50 35 Black 0-3 cm 16.0 No 
51 35 Dark brown 0-3 cm 26.4 No 
52 34 Black 0-3 cm 17.0 No 
53 25 Black 0-3 cm 15.6 No 
54 32 Black 0-3 cm 24.2 Yes 
55 35 Black 0-3 cm 10 No 
56 38 Black 0-3 cm <LLOQ No 
57 35 Black 0-3 cm <LLOQ No 
58 34 Black 0-3 cm <LLOQ Yes, poly-addict 
59 52 Dark brown 0-3 cm <LLOQ No 
   * Poly-addict taking multi-substances and did not specify if he drinks or not. (NF) not found. 
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Figure 49: Chromatogram of subject 22 sample 
 
5.4. Statistical analysis 
The data collected from this study have been presented in a number of statistical 
graphs and tables as shown next. Some of the information given in these tables is 
explained below according to literature (Carletta 1996, Ledgerwood et al. 2008): 
 Hair EtG specificity is the percent of total negative self-reports out of negative 
results from hair analysis. 
 Hair EtG sensitivity is the percent of total positive self-reports out of positive 
results from hair testing. 
 Self-report specificity is the percent of total negative hair reports out of 
negative results from self-reports. 
 Self-report sensitivity is the percent of total positive hair reports out of positive 
results from self-reports. 
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 Kappa coefficient is a statistical measure of inter-rater agreement or inter-
annotator agreement. 
Kappa =  
௉௥(௔)ି௉௥(௘)
ଵି௉௥(௘)  
where Pr(a) is the relative observed agreement among raters, and Pr(e) is the 
hypothetical probability of chance agreement. 
 
Figure 50: Addicts’ alcohol use estimated from hair EtG results 
 
 
Figure 51: Percent of positive and negative cases found with hair EtG analysis and self-report 
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Table 76: Correlation of results between hair EtG and self-report 
 Positive self-report Negative self-report Total 
Positive EtG 24 13 37 
Negative EtG 13 9 22 
Total 37 22 59 
 
Table 77: Measurement of degree of agreement using Kappa 
Kappa Standard error 
95% confidence interval 
Lower 
limit 
Upper 
limit 
0.058* 0.131 0 0.314 
              * Poor agreement (Kappa range from 0-1) 
Table 78: Percentages of specificity and sensitivity for both hair EtG results and self-report 
Hair EtG specificity -SR/-EtG (9/22) 41% 
Hair EtG sensitivity +SR/+EtG (24/37) 65% 
Self-report specificity -ET/-SR (9/22) 41% 
Self-report sensitivity +ET/+SR (24/37) 65% 
          -SR= number of negative self-reports, +EtG= number of positive EtG results 
 
Figure 52: Relationship between addicts’ age and EtG concentration in hair 
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Figure 53: Percent of self-reported concomitant use of illegal drugs by EtG positive subjects 
 
5.5. Discussion 
Alcohol is a non-controlled substance in the vast majority of the world's countries. 
However, its health, social, economic and crime related problems have prompted 
the need for forensic and clinical screening strategies to be available whenever 
requested. Research into alcohol detection has led to the focus on EtG noticeably in 
recent years. Even though, EtG is a minor metabolite of alcohol it can reflect to 
some extent the actual alcohol intake as it is a direct non-volatile and water-soluble 
metabolite of the rapidly eliminated ethanol (Kharbouche et al. 2010, Appenzeller et 
al. 2007). Also the research on the detection of EtG in hair has led to a consensus 
on suggested cut-offs or thresholds that allow for better interpretation of the results. 
SoHT cut-offs are shown in Table 79. 
Table 79: SOHT consensus on EtG level and its interpretation in hair 
Hair sample length EtG concentration in hair Interpretation 
0-3 cm <7 pg/mg Abstinent 
0-3 cm 7-30 pg/mg Social drinker 
0-3 cm >30 pg/mg Excessive drinker 
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Based on this information this study was designed and undertaken to fulfil a number 
of objectives. Each research objective and its finding are discussed in the following 
paragraphs. 
Method development for EtG analysis 
Firstly, in this study two different mass spectrometer instruments were tried with 
different columns. The Exactive Orbitrap system allowed precise ion extraction of 
EtG and the deuterated internal standard (EtG-D5) with mass accuracy within 6ppm. 
The instrument showed its best sensitivity when the injector was set on full loop with 
an injection volume of 25µL. The two columns which were tested on Exactive were 
Zic-HILIC and Zic-pHILIC. The latter provided almost double the sensitivity with 
similar retention time (3 min) as seen from the results in Table 68. Both columns are 
zwitterionic HILIC and were chosen based on the fact that HILIC chromatography is 
capable of separating polar compounds such as EtG. The retention mechanism is 
based on hydrophilic partitioning of analytes between an organic solvent-rich mobile 
phase and an aqueous layer formed on the stationary phase (Jandera 2011). The 
better performance seen with pHILIC could be due to the pH conditions of the 
mobile phase (pH 9). The other instrument, TSQ Vantage, has provided almost 
double the sensitivity of pHILIC-Exactive system without the need of injecting on full 
loop mode when the correct column was used. Initial trials with Ascentis Express 
C18 column showed weak response for 10ng/mL EtG. Also preliminary trials with 
Kinetex HILIC were not successful as no retention could be achieved even though 
the mobile phase was tried on from 40 to 99% acetonitrile. Thus, Acquity BEH C18 
column coupled to TSQ Vantage gave the highest possible sensitivity.        
Secondly, with regard to extraction optimization, two SPE methods and two non-
SPE methods were compared. Disappointingly, several trials with EtG CleanScreen 
cartridges ended up with very low recoveries (5%) despite changing and increasing 
elutants as mentioned in the literature (Lamoureux et al. 2009, Kronstrand, 
Brinkhagen & Nyström 2011b). In contrast, Oasis Max cartridges showed an 
average recovery of 94%. Several published methods have opted for this type of 
cartridge as well (Martins Ferreira, Binz & Yegles 2011, Tarcomnicu et al. 2010, 
Kintz et al. 2008). However, a real sample comparison was carried out between 
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Oasis max SPE and two non-SPE methods (A:W:M and A:M) as mentioned in the 
experimental section. Oasis Max recovery from the real sample not only was 15% 
higher than the A:W:M incubation/filtration method but also gave cleaner 
chromatograms with less background noise. A similar finding was reported in a 
published paper (Tarcomnicu et al. 2010). 
Method validation 
As the SPE/BEH-C18/TSQ-Vantage method was chosen, essential validation was 
carried out with as much adherence to FDA and other published bioanalytical 
guidelines as feasible (Peters, Drummer & Musshoff 2007, FDA 2001). Linearity was 
excellent with r2=1 and LOD and LLOQ were calculated to be 3 and 9pg/mg, 
respectively. The LLOQ was not low enough according to SOHT guidelines. 
However due to the very limited instrument time allowed the method could not be 
refined further. Results below the LLOQ were only considered with age/alcohol 
correlation. Process efficiency or stability during extraction showed good results with 
an average of 90% (CV=4%) EtG recovery. Inter- and intra-day precision were less 
than 10% CV for all the three level concentrations. Average absolute recovery, 
which took into account the matrix effect and stability during incubation, was 64% 
(CV=8%). It could have been improved if there had been more instrument time.          
Alcohol prevalence among addicts 
Out of around 120 addicts residing temporarily for rehabilitation in the drug addiction 
centre in Kuwait 59 agreed to participate in this study. Their EtG results ranged from 
9 to 339pg/mg (after excluding <LLOQ results) which were within the range of those 
reported in the literature, 2-13200pg/mg (Janda, Alt 2001, Morini et al. 2006, Kintz et 
al. 2008). These results are presumed to represent the last 2-3 months as the 
analysed hair segments were either 0-2 or 0-3cm from the scalp.  The study findings 
showed also that 63% (15% heavy and 48% moderate to low) of the included 
addicts had used alcohol in the last 2-3 months. Regardless of the degree of alcohol 
use, alcohol is an illegal substance in Kuwait and these results can be a further 
proof of the smuggling or clandestine local production of this substance. 
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Unfortunately, there was no published data that can be compared with our findings 
except two studies. One looked at the toxicological screening of blood and urine 
between 1992-1997 in Kuwait where they found only 10% of the addicts were 
alcohol positive (Radovanovic et al. 2001). The other one was an aviation related 
study which was a questionnaire type study. They reported that alcohol use among 
flying crews was 37% and among clerks working in a ministry it was 4% (Omar et al. 
2005). In the first study the analysis was carried out during the 1990s and they 
tested ethanol (not the EtG), which has a short half-life, so their data refer only to 
the very recent use of alcohol, the previous 1-2 days. The second study was based 
on self-report only. Therefore, there is no proven data of how prevalent alcohol 
abuse is in Kuwait. The present study should present some reliable evidence of 
alcohol behaviour among the studied population. 
Assessment of self-report validity 
Alcohol use is not only illegal in Kuwait but also culturally and religiously 
unacceptable behaviour in that particular region of the world, even though in real life 
there is a considerable percentage of the population that uses alcohol discreetly. 
Therefore, studying or investigating alcohol prevalence through self-report would 
have some degree of unreliability. In the present study comparison between self-
report and EtG results gave a low agreement index result (Kappa=0.058), even 
though positive EtG and positive self-report results have a 65% match. Both hair 
EtG sensitivity and self-report sensitivity have a score of 65%. On the other hand, 
negative EtG and negative self-report results have a 41% match, while hair EtG 
specificity and self-report specificity both scored 41%. Previous studies have as well 
indicated that under-reporting is common even for pure research (non-medicolegal) 
purposes (Lees et al. 2012, Johnson, Fendrich 2005).     
Correlation with age and other drugs of abuse 
Analysing hair EtG results in relation to age has shown a weak positive correlation 
(r=0.2) between alcohol consumption and age of the addicts as seen in Figure 51. 
Similar findings were reported in a Spanish study, where correlation between 
alcohol positive cases and age was r=0.14 (Gómez-Talegón et al. 2012). Higushi et 
al studied 3 different groups, Japanese, Japanese-Americans and Caucasians 
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(Higuchi et al. 2006). Their findings were only similar to the present study findings 
with the Japanese group, where alcohol consumption was more in older than 
younger drinkers. However, on the contrary the percentage of heavier drinkers was 
higher among younger people in the case of Japanese-Americans and Caucasians. 
A possible explanation to the slight increase of alcohol level with age among the 
Kuwaiti addicts could be due to the very high prices of the smuggled alcohol, as 
older men normally have more financial capability than younger men.  
With respect to the consumption of other substances by the studied subjects, it 
worth mentioning that benzodiazepines, cannabis and amfetamines were found to 
be the most used substances with alcohol (59, 57 and 54%, respectively) according 
to the self-reports and hair EtG results, while heroin and cocaine were the least, 46 
and 30%, respectively, as seen in Figure 52. A recent Swedish study examining a 
toxicological data base for drinking drivers had very similar findings (Jones, 
Holmgren 2012). Benzodiazepines were the major substances co-ingested with 
alcohol, followed by cannabis, amfetamine, cocaine and heroin, respectively. These 
findings might be similar to the prevalence of these illicit drugs globally regardless of 
the concomitant alcohol use. 
5.6. Limitations  
The main limitation of the study was the LLOQ which should be lower than 9pg/mg 
and the percentage of absolute recovery was not too high, but the use of a 
deuterated internal standard can compensate for the losses. All those issues were 
due to the very limited instrument time available. Also the number of recruited 
subjects was limited and could not be increased because many addicts have very 
short hair/hairless or refused to participate.   
5.7. Conclusion 
Alcohol abuse is a worldwide problem that needs to be assessed and studied 
carefully within each country. The detection of a minor and specific metabolite of 
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alcohol, ethyl glucuronide in hair provides paramount information with regard to 
alcohol consumption.  A SPE-LC-MS/MS method was developed and validated for 
the detection and quantitation of EtG in hair. The method was used to investigate 
alcohol prevalence among addicts attending a general addiction centre in Kuwait. 
The main findings are that 63% of addicts were EtG positive, self-reports and hair 
EtG results have a weak agreement and a weak correlation was found between age 
and alcohol consumption. 
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6. Chapter 6 - Conclusion and future work   
6.1. Conclusion 
A number of investigations were carried out during this project on the potential use 
of alternative clinical and toxicological samples, namely, hair, oral fluids and dried 
blood spots. Special consideration has been given to hair as three chapters were 
mostly focusing on it.  
The main aim of the second chapter was to develop and validate an analytical 
screening method for detection and quantitation of basic and weak basic drugs in 
hair samples. The method was based on the extraction of drugs from hair through 
incubation in methanolic solution containing mainly methanol with acetonitrile and 
formic acid in deionized water. Due to the very limited access to instrumentation 
during the research the aim of method validation was not fully achieved, and not for 
all the investigated basic drugs. One of the main investigations in this chapter was to 
compare the methanolic method with an alkaline digestion method (1M NaOH) that 
was followed by liquid-liquid extraction with MTBE. A filtration step with filtration vials 
was added during method development and their materials were compared. After 
filtration, extracts were injected directly onto a C18 column coupled to a Sciex ABI 
2000 MS/MS. The mobile phase was based on 50% methanol with 0.1% formic acid 
and 2mM ammonium acetate (isocratic). Both methods were compared by applying 
them to real samples from ante-mortem and post-mortem cases. Development and 
validation results showed that calibration was linear with r2 of 0.991 - 0.999 for 20 
tested analytes. The matrix effect was assessed to be between 91.4% - 110.2% for 
18 analytes. PTFE filter material showed better recoveries over the GMF and PVDF 
based filters. Stability of analytes during extraction in general was better with 
methanolic incubation than alkaline digestion. With regard to real sample recovery, 6 
out of 10 analytes were recovered better with alkaline digestion. However, the 
methanolic method was capable of extracting most of the targeted drugs (8 out of 
10) in the real hair samples but only part of the total incorporated drug, as for 
Chapter 6 - Conclusion and future work  
Page 219 of 255 
 
instance codeine and mirtazapine had around 10% and 30% of the recovery 
compared to the alkaline digestion. Therefore, these results suggest that a 
combination of both methods (methanolic and alkaline extractions) in hair sample 
processing for general detection of basic and weak basic drugs may produce better 
results. However, not all basic drugs are stable under alkaline digestion, as sulpiride 
and amlodipine, for example, were completely undetected under these conditions. 
In the third chapter, five drugs and one active metabolite have been chosen 
(procyclidine, quetiapine, chlorprothixene, haloperidol, risperidone and OH-
risperidone) for investigation into the relationship between the given dose and the 
concentration detected in hair, blood and oral fluids of subjects under controlled 
drug administration. These drugs were chosen because of their wide prescription to 
psychiatric patients, high potential of short and long term side effects and toxicity 
and also for sharing some similarity with most of drugs of abuse, which target 
generally the brain cells. Nearly all the subjects have been taking these drugs for at 
least two weeks and should have established a steady-state level of the drugs. In 
order to carry out the investigations an analytical method for all the three types of 
samples had to be developed and validated. As for blood and oral fluids samples, 
four extraction methods have been tested, Tris buffer pH9, protein crash, 0.01M and 
1M NaOH. NaOH (1M) and protein crash showed the highest recoveries. Extraction 
with 1M NaOH and MTBE solvent was chosen with total analyte recoveries during 
method development of 58-110%. This method was validated with acceptable 
results. With regards to the hair method also four extraction methods were tested, 
digestion with NaOH, Na2S and proteinase K and incubation with MAF. NaOH 
digestion and MAF incubation gave the highest recoveries for the analytes. 
However, due to the previous chapter findings and recommendations, the two 
methods were combined to ensure the highest possible drug extraction yield from 
hair samples. The combined method was validated subsequently. After analysing 
patients samples correlations between drug level in each biological matrix and with 
dose were investigated. The most significant correlation coefficients (r) found were 
those between blood and hair concentrations, procyclidine r=0.83 (18 subjects 
p=<0.001), risperidone r=0.96 (14 subjects p=<0.001), haloperidol r=0.90 (10 
subjects p=<0.001), OH-risperidone r=0.24 (13 subjects p=>0.44), quetiapine r=0.28 
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(14 subjects p=>0.33) and chlorprothixene r=0.32 (13 subjects p=>0.32). 
Risperidone and haloperidol showed remarkable correlation results as nearly all the 
correlation coefficients between dose/hair, blood and saliva, hair/blood and oral 
fluids, and blood/oral fluids drug levels were significant with r ≥0.58. Among the 
interesting results is the strong correlation found between drugs half-lives and the 
mean ratio of hair concentration/dose (r= 0.96, p≤0.003). 
Remaining patients’ blood samples from chapter 3 studies with positive results for 
the six compounds investigated in the chapter have been used for chapter 4 DBS 
stability evaluation studies. A validated method has been developed which can be 
used for the extraction and quantitative analysis of drugs in small volumes of blood 
spotted and dried on filter papers or Guthrie cards. The DBS technique provides a 
suitable procedure for the storage and analysis of samples in therapeutic drug 
monitoring and forensic toxicology because they are easy and safer to handle, 
transport and store in the laboratory, even in the absence of refrigeration. The 
stability of antipyschotics in DBS from real patients’ samples was assessed by 
storing them at four different temperatures (25, 4, -20 and -80°C) with and without 
prior impregnation of the DBS cards with sodium fluoride. After the development and 
validation of a LLE-LC-MS method, which was based on 1hr incubation in MAF 
solution, samples were analysed at days 0, 45, 90 and 180. Results showed a 
significant stability of all the compounds (procyclidine, quetiapine, risperidone, OH-
risperidone, chlorprothixene and haloperidol) in all the different storage conditions 
and no significant increase or decrease in drug concentrations with sodium fluoride 
impregnation. Possibly a much longer period than 6 months is needed to see if NaF 
has an effect on drug stability. 
Finally, in chapter 5, the analysis of minor and specific metabolite of alcohol in hair 
EtG was explored. Fifty nine hair samples were collected from patients attending the 
addiction treatment centre in Kuwait for evaluating alcohol prevalence among 
Kuwaiti drug addicts and to correlate the results with their self-reported intake. After 
trials with five different HPLC columns, two SPE cartridges, two LLE extraction 
procedures and two mass spectrometer instruments a SPE-LC-MS/MS method was 
developed and validated for the detection and quantitation of EtG in hair. The 
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method has a limit of detection (LOD) of 3pg/mg and limit of quantitation (LLOQ) of 
9pg/mg.  Following the application of the developed method with the subjects 
samples, the main findings were that 63% of the addicts were EtG positive, self-
reports and hair EtG results have a weak agreement (Kappa=0.058) and a weak 
correlation was found between age and alcohol consumption. 
6.2. Future Work 
A simpler and fast general screening method for basic drugs in hair would be of 
great benefit to the forensic toxicology laboratories. Although the methods 
developed in chapters 2 and 3 are of extensive capability of extracting basic drugs, 
they are relatively lengthy requiring two working days to complete analysis of a set 
of hair samples including calibrators and QCs. Therefore there is plenty of room for 
improvement especially if access to instrumentation is not restricted.  
Studies in chapter 3 aimed to look mainly into the relationships of the steady-state 
drug levels in the three different matrices with the given dose and with each other. 
As some ideas have been gathered and some significant correlations were shown 
the next or future studies should have a much larger number of participants. Also 
analysis of different hair segments should be considered in order to see if the 
steady-state level in hair is constant during long term therapy. Other future work 
should include a single dose study for a large group of subjects as well to see the 
drug disposition pattern in hair. Also research on the development of a faster and 
simpler hair analysis method for basic, acidic and neutral drugs would be very 
beneficial. A large scale study looking into and assessing hair growth variation 
among different health, age and ethnic backgrounds would be helpful, as the 1cm 
per month average hair growth used quotation has not been investigated thoroughly 
especially with respect to all the factors affecting the growth.  There is also a need 
for more alternative matrices (e.g. oral fluids and hair) data from ante-mortem and 
post-mortem cases in order to establish reference drug ranges. 
With regards to DBS, a further evaluation of the stability of the compounds in DBS 
samples over longer periods (one or two years) in similar conditions to those in 
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chapter 4 with possible comparison to conventional blood samples would be of 
interest. Also investigating the usefulness of the addition of preservatives to DBS 
cards on long term storage and the optimum concentration needed would add a 
valuable insight.  
Finally, further research on the development of a more sensitive method for 
quantitation of EtG in hair with lower LOD and LLOQ would be of interest. Although 
solid phase extraction has shown superiority over liquid-liquid extraction for the 
analysis of EtG as shown in chapter 5, LLE seems to have potential for 
improvement. A further investigation with different solutions could be of interest 
especially if that would reduce the cost of EtG analysis. Another interesting research 
project would be comparing EtG levels in hair with other biological matrices. 
Investigation into other alcohol markers would be a possibility as well. Lastly, the 
developed EtG analysis in hair method could be used for the investigation of alcohol 
prevalence in other groups in society. 
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8.4. Illustration of Triple Quadrupole Mass 
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8.5. Mechanism of electrospray ionization (Ho et al. 
2003) 
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8.6. Hair calibration lines for all analytes 
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OH-Risperidone
Y = -0.00559347+0.000699275*X   R^2 = 0.9955   W: 1/X
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